1	The	DT	O	the	det	4	SENT_1	[p1l714t81r752b103],
2	NEW	NNP	O	NEW	nn	4	SENT_1	[p1l764t83r844b103],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_1	[p1l858t83r1033b103],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_1	[p1l1047t83r1213b110],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_1	[p1l1227t81r1443b109],

1	EDITORIALS	NNS	O	editorial	_	0	SENT_2	[p1l901t265r1257b297],

1	\	NN	O	\	nn	3	SENT_3	[p1l1033t416r1065b443],
2	‘	CD	NUMBER	‘	num	3	SENT_3	[p1l1033t416r1065b443],
3	\	NN	O	\	_	0	SENT_3	[p1l1033t416r1065b443],
4	£	CD	NUMBER	£	num	5	SENT_3	[p1l1033t416r1065b443],
5	N5	NN	O	n5	dep	3	SENT_3	[p1l1094t416r1132b447],
6	)	CD	NUMBER	)	rcmod	5	SENT_3	[p1l1094t416r1132b447],
7	:	:	O	:	_	0	SENT_3	[p1l1094t416r1132b447],
8	K	NNP	O	K	dep	10	SENT_3	[p1l1012t435r1082b487],
9	1	CD	PERCENT	1	num	10	SENT_3	[p1l1125t446r1148b482],
10	%	NN	PERCENT	%	dep	6	SENT_3	[p1l1125t446r1148b482],
11	,	,	O	,	_	0	SENT_3	[p1l1125t446r1148b482],
12	5	CD	NUMBER	5	number	13	SENT_3	[p1l1012t478r1032b509],
13	\	CD	NUMBER	\	num	19	SENT_3	[p1l1084t488r1104b506],
14	E	NN	O	e	nn	19	SENT_3	[p1l1128t483r1147b503],
15	o	NN	O	o	nn	19	SENT_3	[p1l1021t507r1036b519],
16	1925	CD	PERCENT	1925	num	19	SENT_3	[p1l1067t508r1093b518],
17	6	CD	PERCENT	6	number	18	SENT_3	[p1l1116t504r1140b529],
18	%	NN	PERCENT	%	amod	19	SENT_3	[p1l1116t504r1140b529],
19	7I	NN	O	7us	appos	10	SENT_3	[p1l1036t519r1113b549],
20	>	JJR	O	>	dep	6	SENT_3	[p1l1036t519r1113b549],
21	'	''	O	'	_	0	SENT_3	[p1l1036t519r1113b549],
22	mm0	JJ	O	mm0	amod	23	SENT_3	[p1l1036t519r1113b549],
23	\	NN	O	\	dep	3	SENT_3	[p1l1036t519r1113b549],

1	Targeting	NN	O	targeting	nsubj	2	SENT_4	[p1l720t637r968b699],
2	Targeted	VBN	O	target	_	0	SENT_4	[p1l983t636r1207b699],
3	Therapy	NN	O	therapy	dobj	2	SENT_4	[p1l1226t636r1441b699],

1	Mark	NNP	PERSON	Mark	nn	3	SENT_5	[p1l906t712r991b743],
2	R.	NNP	PERSON	R.	nn	3	SENT_5	[p1l1005t715r1033b743],
3	Green	NNP	PERSON	Green	_	0	SENT_5	[p1l1048t714r1158b748],
4	,	,	O	,	_	0	SENT_5	[p1l1048t714r1158b748],
5	M.D.	NNP	O	M.D.	appos	3	SENT_5	[p1l1176t715r1255b743],

1	The	DT	O	the	det	2	SENT_6	[p1l7t913r171b992],
2	emergence	NN	O	emergence	nsubj	8	SENT_6	[p1l205t939r672b1014],
3	of	IN	O	of	_	0	SENT_6	[p1l706t913r807b992],
4	effective	JJ	O	effective	amod	6	SENT_6	[p1l822t913r1175b992],
5	cancer	NN	O	cancer	nn	6	SENT_6	[p1l1209t939r1490b992],
6	chemotherapy	NN	O	chemotherapy	prep_of	2	SENT_6	[p1l1520t913r2139b1014],
7	is	VBZ	O	be	cop	8	SENT_6	[p1l10t1042r76b1120],
8	one	CD	NUMBER	one	_	0	SENT_6	[p1l115t1067r269b1120],
9	of	IN	O	of	_	0	SENT_6	[p1l307t1041r409b1120],
10	the	DT	O	the	det	13	SENT_6	[p1l427t1041r558b1120],
11	major	JJ	O	major	amod	13	SENT_6	[p1l595t1042r847b1142],
12	medical	JJ	O	medical	amod	13	SENT_6	[p1l881t1041r1219b1120],
13	advances	NNS	O	advance	prep_of	8	SENT_6	[p1l1255t1041r1640b1120],
14	of	IN	O	of	_	0	SENT_6	[p1l1679t1041r1781b1120],
15	the	DT	O	the	det	17	SENT_6	[p1l1799t1041r1930b1120],
16	second	JJ	DATE	second	amod	17	SENT_6	[p1l1969t1068r2133b1120, p1l11t1169r175b1248],
17	half	NN	DATE	half	prep_of	13	SENT_6	[p1l200t1169r383b1248],
18	of	IN	DATE	of	_	0	SENT_6	[p1l389t1169r491b1248],
19	the	DT	DATE	the	det	21	SENT_6	[p1l498t1169r629b1248],
20	20th	JJ	DATE	20th	amod	21	SENT_6	[p1l654t1169r847b1248],
21	century	NN	DATE	century	prep_of	17	SENT_6	[p1l873t1186r1205b1270],
22	.	.	O	.	_	0	SENT_6	[p1l873t1186r1205b1270],

1	In	IN	O	in	_	0	SENT_7	[p1l1234t1177r1322b1247],
2	certain	JJ	O	certain	amod	3	SENT_7	[p1l1348t1170r1642b1248],
3	neoplasms	NNS	O	neoplasm	prep_in	4	SENT_7	[p1l1668t1169r2132b1270],
4	—	VBP	O	—	_	0	SENT_7	[p1l7t1342r115b1350],
5	such	JJ	O	such	_	0	SENT_7	[p1l141t1297r333b1376],
6	as	IN	O	as	_	0	SENT_7	[p1l358t1324r441b1376],
7	gestational	JJ	O	gestational	amod	8	SENT_7	[p1l468t1297r926b1398],
8	choriocarcinoma	NN	O	choriocarcinoma	prep_such_as	4	SENT_7	[p1l952t1297r1682b1393],
9	,	,	O	,	_	0	SENT_7	[p1l952t1297r1682b1393],
10	childhood	NN	O	childhood	appos	8	SENT_7	[p1l1713t1297r2136b1376],
11	acute	JJ	O	acute	amod	13	SENT_7	[p1l10t1442r226b1504],
12	lymphoblastic	JJ	O	lymphoblastic	amod	13	SENT_7	[p1l260t1425r873b1526],
13	leukemia	NN	O	leukemia	nsubj	4	SENT_7	[p1l909t1425r1320b1521],
14	,	,	O	,	_	0	SENT_7	[p1l909t1425r1320b1521],
15	and	CC	O	and	_	0	SENT_7	[p1l1361t1425r1519b1504],
16	subgroups	NNS	O	subgroup	nsubj	4	SENT_7	[p1l1557t1425r2011b1526],
17	of	IN	O	of	_	0	SENT_7	[p1l2051t1425r2153b1504],
18	Hodgkin	NN	PERSON	hodgkin	poss	20	SENT_7	[p1l10t1553r450b1654],
19	’s	POS	O	’s	_	0	SENT_7	[p1l10t1553r450b1654],
20	disease	NN	O	disease	prep_of	16	SENT_7	[p1l489t1553r787b1632],
21	and	CC	O	and	_	0	SENT_7	[p1l822t1553r976b1632],
22	non	JJ	O	non	conj_and	20	SENT_7	[p1l1011t1553r1649b1654],
23	.	.	O	.	_	0	SENT_7	[p1l1011t1553r1649b1654],

1	—	NN	O	—	_	0	SENT_8	[p1l1011t1553r1649b1654],
2	.	.	O	.	_	0	SENT_8	[p1l1011t1553r1649b1654],

1	Hodgkin	NN	PERSON	hodgkin	poss	5	SENT_9	[p1l1011t1553r1649b1654],
2	’s	POS	O	’s	_	0	SENT_9	[p1l1011t1553r1649b1654],
3	lymphoma	NN	O	lymphoma	nn	5	SENT_9	[p1l1686t1553r2138b1654],
4	—	NN	O	—	nn	5	SENT_9	[p1l7t1726r115b1734],
5	chemotherapy	NN	O	chemotherapy	nsubj	8	SENT_9	[p1l135t1681r736b1782],
6	is	VBZ	O	be	cop	8	SENT_9	[p1l755t1682r819b1760],
7	often	RB	O	often	advmod	8	SENT_9	[p1l846t1681r1061b1760],
8	curative	JJ	O	curative	_	0	SENT_9	[p1l1086t1682r1431b1777],
9	,	,	O	,	_	0	SENT_9	[p1l1086t1682r1431b1777],
10	and	CC	O	and	_	0	SENT_9	[p1l1460t1681r1615b1760],
11	the	DT	O	the	det	12	SENT_9	[p1l1639t1681r1767b1760],
12	promise	NN	O	promise	nsubj	18	SENT_9	[p1l1790t1682r2135b1782],
13	of	IN	O	of	_	0	SENT_9	[p1l11t1809r112b1888],
14	long	JJ	O	long	amod	17	SENT_9	[p1l118t1809r540b1910],
15	—	JJ	O	—	amod	17	SENT_9	[p1l118t1809r540b1910],
16	term	NN	O	term	nn	17	SENT_9	[p1l118t1809r540b1910],
17	survival	NN	O	survival	prep_of	12	SENT_9	[p1l568t1809r882b1888],
18	makes	VBZ	O	make	conj_and	8	SENT_9	[p1l908t1809r1175b1889],
19	therapy	NN	O	therapy	iobj	18	SENT_9	[p1l1204t1809r1518b1910],
20	well	RB	O	well	advmod	21	SENT_9	[p1l1535t1809r1708b1888],
21	Worth	JJ	O	worth	amod	23	SENT_9	[p1l1730t1809r1981b1889],
22	the	DT	O	the	det	23	SENT_9	[p1l2007t1809r2135b1888],
23	risk	NN	O	risk	dobj	18	SENT_9	[p1l11t1937r170b2017],
24	of	IN	O	of	_	0	SENT_9	[p1l189t1937r289b2016],
25	adverse	JJ	O	adverse	amod	26	SENT_9	[p1l292t1937r600b2016],
26	effects	NNS	O	effect	prep_of	23	SENT_9	[p1l624t1937r889b2016],
27	and	CC	O	and	_	0	SENT_9	[p1l913t1937r1067b2016],
28	the	DT	O	the	det	30	SENT_9	[p1l1091t1937r1218b2016],
29	ﬁnancial	JJ	O	ﬁnancial	amod	30	SENT_9	[p1l1241t1937r1601b2016],
30	costs	NNS	O	cost	prep_of	23	SENT_9	[p1l1624t1954r1855b2016],
31	.	.	O	.	_	0	SENT_9	[p1l1624t1954r1855b2016],

1	Moreover	RB	O	moreover	advmod	14	SENT_10	[p1l1880t1945r2133b2016, p1l11t2091r210b2161],
2	,	,	O	,	_	0	SENT_10	[p1l1880t1945r2133b2016, p1l11t2091r210b2161],
3	adjuvant	JJ	O	adjuvant	amod	4	SENT_10	[p1l243t2065r611b2166],
4	chemotherapy	NN	O	chemotherapy	nsubj	14	SENT_10	[p1l636t2065r1254b2166],
5	for	IN	O	for	_	0	SENT_10	[p1l1278t2065r1404b2144],
6	breast	NN	O	breast	nn	8	SENT_10	[p1l1430t2065r1715b2161],
7	,	,	O	,	_	0	SENT_10	[p1l1430t2065r1715b2161],
8	colon	NN	O	colon	prep_for	4	SENT_10	[p1l1749t2065r2012b2161],
9	,	,	O	,	_	0	SENT_10	[p1l1749t2065r2012b2161],
10	or	CC	O	or	_	0	SENT_10	[p1l2047t2091r2137b2144],
11	lung	NN	O	lung	nn	12	SENT_10	[p1l10t2193r207b2294],
12	cancer	NN	O	cancer	prep_for	4	SENT_10	[p1l241t2219r522b2272],
13	can	MD	O	can	aux	14	SENT_10	[p1l556t2219r702b2272],
14	augment	VB	O	augment	_	0	SENT_10	[p1l738t2210r1124b2294],
15	the	DT	O	the	det	17	SENT_10	[p1l1155t2193r1287b2272],
16	survival	NN	O	survival	nn	17	SENT_10	[p1l1326t2193r1651b2272],
17	beneﬁt	NN	O	beneﬁt	dobj	14	SENT_10	[p1l1688t2193r1991b2272],
18	afforded	VBN	O	afford	partmod	17	SENT_10	[p1l2021t2193r2133b2272, p1l11t2321r293b2400],
19	by	IN	O	by	_	0	SENT_10	[p1l324t2321r422b2422],
20	surgical	JJ	O	surgical	amod	21	SENT_10	[p1l450t2321r789b2422],
21	management	NN	O	management	agent	18	SENT_10	[p1l819t2338r1410b2422],
22	.	.	O	.	_	0	SENT_10	[p1l819t2338r1410b2422],

1	Even	RB	O	even	advmod	15	SENT_11	[p1l1445t2329r1648b2400],
2	in	IN	O	in	_	0	SENT_11	[p1l1678t2322r1761b2399],
3	patients	NNS	O	patient	prep_in	15	SENT_11	[p1l1790t2322r2132b2422],
4	With	IN	O	with	_	0	SENT_11	[p1l6t2449r195b2529],
5	advanced	JJ	O	advanced	amod	7	SENT_11	[p1l226t2449r612b2528],
6	solid	JJ	O	solid	amod	7	SENT_11	[p1l646t2449r845b2528],
7	tumors	NNS	O	tumor	prep_with	15	SENT_11	[p1l877t2466r1174b2528],
8	or	CC	O	or	_	0	SENT_11	[p1l1209t2475r1297b2528],
9	recurrences	NNS	O	recurrence	prep_with	15	SENT_11	[p1l1326t2475r1806b2528],
10	despite	IN	O	despite	_	0	SENT_11	[p1l1841t2449r2135b2550],
11	surgery	NN	O	surgery	prep_despite	15	SENT_11	[p1l12t2603r335b2678],
12	,	,	O	,	_	0	SENT_11	[p1l12t2603r335b2678],
13	chemotherapy	NN	O	chemotherapy	nsubj	15	SENT_11	[p1l364t2577r965b2678],
14	can	MD	O	can	aux	15	SENT_11	[p1l984t2603r1126b2656],
15	offer	VB	O	offer	_	0	SENT_11	[p1l1150t2577r1349b2656],
16	lengthened	VBN	O	lengthen	dep	15	SENT_11	[p1l1367t2577r1838b2678],
17	survival	NN	O	survival	dobj	16	SENT_11	[p1l1862t2578r2134b2656, p1l10t2705r81b2784],
18	of	IN	O	of	_	0	SENT_11	[p1l104t2705r204b2784],
19	worthwhile	JJ	O	worthwhile	amod	20	SENT_11	[p1l206t2705r700b2785],
20	quality	NN	O	quality	prep_of	17	SENT_11	[p1l727t2705r1032b2806],
21	.	.	O	.	_	0	SENT_11	[p1l727t2705r1032b2806],

1	In	IN	O	in	_	0	SENT_12	[p1l1063t2713r1151b2783],
2	these	DT	O	these	det	3	SENT_12	[p1l1177t2705r1400b2784],
3	patients	NNS	O	patient	prep_in	11	SENT_12	[p1l1425t2706r1794b2806],
4	,	,	O	,	_	0	SENT_12	[p1l1425t2706r1794b2806],
5	however	RB	O	however	advmod	11	SENT_12	[p1l1825t2705r2133b2784, p1l11t2859r111b2929],
6	,	,	O	,	_	0	SENT_12	[p1l1825t2705r2133b2784, p1l11t2859r111b2929],
7	the	DT	O	the	det	9	SENT_12	[p1l145t2833r277b2912],
8	therapeutic	JJ	O	therapeutic	amod	9	SENT_12	[p1l306t2833r793b2934],
9	index	NN	O	index	nsubj	11	SENT_12	[p1l820t2833r1057b2912],
10	is	VBZ	O	be	cop	11	SENT_12	[p1l1082t2834r1148b2912],
11	narrow	JJ	O	narrow	_	0	SENT_12	[p1l1180t2859r1513b2912],
12	:	:	O	:	_	0	SENT_12	[p1l1180t2859r1513b2912],
13	responses	NNS	O	response	nsubj	23	SENT_12	[p1l1546t2859r1975b2934],
14	are	VBP	O	be	cop	16	SENT_12	[p1l2006t2859r2134b2912],
15	usually	RB	O	usually	advmod	16	SENT_12	[p1l11t2961r306b3062],
16	partial	JJ	O	partial	parataxis	11	SENT_12	[p1l327t2961r616b3062],
17	,	,	O	,	_	0	SENT_12	[p1l327t2961r616b3062],
18	often	RB	O	often	advmod	20	SENT_12	[p1l650t2961r863b3040],
19	disappointingly	RB	O	disappointingly	advmod	20	SENT_12	[p1l891t2961r1545b3062],
20	brief	JJ	O	brief	parataxis	11	SENT_12	[p1l1569t2961r1782b3057],
21	,	,	O	,	_	0	SENT_12	[p1l1569t2961r1782b3057],
22	and	CC	O	and	_	0	SENT_12	[p1l1815t2961r1969b3040],
23	unpredictable	JJ	O	unpredictable	parataxis	11	SENT_12	[p1l1996t2987r2135b3040, p1l9t3089r497b3190],
24	.	.	O	.	_	0	SENT_12	[p1l1996t2987r2135b3040, p1l9t3089r497b3190],

1	These	DT	O	these	det	2	SENT_13	[p1l521t3089r769b3168],
2	circumstances	NNS	O	circumstance	nsubj	3	SENT_13	[p1l792t3090r1387b3168],
3	highlight	VBP	O	highlight	_	0	SENT_13	[p1l1411t3089r1800b3190],
4	the	DT	O	the	det	5	SENT_13	[p1l1817t3089r1944b3168],
5	limitations	NNS	O	limitation	dobj	3	SENT_13	[p1l1966t3089r2135b3167, p1l10t3218r321b3296],
6	of	IN	O	of	_	0	SENT_13	[p1l351t3217r453b3296],
7	traditional	JJ	O	traditional	amod	9	SENT_13	[p1l461t3217r912b3296],
8	cytotoxic	JJ	O	cytotoxic	amod	9	SENT_13	[p1l940t3218r1322b3318],
9	chemotherapy	NN	O	chemotherapy	prep_of	5	SENT_13	[p1l1349t3217r1980b3318],
10	.	.	O	.	_	0	SENT_13	[p1l1349t3217r1980b3318],

1	Against	IN	O	against	_	0	SENT_14	[p1l136t3346r465b3446],
2	this	DT	O	this	det	3	SENT_14	[p1l501t3345r654b3424],
3	background	NN	O	background	prep_against	21	SENT_14	[p1l698t3345r1230b3446],
4	,	,	O	,	_	0	SENT_14	[p1l698t3345r1230b3446],
5	the	DT	O	the	det	6	SENT_14	[p1l1277t3345r1406b3424],
6	advent	NN	O	advent	nsubj	21	SENT_14	[p1l1447t3345r1727b3424],
7	of	IN	O	of	_	0	SENT_14	[p1l1764t3345r1864b3424],
8	therapies	NNS	O	therapy	prep_of	6	SENT_14	[p1l1887t3345r2134b3424, p1l9t3474r177b3574],
9	based	VBN	O	base	partmod	8	SENT_14	[p1l210t3473r451b3552],
10	on	IN	O	on	_	0	SENT_14	[p1l481t3499r588b3552],
11	mechanisms	NNS	O	mechanism	prep_on	9	SENT_14	[p1l617t3473r1152b3552],
12	that	WDT	O	that	nsubj	13	SENT_14	[p1l1185t3473r1352b3552],
13	target	VBP	O	target	rcmod	11	SENT_14	[p1l1376t3490r1626b3574],
14	critical	JJ	O	critical	amod	16	SENT_14	[p1l1651t3473r1935b3552],
15	molecular	JJ	O	molecular	amod	16	SENT_14	[p1l1964t3499r2134b3552, p1l10t3601r295b3680],
16	pathways	NNS	O	pathway	nsubj	20	SENT_14	[p1l329t3601r721b3702],
17	of	IN	O	of	_	0	SENT_14	[p1l762t3601r863b3680],
18	tumors	NNS	O	tumor	prep_of	16	SENT_14	[p1l883t3618r1184b3680],
19	has	VBZ	O	have	aux	20	SENT_14	[p1l1225t3601r1366b3680],
20	evoked	VBN	O	evoke	ccomp	13	SENT_14	[p1l1407t3601r1700b3681],
21	consider	VBP	O	consider	_	0	SENT_14	[p1l1739t3601r2133b3680],
22	—	CD	NUMBER	—	npadvmod	23	SENT_14	[p1l1739t3601r2133b3680],
23	able	JJ	O	able	amod	24	SENT_14	[p1l10t3730r185b3809],
24	interest	NN	O	interest	dobj	21	SENT_14	[p1l210t3731r558b3809],
25	.	.	O	.	_	0	SENT_14	[p1l210t3731r558b3809],

1	When	WRB	O	when	advmod	3	SENT_15	[p1l586t3730r843b3809],
2	there	EX	O	there	expl	3	SENT_15	[p1l869t3730r1086b3809],
3	is	VBZ	O	be	advcl	24	SENT_15	[p1l1111t3731r1177b3809],
4	a	DT	O	a	det	6	SENT_15	[p1l1204t3757r1249b3809],
5	clear	JJ	O	clear	amod	6	SENT_15	[p1l1273t3730r1478b3809],
6	cut	NN	O	cut	nsubj	3	SENT_15	[p1l1501t3747r1634b3809],
7	“	CD	NUMBER	“	num	9	SENT_15	[p1l1659t3730r2138b3809],
8	molecular	JJ	O	molecular	amod	9	SENT_15	[p1l1659t3730r2138b3809],
9	driver	NN	O	driver	dep	6	SENT_15	[p2l11t43r327b139],
10	,	,	O	,	_	0	SENT_15	[p2l11t43r327b139],
11	”	RB	O	”	advmod	6	SENT_15	[p2l11t43r327b139],
12	as	IN	O	as	_	0	SENT_15	[p2l364t70r449b122],
13	in	IN	O	in	_	0	SENT_15	[p2l483t44r566b121],
14	Philadelphia	NNP	LOCATION	Philadelphia	nn	16	SENT_15	[p2l598t43r1139b144],
15	chromosome	NN	O	chromosome	nn	16	SENT_15	[p2l1171t43r2134b144],
16	—	NN	O	—	nsubj	3	SENT_15	[p2l1171t43r2134b144],
17	positive	JJ	O	positive	amod	20	SENT_15	[p2l1171t43r2134b144],
18	chronic	JJ	O	chronic	amod	20	SENT_15	[p2l11t171r335b250],
19	myelogenous	JJ	O	myelogenous	amod	20	SENT_15	[p2l373t171r935b272],
20	leukemia	NN	O	leukemia	dep	16	SENT_15	[p2l974t171r1384b267],
21	,	,	O	,	_	0	SENT_15	[p2l974t171r1384b267],
22	imatinib	NN	O	imatinib	nn	23	SENT_15	[p2l1427t171r1783b250],
23	therapy	NN	O	therapy	nsubj	24	SENT_15	[p2l1823t171r2140b272],
24	induces	VBZ	O	induce	_	0	SENT_15	[p2l10t299r327b378],
25	dramatic	JJ	O	dramatic	amod	30	SENT_15	[p2l349t299r713b378],
26	and	CC	O	and	cc	25	SENT_15	[p2l731t299r885b378],
27	often	RB	O	often	advmod	25	SENT_15	[p2l904t299r1116b378],
28	durable	JJ	O	durable	amod	30	SENT_15	[p2l1136t299r1446b378],
29	clinical	JJ	O	clinical	amod	30	SENT_15	[p2l1467t299r1759b378],
30	responses	NNS	O	response	dobj	24	SENT_15	[p2l1777t325r2135b400, p2l11t454r92b506],
31	in	IN	O	in	_	0	SENT_15	[p2l123t428r204b505],
32	most	JJS	O	most	amod	33	SENT_15	[p2l233t444r450b506],
33	patients	NNS	O	patient	prep_in	30	SENT_15	[p2l473t428r833b528],
34	.	.	O	.	_	0	SENT_15	[p2l473t428r833b528],

1	The	DT	O	the	det	3	SENT_16	[p2l864t427r1026b506],
2	therapeutic	JJ	O	therapeutic	amod	3	SENT_16	[p2l1056t427r1531b528],
3	index	NN	O	index	nsubj	5	SENT_16	[p2l1559t427r1792b506],
4	is	VBZ	O	be	cop	5	SENT_16	[p2l1818t428r1882b506],
5	high	JJ	O	high	_	0	SENT_16	[p2l1914t427r2130b528],
6	,	,	O	,	_	0	SENT_16	[p2l1914t427r2130b528],
7	and	CC	O	and	_	0	SENT_16	[p2l10t555r166b634],
8	optimally	RB	O	optimally	advmod	9	SENT_16	[p2l202t555r603b656],
9	effective	JJ	O	effective	amod	10	SENT_16	[p2l635t555r979b634],
10	treatment	NN	O	treatment	nsubjpass	13	SENT_16	[p2l1016t572r1430b634],
11	can	MD	O	can	aux	13	SENT_16	[p2l1461t581r1605b634],
12	be	VB	O	be	auxpass	13	SENT_16	[p2l1642t555r1737b634],
13	achieved	VBN	O	achieve	conj_and	5	SENT_16	[p2l1772t555r2135b634],
14	at	IN	O	at	_	0	SENT_16	[p2l10t700r89b762],
15	a	DT	O	a	det	16	SENT_16	[p2l112t710r156b762],
16	dose	NN	O	dose	prep_at	13	SENT_16	[p2l184t683r378b762],
17	below	IN	O	below	_	0	SENT_16	[p2l407t683r662b762],
18	the	DT	O	the	det	19	SENT_16	[p2l687t683r816b762],
19	maximal	JJ	O	maximal	prep_below	13	SENT_16	[p2l845t683r1211b762],
20	tolerated	VBN	O	tolerate	partmod	19	SENT_16	[p2l1240t683r1611b762],
21	dose	NN	O	dose	dobj	20	SENT_16	[p2l1641t683r1858b762],
22	.	.	O	.	_	0	SENT_16	[p2l1641t683r1858b762],

1	In	IN	O	in	_	0	SENT_17	[p2l1890t691r1977b761],
2	the	DT	O	the	det	5	SENT_17	[p2l2006t683r2135b762],
3	common	JJ	O	common	amod	5	SENT_17	[p2l11t837r392b890],
4	solid	JJ	O	solid	amod	5	SENT_17	[p2l418t811r621b890],
5	tumors	NNS	O	tumor	prep_in	11	SENT_17	[p2l646t828r973b907],
6	,	,	O	,	_	0	SENT_17	[p2l646t828r973b907],
7	by	IN	O	by	_	0	SENT_17	[p2l1004t811r1100b912],
8	contrast	NN	O	contrast	prep_by	11	SENT_17	[p2l1122t828r1487b907],
9	,	,	O	,	_	0	SENT_17	[p2l1122t828r1487b907],
10	there	EX	O	there	expl	11	SENT_17	[p2l1518t811r1730b890],
11	are	VBP	O	be	_	0	SENT_17	[p2l1754t837r1881b890],
12	many	JJ	O	many	amod	14	SENT_17	[p2l1905t837r2140b912],
13	potential	JJ	O	potential	amod	14	SENT_17	[p2l9t939r386b1040],
14	targets	NNS	O	target	nsubj	11	SENT_17	[p2l409t956r700b1040],
15	but	CC	O	but	prep	14	SENT_17	[p2l728t939r872b1018],
16	no	DT	O	no	det	20	SENT_17	[p2l891t965r998b1018],
17	obvious	JJ	O	obvious	amod	18	SENT_17	[p2l1026t939r1358b1018],
18	critical	JJ	O	critical	amod	20	SENT_17	[p2l1386t939r1678b1018],
19	molecular	JJ	O	molecular	amod	20	SENT_17	[p2l1703t939r2137b1018],
20	driver	NN	O	driver	dep	15	SENT_17	[p2l11t1067r278b1163],
21	,	,	O	,	_	0	SENT_17	[p2l11t1067r278b1163],
22	making	VBG	O	make	partmod	14	SENT_17	[p2l314t1067r645b1168],
23	the	DT	O	the	det	24	SENT_17	[p2l670t1067r799b1146],
24	development	NN	O	development	dobj	22	SENT_17	[p2l829t1067r1379b1168],
25	of	IN	O	of	_	0	SENT_17	[p2l1402t1067r1503b1146],
26	targeted	VBN	O	target	amod	27	SENT_17	[p2l1513t1067r1859b1168],
27	therapy	NN	O	therapy	prep_of	24	SENT_17	[p2l1887t1067r2134b1146, p2l9t1221r109b1296],
28	much	RB	O	much	advmod	30	SENT_17	[p2l130t1195r369b1274],
29	more	RBR	O	more	advmod	30	SENT_17	[p2l394t1221r614b1274],
30	challenging	JJ	O	challenging	amod	27	SENT_17	[p2l640t1195r1161b1296],
31	.	.	O	.	_	0	SENT_17	[p2l640t1195r1161b1296],

1	Signal	NN	O	signal	nn	2	SENT_18	[p2l142t1323r996b1424],
2	—	NN	O	—	nsubj	6	SENT_18	[p2l142t1323r996b1424],
3	transduction	NN	O	transduction	nn	4	SENT_18	[p2l142t1323r996b1424],
4	research	NN	O	research	dep	2	SENT_18	[p2l1050t1323r1412b1402],
5	has	VBZ	O	have	aux	6	SENT_18	[p2l1465t1323r1608b1402],
6	shown	VBN	O	show	_	0	SENT_18	[p2l1665t1323r1949b1402],
7	the	DT	O	the	det	8	SENT_18	[p2l2003t1323r2134b1402],
8	importance	NN	O	importance	dobj	6	SENT_18	[p2l10t1452r507b1552],
9	of	IN	O	of	_	0	SENT_18	[p2l539t1451r641b1530],
10	members	NNS	O	member	prep_of	8	SENT_18	[p2l653t1451r1055b1530],
11	of	IN	O	of	_	0	SENT_18	[p2l1089t1451r1191b1530],
12	the	DT	O	the	det	21	SENT_18	[p2l1203t1451r1334b1530],
13	human	JJ	O	human	amod	21	SENT_18	[p2l1366t1451r1669b1530],
14	epidermal	JJ	O	epidermal	amod	21	SENT_18	[p2l1700t1451r2135b1552],
15	growth	NN	O	growth	nn	21	SENT_18	[p2l10t1579r319b1680],
16	factor	NN	O	factor	nn	21	SENT_18	[p2l345t1579r593b1658],
17	receptor	NN	O	receptor	nn	21	SENT_18	[p2l615t1596r966b1680],
18	(	CD	NUMBER	(	num	21	SENT_18	[p2l993t1586r1247b1671],
19	HER	NN	O	her	nn	21	SENT_18	[p2l993t1586r1247b1671],
20	)	NN	O	)	nn	21	SENT_18	[p2l993t1586r1247b1671],
21	family	NN	O	family	prep_of	10	SENT_18	[p2l1277t1579r1542b1680],
22	of	IN	O	of	_	0	SENT_18	[p2l1562t1579r1663b1658],
23	transmem	NN	O	transmem	nn	27	SENT_18	[p2l1669t1596r2134b1658],
24	—	NN	O	—	nn	27	SENT_18	[p2l1669t1596r2134b1658],
25	brane	NN	O	brane	nn	27	SENT_18	[p2l11t1707r246b1786],
26	tyrosine	NN	O	tyrosine	nn	27	SENT_18	[p2l270t1708r600b1808],
27	kinases	NNS	O	kinase	prep_of	21	SENT_18	[p2l624t1707r930b1787],
28	in	IN	O	in	_	0	SENT_18	[p2l955t1708r1036b1785],
29	a	DT	O	a	det	30	SENT_18	[p2l1059t1734r1103b1786],
30	number	NN	O	number	prep_in	6	SENT_18	[p2l1126t1707r1458b1786],
31	of	IN	O	of	_	0	SENT_18	[p2l1479t1707r1579b1786],
32	solid	JJ	O	solid	amod	33	SENT_18	[p2l1586t1707r1785b1786],
33	tumors	NNS	O	tumor	prep_of	30	SENT_18	[p2l1809t1724r2131b1786],
34	.	.	O	.	_	0	SENT_18	[p2l1809t1724r2131b1786],

1	One	CD	NUMBER	one	num	2	SENT_19	[p2l11t1841r185b1914],
2	member	NN	O	member	nsubj	7	SENT_19	[p2l215t1835r578b1914],
3	of	IN	O	of	_	0	SENT_19	[p2l605t1835r707b1914],
4	this	DT	O	this	det	5	SENT_19	[p2l718t1835r873b1914],
5	family	NN	O	family	prep_of	2	SENT_19	[p2l905t1835r1176b1936],
6	is	VBZ	O	be	cop	7	SENT_19	[p2l1200t1836r1267b1914],
7	HER2	NN	O	her2	_	0	SENT_19	[p2l1297t1841r1548b1919],
8	(	CD	NUMBER	(	num	10	SENT_19	[p2l1584t1835r1939b1927],
9	ErbB2	NN	O	erbb2	nn	10	SENT_19	[p2l1584t1835r1939b1927],
10	)	NN	O	)	dep	7	SENT_19	[p2l1584t1835r1939b1927],
11	.	.	O	.	_	0	SENT_19	[p2l1584t1835r1939b1927],

1	The	DT	O	the	det	2	SENT_20	[p2l1971t1835r2134b1914],
2	gene	NN	O	gene	nsubjpass	7	SENT_20	[p2l10t1989r213b2064],
3	for	IN	O	for	_	0	SENT_20	[p2l243t1963r366b2042],
4	this	DT	O	this	det	5	SENT_20	[p2l393t1963r545b2042],
5	receptor	NN	O	receptor	prep_for	2	SENT_20	[p2l576t1980r928b2064],
6	is	VBZ	O	be	auxpass	7	SENT_20	[p2l953t1964r1018b2042],
7	amplified	VBN	O	amplify	_	0	SENT_20	[p2l1048t1963r1453b2064],
8	in	IN	O	in	_	0	SENT_20	[p2l1481t1964r1562b2041],
9	up	RB	O	up	advmod	12	SENT_20	[p2l1592t1989r1696b2064],
10	to	TO	O	to	_	0	SENT_20	[p2l1727t1980r1806b2042],
11	30	CD	PERCENT	30	prep_to	9	SENT_20	[p2l1837t1969r1936b2042],
12	percent	NN	PERCENT	percent	prep_in	7	SENT_20	[p2l1966t1989r2134b2064, p2l11t2108r193b2170],
13	of	IN	O	of	_	0	SENT_20	[p2l228t2091r329b2170],
14	breast	NN	O	breast	nn	15	SENT_20	[p2l350t2091r615b2170],
15	cancers	NNS	O	cancer	prep_of	12	SENT_20	[p2l650t2117r996b2187],
16	,	,	O	,	_	0	SENT_20	[p2l650t2117r996b2187],
17	leading	VBG	O	lead	partmod	12	SENT_20	[p2l1038t2091r1361b2192],
18	to	TO	O	to	_	0	SENT_20	[p2l1396t2108r1476b2170],
19	aggressive	JJ	O	aggressive	prep_to	17	SENT_20	[p2l1515t2092r1962b2192],
20	be	VB	O	be	cop	22	SENT_20	[p2l2002t2091r2133b2170],
21	—	JJ	O	—	amod	22	SENT_20	[p2l2002t2091r2133b2170],
22	havior	NN	O	havior	ccomp	17	SENT_20	[p2l11t2219r279b2298],
23	and	CC	O	and	_	0	SENT_20	[p2l299t2219r455b2298],
24	an	DT	O	a	det	26	SENT_20	[p2l477t2245r578b2298],
25	unfavorable	JJ	O	unfavorable	amod	26	SENT_20	[p2l601t2219r1099b2298],
26	prognosis	NN	O	prognosis	conj_and	22	SENT_20	[p2l1122t2220r1567b2320],
27	.	.	O	.	_	0	SENT_20	[p2l1122t2220r1567b2320],

1	However	RB	O	however	advmod	9	SENT_21	[p2l1594t2227r1980b2315],
2	,	,	O	,	_	0	SENT_21	[p2l1594t2227r1980b2315],
3	the	DT	O	the	det	7	SENT_21	[p2l2008t2219r2135b2298],
4	overexpressed	JJ	O	overexpressed	amod	7	SENT_21	[p2l11t2347r620b2448],
5	HER2	NN	O	her2	nn	7	SENT_21	[p2l652t2353r903b2431],
6	receptor	NN	O	receptor	nn	7	SENT_21	[p2l937t2364r1296b2448],
7	protein	NN	O	protein	nsubj	9	SENT_21	[p2l1325t2348r1638b2448],
8	also	RB	O	also	advmod	9	SENT_21	[p2l1670t2347r1841b2426],
9	serves	VBZ	O	serve	_	0	SENT_21	[p2l1877t2374r2132b2426],
10	as	IN	O	as	_	0	SENT_21	[p2l10t2502r95b2554],
11	a	DT	O	a	det	12	SENT_21	[p2l135t2502r179b2554],
12	target	NN	O	target	prep_as	9	SENT_21	[p2l213t2492r463b2576],
13	for	IN	O	for	_	0	SENT_21	[p2l492t2475r615b2554],
14	anti	JJ	O	anti	prep_for	12	SENT_21	[p2l647t2476r1094b2559],
15	.	.	O	.	_	0	SENT_21	[p2l647t2476r1094b2559],

1	—	NN	O	—	_	0	SENT_22	[p2l647t2476r1094b2559],
2	.	.	O	.	_	0	SENT_22	[p2l647t2476r1094b2559],

1	HER2	NN	O	her2	nn	2	SENT_23	[p2l647t2476r1094b2559],
2	antibody	NN	O	antibody	_	0	SENT_23	[p2l1129t2475r1501b2576],
3	(	CD	NUMBER	(	num	6	SENT_23	[p2l1536t2475r2130b2567],
4	trastuzumab	NN	O	trastuzumab	nn	6	SENT_23	[p2l1536t2475r2130b2567],
5	)	NN	O	)	nn	6	SENT_23	[p2l1536t2475r2130b2567],
6	therapy	NN	O	therapy	dep	2	SENT_23	[p2l11t2603r339b2704],
7	.	.	O	.	_	0	SENT_23	[p2l11t2603r339b2704],

1	The	DT	O	the	det	2	SENT_24	[p2l373t2603r534b2682],
2	presence	NN	O	presence	nsubjpass	9	SENT_24	[p2l564t2629r938b2704],
3	or	CC	O	or	_	0	SENT_24	[p2l970t2629r1059b2682],
4	absence	NN	O	absence	conj_or	2	SENT_24	[p2l1087t2603r1423b2682],
5	of	IN	O	of	_	0	SENT_24	[p2l1455t2603r1556b2682],
6	amplification	NN	O	amplification	prep_of	2	SENT_24	[p2l1567t2603r2135b2704],
7	can	MD	O	can	aux	9	SENT_24	[p2l11t2757r156b2810],
8	be	VB	O	be	auxpass	9	SENT_24	[p2l181t2731r277b2810],
9	used	VBN	O	use	_	0	SENT_24	[p2l303t2731r498b2810],
10	to	TO	O	to	aux	11	SENT_24	[p2l523t2748r602b2810],
11	differentiate	VB	O	differentiate	xcomp	9	SENT_24	[p2l630t2731r1144b2810],
12	patients	NNS	O	patient	dobj	11	SENT_24	[p2l1168t2732r1503b2832],
13	who	WP	O	who	nsubj	15	SENT_24	[p2l1526t2731r1712b2811],
14	may	MD	O	may	aux	15	SENT_24	[p2l1740t2757r1920b2832],
15	have	VB	O	have	rcmod	12	SENT_24	[p2l1942t2731r2134b2811],
16	a	DT	O	a	det	17	SENT_24	[p2l10t2886r54b2938],
17	response	NN	O	response	dobj	15	SENT_24	[p2l95t2885r481b2960],
18	to	TO	O	to	_	0	SENT_24	[p2l524t2876r605b2938],
19	the	DT	O	the	det	20	SENT_24	[p2l648t2859r779b2938],
20	antibody	NN	O	antibody	prep_to	15	SENT_24	[p2l821t2859r1200b2960],
21	from	IN	O	from	_	0	SENT_24	[p2l1238t2859r1448b2938],
22	those	DT	O	those	prep_from	20	SENT_24	[p2l1491t2859r1722b2938],
23	who	WP	O	who	nsubj	26	SENT_24	[p2l1759t2859r1943b2938],
24	will	MD	O	will	aux	26	SENT_24	[p2l1979t2859r2135b2938],
25	not	RB	O	not	neg	26	SENT_24	[p2l11t3004r154b3066],
26	have	VB	O	have	rcmod	22	SENT_24	[p2l187t2987r375b3066],
27	a	DT	O	a	det	28	SENT_24	[p2l413t3014r458b3066],
28	response	NN	O	response	dobj	26	SENT_24	[p2l494t3013r897b3088],
29	.	.	O	.	_	0	SENT_24	[p2l494t3013r897b3088],

1	The	DT	O	the	det	2	SENT_25	[p2l937t2987r1099b3066],
2	likelihood	NN	O	likelihood	nsubj	12	SENT_25	[p2l1136t2987r1565b3067],
3	of	IN	O	of	_	0	SENT_25	[p2l1604t2987r1704b3066],
4	tumor	NN	O	tumor	nn	5	SENT_25	[p2l1724t3004r1987b3066],
5	regression	NN	O	regression	prep_of	2	SENT_25	[p2l2023t3013r2134b3066, p2l10t3116r370b3216],
6	with	IN	O	with	_	0	SENT_25	[p2l393t3115r582b3194],
7	trastuzumab	NN	O	trastuzumab	nn	8	SENT_25	[p2l609t3115r1140b3194],
8	therapy	NN	O	therapy	prep_with	5	SENT_25	[p2l1168t3115r1486b3216],
9	may	MD	O	may	aux	12	SENT_25	[p2l1508t3141r1685b3216],
10	be	VB	O	be	cop	12	SENT_25	[p2l1708t3115r1803b3194],
11	as	RB	O	as	advmod	12	SENT_25	[p2l1830t3142r1914b3194],
12	high	JJ	O	high	_	0	SENT_25	[p2l1943t3115r2135b3216],
13	as	IN	O	as	_	0	SENT_25	[p2l10t3270r95b3322],
14	35	CD	PERCENT	35	num	15	SENT_25	[p2l142t3249r240b3322],
15	percent	NN	PERCENT	percent	prep_as	12	SENT_25	[p2l286t3260r614b3344],
16	among	IN	O	among	_	0	SENT_25	[p2l652t3269r956b3344],
17	patients	NNS	O	patient	prep_among	15	SENT_25	[p2l995t3244r1337b3344],
18	with	IN	O	with	_	0	SENT_25	[p2l1379t3243r1571b3322],
19	tumors	NNS	O	tumor	prep_with	17	SENT_25	[p2l1616t3260r1922b3322],
20	that	WDT	O	that	nsubj	22	SENT_25	[p2l1970t3243r2139b3322],
21	strongly	RB	O	strongly	advmod	22	SENT_25	[p2l12t3371r351b3472],
22	overexpress	VBP	O	overexpress	rcmod	19	SENT_25	[p2l385t3397r865b3472],
23	HER2	NN	O	her2	dobj	22	SENT_25	[p2l905t3366r1218b3455],
24	}	CD	NUMBER	}	num	23	SENT_25	[p2l905t3366r1218b3455],
25	The	DT	O	the	det	26	SENT_25	[p2l1254t3371r1413b3450],
26	addition	NN	O	addition	nsubj	29	SENT_25	[p2l1451t3371r1794b3450],
27	of	IN	O	of	_	0	SENT_25	[p2l1834t3371r1934b3450],
28	chemotherapy	NN	O	chemotherapy	prep_of	26	SENT_25	[p2l1958t3371r2134b3450, p2l11t3499r463b3600],
29	enhances	VBZ	O	enhance	rcmod	23	SENT_25	[p2l481t3499r867b3578],
30	responses	NNS	O	response	dobj	29	SENT_25	[p2l891t3525r1304b3600],
31	to	TO	O	to	_	0	SENT_25	[p2l1329t3516r1407b3578],
32	the	DT	O	the	det	33	SENT_25	[p2l1431t3499r1558b3578],
33	antibody	NN	O	antibody	prep_to	29	SENT_25	[p2l1580t3499r1956b3600],
34	,	,	O	,	_	0	SENT_25	[p2l1580t3499r1956b3600],
35	and	CC	O	and	_	0	SENT_25	[p2l1982t3499r2136b3578],
36	treatment	NN	O	treatment	nsubj	43	SENT_25	[p2l11t3644r434b3706],
37	of	IN	O	of	_	0	SENT_25	[p2l464t3627r566b3706],
38	appropriately	RB	O	appropriately	advmod	40	SENT_25	[p2l581t3627r1162b3728],
39	selected	VBN	O	select	amod	40	SENT_25	[p2l1193t3627r1535b3706],
40	patients	NNS	O	patient	prep_of	36	SENT_25	[p2l1568t3628r1911b3728],
41	with	IN	O	with	_	0	SENT_25	[p2l1943t3627r2135b3706],
42	trastuzumab	NN	O	trastuzumab	prep_with	40	SENT_25	[p3l11t23r542b102],
43	prolongs	VBZ	O	prolong	conj_and	12	SENT_25	[p3l567t23r947b124],
44	overall	JJ	O	overall	amod	45	SENT_25	[p3l975t23r1253b102],
45	survival	NN	O	survival	dobj	43	SENT_25	[p3l1279t19r1665b102],
46	?	.	O	?	_	0	SENT_25	[p3l1279t19r1665b102],

1	The	DT	O	the	det	7	SENT_26	[p3l136t151r296b230],
2	epidermal	JJ	O	epidermal	dep	3	SENT_26	[p3l344t151r762b252],
3	growth	NN	O	growth	amod	7	SENT_26	[p3l808t151r1108b252],
4	factor	NN	O	factor	nn	7	SENT_26	[p3l1154t151r1396b230],
5	receptor	NN	O	receptor	nn	7	SENT_26	[p3l1440t168r1786b252],
6	(	CD	NUMBER	(	num	7	SENT_26	[p3l1834t157r2130b247],
7	EGFR	NN	ORGANIZATION	egfr	nsubj	29	SENT_26	[p3l1834t157r2130b247],
8	,	,	O	,	_	0	SENT_26	[p3l1834t157r2130b247],
9	also	RB	O	also	advmod	10	SENT_26	[p3l10t278r175b356],
10	known	VBN	O	know	partmod	7	SENT_26	[p3l198t278r487b357],
11	as	IN	O	as	_	0	SENT_26	[p3l507t305r591b356],
12	ErbB1	NN	O	erbb1	nn	15	SENT_26	[p3l612t278r871b356],
13	or	CC	O	or	_	0	SENT_26	[p3l893t304r982b356],
14	HER1	NN	O	her1	nn	15	SENT_26	[p3l998t284r1303b373],
15	)	NN	O	)	prep_as	10	SENT_26	[p3l998t284r1303b373],
16	,	,	O	,	_	0	SENT_26	[p3l998t284r1303b373],
17	another	DT	O	another	det	23	SENT_26	[p3l1329t278r1655b356],
18	transmem	NN	O	transmem	nn	23	SENT_26	[p3l1674t295r2134b356],
19	—	NN	O	—	nn	23	SENT_26	[p3l1674t295r2134b356],
20	brane	NN	O	brane	nn	23	SENT_26	[p3l11t406r248b485],
21	receptor	NN	O	receptor	nn	23	SENT_26	[p3l283t423r633b507],
22	tyrosine	NN	O	tyrosine	nn	23	SENT_26	[p3l665t407r1000b507],
23	kinase	NN	O	kinase	appos	15	SENT_26	[p3l1034t406r1305b486],
24	of	IN	O	of	_	0	SENT_26	[p3l1341t406r1441b485],
25	the	DT	O	the	det	27	SENT_26	[p3l1458t406r1587b485],
26	HER	NN	O	her	nn	27	SENT_26	[p3l1621t413r1828b490],
27	family	NN	O	family	prep_of	23	SENT_26	[p3l1853t406r2130b507],
28	,	,	O	,	_	0	SENT_26	[p3l1853t406r2130b507],
29	has	VBZ	O	have	_	0	SENT_26	[p3l11t534r151b613],
30	important	JJ	O	important	amod	31	SENT_26	[p3l179t535r607b635],
31	roles	NNS	O	role	dobj	29	SENT_26	[p3l629t534r828b613],
32	in	IN	O	in	_	0	SENT_26	[p3l856t535r937b612],
33	the	DT	O	the	det	34	SENT_26	[p3l963t534r1091b613],
34	proliferation	NN	O	proliferation	prep_in	31	SENT_26	[p3l1117t534r1645b635],
35	and	CC	O	and	_	0	SENT_26	[p3l1670t534r1825b613],
36	metastasis	NN	O	metastasis	prep_in	31	SENT_26	[p3l1851t551r2134b613, p3l11t663r197b741],
37	of	IN	O	of	_	0	SENT_26	[p3l223t662r325b741],
38	tumor	NN	O	tumor	nn	39	SENT_26	[p3l330t679r597b741],
39	cells	NNS	O	cell	prep_of	34	SENT_26	[p3l618t662r823b741],
40	.	.	O	.	_	0	SENT_26	[p3l618t662r823b741],

1	It	PRP	O	it	nsubjpass	4	SENT_27	[p3l847t670r912b741],
2	is	VBZ	O	be	auxpass	4	SENT_27	[p3l926t663r990b741],
3	frequently	RB	O	frequently	advmod	4	SENT_27	[p3l1012t662r1436b763],
4	overexpressed	VBN	O	overexpress	_	0	SENT_27	[p3l1452t662r2037b763],
5	in	IN	O	in	_	0	SENT_27	[p3l2056t663r2136b740],
6	common	JJ	O	common	amod	8	SENT_27	[p3l11t816r387b869],
7	solid	JJ	O	solid	amod	8	SENT_27	[p3l424t790r625b869],
8	tumors	NNS	O	tumor	prep_in	4	SENT_27	[p3l664t807r965b869],
9	and	CC	O	and	_	0	SENT_27	[p3l1004t790r1160b869],
10	has	VBZ	O	have	aux	14	SENT_27	[p3l1197t790r1338b869],
11	become	VBN	O	become	cop	14	SENT_27	[p3l1379t790r1707b869],
12	a	DT	O	a	det	14	SENT_27	[p3l1744t817r1788b869],
13	favored	JJ	O	favored	amod	14	SENT_27	[p3l1824t790r2135b869],
14	target	NN	O	target	conj_and	4	SENT_27	[p3l11t935r265b1019],
15	for	IN	O	for	_	0	SENT_27	[p3l284t918r409b997],
16	orally	RB	O	orally	advmod	17	SENT_27	[p3l432t918r673b1019],
17	administered	VBN	O	administer	amod	19	SENT_27	[p3l692t918r1262b997],
18	small	JJ	O	small	amod	19	SENT_27	[p3l1288t918r1952b997],
19	—	NN	O	—	prep_for	14	SENT_27	[p3l1288t918r1952b997],
20	molecule	NN	O	molecule	nn	23	SENT_27	[p3l1288t918r1952b997],
21	and	CC	O	and	_	0	SENT_27	[p3l1976t918r2134b997],
22	antibody	NN	O	antibody	nn	23	SENT_27	[p3l10t1046r665b1147],
23	—	NN	O	—	dobj	4	SENT_27	[p3l10t1046r665b1147],
24	based	VBN	O	base	partmod	23	SENT_27	[p3l10t1046r665b1147],
25	therapy	NN	O	therapy	dobj	24	SENT_27	[p3l691t1046r1013b1147],
26	.	.	O	.	_	0	SENT_27	[p3l691t1046r1013b1147],

1	In	IN	O	in	_	0	SENT_28	[p3l1042t1054r1128b1124],
2	May	NNP	DATE	May	prep_in	12	SENT_28	[p3l1149t1054r1326b1147],
3	2003	CD	DATE	2003	num	2	SENT_28	[p3l1345t1052r1573b1142],
4	,	,	O	,	_	0	SENT_28	[p3l1345t1052r1573b1142],
5	the	DT	O	the	det	8	SENT_28	[p3l1603t1046r1730b1125],
6	orally	RB	O	orally	advmod	7	SENT_28	[p3l1755t1046r1987b1147],
7	administered	VBN	O	administer	amod	8	SENT_28	[p3l2006t1046r2135b1125, p3l11t1174r458b1253],
8	EGFR	NN	ORGANIZATION	egfr	appos	2	SENT_28	[p3l486t1180r743b1258],
9	inhibitor	NN	O	inhibitor	nn	10	SENT_28	[p3l762t1174r1138b1253],
10	geﬁtinib	NN	O	geﬁtinib	nsubjpass	12	SENT_28	[p3l1167t1174r1521b1275],
11	was	VBD	O	be	auxpass	12	SENT_28	[p3l1550t1201r1711b1253],
12	approved	VBN	O	approve	_	0	SENT_28	[p3l1745t1174r2135b1275],
13	by	IN	O	by	_	0	SENT_28	[p3l11t1302r108b1403],
14	the	DT	O	the	det	18	SENT_28	[p3l131t1302r260b1381],
15	Food	NNP	ORGANIZATION	Food	nn	18	SENT_28	[p3l287t1302r501b1381],
16	and	CC	ORGANIZATION	and	_	0	SENT_28	[p3l527t1302r683b1381],
17	Drug	NNP	ORGANIZATION	Drug	nn	18	SENT_28	[p3l709t1309r928b1403],
18	Administration	NNP	ORGANIZATION	Administration	agent	12	SENT_28	[p3l948t1302r1597b1381],
19	as	IN	O	as	_	0	SENT_28	[p3l1624t1329r1708b1381],
20	third	JJ	ORDINAL	third	amod	23	SENT_28	[p3l1738t1302r2135b1381],
21	—	NN	O	—	nn	23	SENT_28	[p3l1738t1302r2135b1381],
22	line	NN	O	line	nn	23	SENT_28	[p3l1738t1302r2135b1381],
23	therapy	NN	O	therapy	prep_as	12	SENT_28	[p3l11t1430r328b1531],
24	for	IN	O	for	_	0	SENT_28	[p3l351t1430r474b1509],
25	non	JJ	O	non	amod	31	SENT_28	[p3l499t1430r1131b1509],
26	—	JJ	O	—	amod	31	SENT_28	[p3l499t1430r1131b1509],
27	small	JJ	O	small	amod	31	SENT_28	[p3l499t1430r1131b1509],
28	—	NN	O	—	nn	31	SENT_28	[p3l499t1430r1131b1509],
29	cell	NN	O	cell	nn	31	SENT_28	[p3l499t1430r1131b1509],
30	lung	NN	O	lung	nn	31	SENT_28	[p3l1157t1430r1351b1531],
31	cancer	NN	O	cancer	prep_for	23	SENT_28	[p3l1376t1456r1668b1509],
32	.	.	O	.	_	0	SENT_28	[p3l1376t1456r1668b1509],

1	In	IN	O	in	_	0	SENT_29	[p3l1700t1438r1787b1508],
2	phase	NN	O	phase	nn	4	SENT_29	[p3l1813t1430r2059b1531],
3	1	CD	NUMBER	1	num	4	SENT_29	[p3l2091t1436r2135b1508],
4	studies	NNS	O	study	prep_in	39	SENT_29	[p3l12t1558r331b1654],
5	,	,	O	,	_	0	SENT_29	[p3l12t1558r331b1654],
6	geﬁtinib	NN	O	geﬁtinib	nsubj	8	SENT_29	[p3l367t1558r722b1659],
7	was	VBD	O	be	cop	8	SENT_29	[p3l750t1585r909b1637],
8	active	JJ	O	active	conj_and	8	SENT_29	[p3l939t1559r1168b1637],
9	against	IN	O	against	_	0	SENT_29	[p3l1196t1559r1498b1659],
10	non	JJ	O	non	amod	16	SENT_29	[p3l1521t1558r2137b1637],
11	—	JJ	O	—	amod	16	SENT_29	[p3l1521t1558r2137b1637],
12	small	JJ	O	small	amod	16	SENT_29	[p3l1521t1558r2137b1637],
13	—	NN	O	—	nn	16	SENT_29	[p3l1521t1558r2137b1637],
14	cell	NN	O	cell	nn	16	SENT_29	[p3l1521t1558r2137b1637],
15	lung	NN	O	lung	nn	16	SENT_29	[p3l10t1687r200b1788],
16	cancer	NN	O	cancer	prep_against	8	SENT_29	[p3l224t1713r494b1766],
17	across	IN	O	across	_	0	SENT_29	[p3l517t1713r775b1766],
18	a	DT	O	a	det	20	SENT_29	[p3l806t1714r850b1766],
19	broad	JJ	O	broad	amod	20	SENT_29	[p3l879t1687r1122b1766],
20	range	NN	O	range	prep_across	8	SENT_29	[p3l1153t1713r1389b1788],
21	of	IN	O	of	_	0	SENT_29	[p3l1420t1687r1521b1766],
22	doses	NNS	O	dose	prep_of	20	SENT_29	[p3l1533t1683r1837b1783],
23	,3	CD	NUMBER	,3	dep	22	SENT_29	[p3l1533t1683r1837b1783],
24	and	CC	O	and	_	0	SENT_29	[p3l1869t1687r2024b1766],
25	in	IN	O	in	_	0	SENT_29	[p3l2054t1688r2135b1765],
26	randomized	JJ	O	randomized	amod	27	SENT_29	[p3l11t1815r522b1894],
27	phase	NN	O	phase	prep_in	8	SENT_29	[p3l552t1815r798b1916],
28	2	CD	NUMBER	2	num	29	SENT_29	[p3l830t1821r877b1893],
29	trials	NNS	O	trial	dep	8	SENT_29	[p3l913t1815r1152b1911],
30	,	,	O	,	_	0	SENT_29	[p3l913t1815r1152b1911],
31	response	NN	O	response	nn	32	SENT_29	[p3l1192t1841r1578b1916],
32	rates	NNS	O	rate	nsubjpass	39	SENT_29	[p3l1613t1832r1815b1894],
33	of	IN	O	of	_	0	SENT_29	[p3l1852t1815r1954b1894],
34	9	CD	NUMBER	9	number	36	SENT_29	[p3l1970t1821r2017b1894],
35	to	TO	O	to	dep	36	SENT_29	[p3l2052t1832r2133b1894],
36	19	CD	PERCENT	19	num	37	SENT_29	[p3l14t1949r112b2022],
37	percent	NN	PERCENT	percent	prep_of	32	SENT_29	[p3l140t1960r468b2044],
38	were	VBD	O	be	auxpass	39	SENT_29	[p3l487t1969r692b2022],
39	reported	VBN	O	report	_	0	SENT_29	[p3l722t1943r1088b2044],
40	with	IN	O	with	_	0	SENT_29	[p3l1113t1943r1305b2023],
41	the	DT	O	the	det	42	SENT_29	[p3l1335t1943r1466b2022],
42	use	NN	O	use	prep_with	39	SENT_29	[p3l1495t1970r1637b2022],
43	of	IN	O	of	_	0	SENT_29	[p3l1667t1943r1769b2022],
44	doses	NNS	O	dose	prep_of	42	SENT_29	[p3l1780t1943r2019b2022],
45	of	IN	O	of	_	0	SENT_29	[p3l2051t1943r2153b2022],
46	250	CD	NUMBER	250	num	49	SENT_29	[p3l11t2077r166b2150],
47	or	CC	O	or	_	0	SENT_29	[p3l193t2097r284b2150],
48	500	CD	NUMBER	500	conj_or	46	SENT_29	[p3l308t2077r462b2150],
49	mg	NN	O	mg	prep_of	44	SENT_29	[p3l488t2097r629b2172],
50	per	IN	O	per	_	0	SENT_29	[p3l650t2097r791b2172],
51	day	NN	DURATION	day	prep_per	49	SENT_29	[p3l815t2071r969b2172],
52	.	.	O	.	_	0	SENT_29	[p3l815t2071r969b2172],

1	Another	DT	O	another	det	3	SENT_30	[p3l993t2071r1338b2150],
2	30	CD	PERCENT	30	num	3	SENT_30	[p3l1358t2077r1456b2150],
3	percent	NN	PERCENT	percent	nsubj	8	SENT_30	[p3l1478t2088r1793b2172],
4	or	CC	O	or	_	0	SENT_30	[p3l1811t2097r1900b2150],
5	more	JJR	O	more	conj_or	3	SENT_30	[p3l1918t2097r2135b2150],
6	of	IN	O	of	_	0	SENT_30	[p3l11t2199r111b2278],
7	patients	NNS	O	patient	prep_of	5	SENT_30	[p3l119t2200r448b2300],
8	had	VBD	O	have	_	0	SENT_30	[p3l478t2199r631b2278],
9	stable	JJ	O	stable	amod	10	SENT_30	[p3l660t2199r903b2278],
10	disease	NN	O	disease	dobj	8	SENT_30	[p3l932t2194r1365b2278],
11	.45	CD	NUMBER	.45	num	13	SENT_30	[p3l932t2194r1365b2278],
12	Many	JJ	O	many	amod	13	SENT_30	[p3l1394t2207r1632b2300],
13	patients	NNS	O	patient	nsubj	14	SENT_30	[p3l1656t2200r1990b2300],
14	reported	VBD	O	report	rcmod	10	SENT_30	[p3l2022t2225r2134b2278, p3l9t2327r286b2428],
15	symptomatic	JJ	O	symptomatic	amod	16	SENT_30	[p3l314t2328r862b2428],
16	improvement	NN	O	improvement	dobj	14	SENT_30	[p3l887t2328r1480b2428],
17	.	.	O	.	_	0	SENT_30	[p3l887t2328r1480b2428],

1	Occasional	JJ	O	occasional	amod	2	SENT_31	[p3l1512t2327r1976b2406],
2	patients	NNS	O	patient	nsubj	3	SENT_31	[p3l2002t2353r2134b2428, p3l11t2456r245b2534],
3	had	VBD	O	have	_	0	SENT_31	[p3l283t2455r441b2534],
4	dramatic	JJ	O	dramatic	amod	9	SENT_31	[p3l478t2455r882b2551],
5	,	,	O	,	_	0	SENT_31	[p3l478t2455r882b2551],
6	long	JJ	O	long	amod	9	SENT_31	[p3l923t2455r1452b2556],
7	—	RB	O	—	advmod	8	SENT_31	[p3l923t2455r1452b2556],
8	lasting	JJ	O	lasting	amod	9	SENT_31	[p3l923t2455r1452b2556],
9	responses	NNS	O	response	dobj	3	SENT_31	[p3l1486t2481r1941b2556],
10	.	.	O	.	_	0	SENT_31	[p3l1486t2481r1941b2556],

1	Adverse	JJ	O	adverse	amod	2	SENT_32	[p3l1980t2455r2133b2534, p3l6t2610r218b2662],
2	effects	NNS	O	effect	nsubj	5	SENT_32	[p3l238t2583r500b2662],
3	were	VBD	O	be	cop	5	SENT_32	[p3l517t2610r715b2662],
4	dose	NN	O	dose	nn	5	SENT_32	[p3l735t2583r1262b2679],
5	—	NN	O	—	_	0	SENT_32	[p3l735t2583r1262b2679],
6	related	JJ	O	related	amod	5	SENT_32	[p3l735t2583r1262b2679],
7	,	,	O	,	_	0	SENT_32	[p3l735t2583r1262b2679],
8	and	CC	O	and	_	0	SENT_32	[p3l1286t2583r1439b2662],
9	the	DT	O	the	det	13	SENT_32	[p3l1458t2583r1584b2662],
10	250	CD	NUMBER	250	number	11	SENT_32	[p3l1603t2589r1930b2684],
11	—	CD	NUMBER	—	num	13	SENT_32	[p3l1603t2589r1930b2684],
12	mg	NN	O	mg	nn	13	SENT_32	[p3l1603t2589r1930b2684],
13	dose	NN	O	dose	nsubj	14	SENT_32	[p3l1947t2583r2136b2662],
14	had	VBD	O	have	conj_and	5	SENT_32	[p3l11t2711r166b2790],
15	a	DT	O	a	det	18	SENT_32	[p3l199t2738r244b2790],
16	favorable	JJ	O	favorable	amod	18	SENT_32	[p3l276t2711r662b2790],
17	therapeutic	JJ	O	therapeutic	amod	18	SENT_32	[p3l696t2711r1182b2812],
18	index	NN	O	index	dobj	14	SENT_32	[p3l1217t2711r1476b2790],
19	.	.	O	.	_	0	SENT_32	[p3l1217t2711r1476b2790],

1	In	IN	O	in	_	0	SENT_33	[p3l1517t2719r1605b2789],
2	subsequent	JJ	O	subsequent	amod	3	SENT_33	[p3l1643t2711r2139b2812],
3	studies	NNS	O	study	prep_in	25	SENT_33	[p3l12t2839r312b2918],
4	of	IN	O	of	_	0	SENT_33	[p3l355t2839r456b2918],
5	geﬁtinib	NN	O	geﬁtinib	prep_of	3	SENT_33	[p3l478t2839r835b2940],
6	in	IN	O	in	_	0	SENT_33	[p3l871t2840r951b2917],
7	a	DT	O	a	det	9	SENT_33	[p3l985t2866r1030b2918],
8	broader	JJR	O	broader	amod	9	SENT_33	[p3l1064t2839r1389b2918],
9	range	NN	O	range	prep_in	5	SENT_33	[p3l1421t2865r1655b2940],
10	of	IN	O	of	_	0	SENT_33	[p3l1691t2839r1791b2918],
11	patients	NNS	O	patient	prep_of	9	SENT_33	[p3l1806t2840r2134b2940],
12	with	IN	O	with	_	0	SENT_33	[p3l6t2967r193b3047],
13	non	JJ	O	non	amod	19	SENT_33	[p3l217t2967r838b3046],
14	—	JJ	O	—	amod	19	SENT_33	[p3l217t2967r838b3046],
15	small	JJ	O	small	amod	19	SENT_33	[p3l217t2967r838b3046],
16	—	NN	O	—	nn	19	SENT_33	[p3l217t2967r838b3046],
17	cell	NN	O	cell	nn	19	SENT_33	[p3l217t2967r838b3046],
18	lung	NN	O	lung	nn	19	SENT_33	[p3l860t2967r1052b3068],
19	cancer	NN	O	cancer	prep_with	11	SENT_33	[p3l1074t2993r1360b3063],
20	,	,	O	,	_	0	SENT_33	[p3l1074t2993r1360b3063],
21	the	DT	O	the	det	23	SENT_33	[p3l1390t2967r1517b3046],
22	response	NN	O	response	nn	23	SENT_33	[p3l1542t2993r1915b3068],
23	rates	NNS	O	rate	nsubj	25	SENT_33	[p3l1940t2984r2134b3046],
24	were	VBD	O	be	cop	25	SENT_33	[p3l6t3121r207b3175],
25	lower	JJR	O	lower	_	0	SENT_33	[p3l229t3095r482b3191],
26	,	,	O	,	_	0	SENT_33	[p3l229t3095r482b3191],
27	but	CC	O	but	_	0	SENT_33	[p3l511t3095r652b3174],
28	antitumor	NN	O	antitumor	nn	29	SENT_33	[p3l669t3096r1096b3174],
29	activity	NN	O	activity	nsubj	31	SENT_33	[p3l1114t3096r1410b3196],
30	was	VBD	O	be	cop	31	SENT_33	[p3l1424t3122r1585b3175],
31	evident	JJ	O	evident	conj_but	25	SENT_33	[p3l1610t3095r1934b3174],
32	.	.	O	.	_	0	SENT_33	[p3l1610t3095r1934b3174],

1	Disappointingly	RB	O	disappointingly	advmod	8	SENT_34	[p3l1961t3096r2134b3174, p3l10t3223r548b3324],
2	,	,	O	,	_	0	SENT_34	[p3l1961t3096r2134b3174, p3l10t3223r548b3324],
3	in	IN	O	in	dep	1	SENT_34	[p3l577t3224r657b3301],
4	very	RB	O	very	advmod	5	SENT_34	[p3l676t3249r845b3324],
5	recent	JJ	O	recent	amod	6	SENT_34	[p3l864t3240r1121b3302],
6	studies	NNS	O	study	pobj	3	SENT_34	[p3l1141t3223r1451b3319],
7	,	,	O	,	_	0	SENT_34	[p3l1141t3223r1451b3319],
8	adding	VBG	O	add	_	0	SENT_34	[p3l1481t3223r1770b3324],
9	gefitinib	NN	O	gefitinib	dobj	8	SENT_34	[p3l1790t3223r2135b3324],

1	N	NN	O	n	nn	2	SENT_35	[p3l516t3401r529b3416],
2	ENGLJ	NN	O	englj	_	0	SENT_35	[p3l545t3400r629b3422],
3	MED	VBD	O	med	partmod	2	SENT_35	[p3l644t3401r696b3416],
4	35o	CD	NUMBER	35o	dobj	3	SENT_35	[p3l708t3400r787b3422],
5	;	:	O	;	_	0	SENT_35	[p3l708t3400r787b3422],
6	21	CD	NUMBER	21	num	8	SENT_35	[p3l708t3400r787b3422],
7	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	8	SENT_35	[p3l824t3400r1036b3422],
8	MAY	NNP	DATE	MAY	dep	2	SENT_35	[p3l1075t3400r1126b3416],
9	20,2004	CD	DATE	20,2004	number	10	SENT_35	[p3l1138t3400r1258b3422],
10	2191	CD	DATE	2191	dep	8	SENT_35	[p3l1939t3399r2016b3421],

1	The	DT	O	the	det	4	SENT_36	[p3l702t3433r753b3456],
2	New	NNP	O	New	nn	4	SENT_36	[p3l762t3434r824b3456],
3	England	NNP	O	England	nn	4	SENT_36	[p3l833t3433r944b3463],
4	Journal	NNP	O	Journal	_	0	SENT_36	[p3l952t3433r1050b3456],
5	of	IN	O	of	_	0	SENT_36	[p3l1060t3433r1088b3456],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_36	[p3l1095t3433r1220b3456],

1	Downloaded	VBN	O	download	_	0	SENT_37	[p3l144t3473r314b3496],
2	from	IN	O	from	_	0	SENT_37	[p3l323t3473r387b3496],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_37	[p3l396t3473r514b3503],
4	at	IN	O	at	_	0	SENT_37	[p3l524t3477r547b3496],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_37	[p3l556t3473r739b3496],
6	on	IN	O	on	_	0	SENT_37	[p3l748t3480r780b3496],
7	J	NNP	O	J	prep_on	5	SENT_37	[p3l789t3473r801b3496],
8	an	DT	O	a	det	9	SENT_37	[p3l803t3480r833b3496],
9	5	CD	NUMBER	5	tmod	5	SENT_37	[p3l902t3473r924b3500],
10	,	,	O	,	_	0	SENT_37	[p3l902t3473r924b3500],
11	2014	CD	DATE	2014	appos	9	SENT_37	[p3l935t3473r1007b3496],
12	.	.	O	.	_	0	SENT_37	[p3l935t3473r1007b3496],

1	For	IN	O	for	_	0	SENT_38	[p3l1018t3473r1064b3496],
2	personal	JJ	O	personal	amod	3	SENT_38	[p3l1072t3473r1184b3503],
3	use	NN	O	use	pobj	1	SENT_38	[p3l1194t3480r1237b3496],
4	only	RB	O	only	advmod	3	SENT_38	[p3l1247t3473r1311b3503],
5	.	.	O	.	_	0	SENT_38	[p3l1247t3473r1311b3503],

1	No	DT	O	no	det	3	SENT_39	[p3l1322t3473r1362b3496],
2	other	JJ	O	other	amod	3	SENT_39	[p3l1372t3473r1440b3496],
3	uses	NNS	O	use	_	0	SENT_39	[p3l1448t3480r1504b3496],
4	without	IN	O	without	_	0	SENT_39	[p3l1514t3473r1615b3496],
5	permission	NN	O	permission	prep_without	3	SENT_39	[p3l1624t3473r1776b3503],
6	.	.	O	.	_	0	SENT_39	[p3l1624t3473r1776b3503],

1	u	NN	O	u	_	0	SENT_40	[p3l834t3481r849b3496],

1	Copyright	NN	O	copyright	nn	5	SENT_41	[p3l494t3514r629b3544],
2	©	CD	NUMBER	©	num	5	SENT_41	[p3l638t3514r661b3537],
3	2004	CD	DATE	2004	num	5	SENT_41	[p3l672t3514r737b3537],
4	Massac	NNP	LOCATION	Massac	nn	5	SENT_41	[p3l746t3515r844b3537],
5	usetts	NNP	O	usetts	_	0	SENT_41	[p3l863t3518r937b3537],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_41	[p3l947t3514r1055b3537],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_41	[p3l1065t3514r1170b3544],
8	.	.	O	.	_	0	SENT_41	[p3l1065t3514r1170b3544],

1	All	DT	O	all	det	2	SENT_42	[p3l1181t3514r1223b3537],
2	rights	NNS	O	rights	nsubj	3	SENT_42	[p3l1232t3514r1306b3544],
3	reserved	VBN	O	reserve	_	0	SENT_42	[p3l1316t3514r1435b3537],
4	.	.	O	.	_	0	SENT_42	[p3l1316t3514r1435b3537],

1	Th	NN	O	th	_	0	SENT_43	[p3l715t3619r742b3640],
2	e	SYM	O	e	dep	4	SENT_43	[p3l744t3626r752b3640],
3	N	NN	O	n	nn	4	SENT_43	[p3l764t3621r788b3640],
4	E	NN	O	e	rcmod	1	SENT_43	[p3l794t3621r811b3640],
5	W	NN	O	w	nn	14	SENT_43	[p3l815t3621r845b3640],
6	E	NN	O	e	nn	14	SENT_43	[p3l859t3621r876b3640],
7	N	NN	O	n	nn	14	SENT_43	[p3l881t3621r905b3640],
8	G	NN	O	g	nn	14	SENT_43	[p3l911t3621r933b3640],
9	L	NN	O	l	nn	14	SENT_43	[p3l938t3621r955b3640],
10	A	NN	O	a	nn	14	SENT_43	[p3l957t3621r978b3640],
11	ND	NN	O	nd	nn	14	SENT_43	[p3l982t3621r1060b3647],
12	]	CD	NUMBER	]	num	14	SENT_43	[p3l982t3621r1060b3647],
13	OOOOO	NN	O	ooooo	nn	14	SENT_43	[p3l1065t3621r1193b3640],
14	L	NN	O	l	dep	1	SENT_43	[p3l1197t3621r1214b3640],
15	of	IN	O	of	_	0	SENT_43	[p3l1228t3619r1252b3646],
16	IIIIII	NNP	O	IIIIII	nn	17	SENT_43	[p3l1257t3621r1390b3640],
17	NE	NNS	O	ne	prep_of	14	SENT_43	[p3l1397t3621r1444b3640],

1	to	TO	O	to	_	0	SENT_44	[p4l12t125r90b187],
2	chemotherapy	NN	O	chemotherapy	prep_to	6	SENT_44	[p4l117t108r718b209],
3	did	VBD	O	do	aux	6	SENT_44	[p4l741t108r875b187],
4	not	RB	O	not	neg	5	SENT_44	[p4l902t125r1046b187],
5	further	JJ	O	further	dobj	6	SENT_44	[p4l1068t108r1365b188],
6	improve	VB	O	improve	_	0	SENT_44	[p4l1389t109r1738b209],
7	response	NN	O	response	nn	8	SENT_44	[p4l1765t134r2146b209],
8	rates	NNS	O	rate	dobj	6	SENT_44	[p4l11t253r210b315],
9	or	CC	O	or	_	0	SENT_44	[p4l250t262r340b315],
10	survival	NN	O	survival	dobj	6	SENT_44	[p4l375t237r695b316],
11	as	IN	O	as	_	0	SENT_44	[p4l731t263r815b315],
12	compared	VBN	O	compare	prepc_as	6	SENT_44	[p4l855t237r1280b337],
13	with	IN	O	with	pcomp	12	SENT_44	[p4l1313t237r1503b316],
14	chemotherapy	NN	O	chemotherapy	pobj	13	SENT_44	[p4l1541t236r2151b337],
15	alone	RB	O	alone	advmod	17	SENT_44	[p4l11t358r374b444],
16	.6	CD	NUMBER	.6	num	17	SENT_44	[p4l11t358r374b444],
17	’	NN	O	’	nsubj	6	SENT_44	[p4l11t358r374b444],
18	7	CD	NUMBER	7	amod	17	SENT_44	[p4l11t358r374b444],

1	Retrospective	JJ	O	retrospective	amod	2	SENT_45	[p4l139t494r731b594],
2	analyses	NNS	O	analysis	nsubj	10	SENT_45	[p4l768t494r1130b594],
3	of	IN	O	of	_	0	SENT_45	[p4l1171t493r1274b572],
4	large	JJ	O	large	amod	7	SENT_45	[p4l1292t494r1508b594],
5	phase	NN	O	phase	nn	7	SENT_45	[p4l1545t493r1799b594],
6	2	CD	NUMBER	2	num	7	SENT_45	[p4l1836t499r1884b571],
7	studies	NNS	O	study	prep_of	2	SENT_45	[p4l1925t494r2143b573, p4l11t622r125b700],
8	of	IN	O	of	_	0	SENT_45	[p4l157t621r260b700],
9	geﬁtinib	NN	O	geﬁtinib	prep_of	7	SENT_45	[p4l271t621r639b722],
10	showed	VBD	O	show	_	0	SENT_45	[p4l671t622r1003b701],
11	that	IN	O	that	complm	15	SENT_45	[p4l1033t622r1204b700],
12	responses	NNS	O	response	nsubj	15	SENT_45	[p4l1227t647r1659b722],
13	were	VBD	O	be	cop	15	SENT_45	[p4l1686t648r1891b701],
14	more	RBR	O	more	advmod	15	SENT_45	[p4l1921t647r2145b700],
15	frequent	JJ	O	frequent	ccomp	10	SENT_45	[p4l11t749r382b850],
16	among	IN	O	among	_	0	SENT_45	[p4l406t775r711b850],
17	patients	NNS	O	patient	prep_among	15	SENT_45	[p4l737t750r1081b850],
18	who	WP	O	who	nsubj	21	SENT_45	[p4l1108t750r1294b829],
19	had	VBD	O	have	aux	21	SENT_45	[p4l1325t749r1484b828],
20	never	RB	O	never	neg	21	SENT_45	[p4l1513t775r1746b829],
21	smoked	VBN	O	smoke	rcmod	17	SENT_45	[p4l1774t750r2140b845],
22	,	,	O	,	_	0	SENT_45	[p4l1774t750r2140b845],
23	women	NNS	O	woman	prep_among	15	SENT_45	[p4l7t903r355b973],
24	,	,	O	,	_	0	SENT_45	[p4l7t903r355b973],
25	and	CC	O	and	_	0	SENT_45	[p4l390t878r549b956],
26	patients	NNS	O	patient	prep_among	15	SENT_45	[p4l577t878r921b978],
27	with	IN	O	with	_	0	SENT_45	[p4l948t877r1142b957],
28	bronchoalveolar	JJ	O	bronchoalveolar	amod	29	SENT_45	[p4l1172t877r1881b957],
29	carcinoma	NN	O	carcinoma	prep_with	26	SENT_45	[p4l1908t878r2144b956, p4l11t1031r259b1084],
30	or	CC	O	or	_	0	SENT_45	[p4l293t1031r383b1084],
31	adenocarcinomas	NNS	O	adenocarcinoma	conj_or	17	SENT_45	[p4l414t1006r1179b1084],
32	with	IN	O	with	_	0	SENT_45	[p4l1211t1006r1405b1085],
33	bronchoalveolar	JJ	O	bronchoalveolar	amod	34	SENT_45	[p4l1440t1005r2148b1085],
34	features	NNS	O	feature	prep_with	31	SENT_45	[p4l11t1130r408b1214],
35	.8	CD	NUMBER	.8	dep	31	SENT_45	[p4l11t1130r408b1214],
36	Yet	CC	O	yet	cc	10	SENT_45	[p4l430t1142r557b1213],
37	even	RB	O	even	advmod	10	SENT_45	[p4l577t1160r762b1214],
38	within	IN	O	within	_	0	SENT_45	[p4l781t1135r1052b1214],
39	these	DT	O	these	det	41	SENT_45	[p4l1077t1135r1293b1213],
40	selected	VBN	O	select	amod	41	SENT_45	[p4l1319t1134r1649b1213],
41	subgroups	NNS	O	subgroup	prep_within	48	SENT_45	[p4l1674t1135r2140b1235],
42	,	,	O	,	_	0	SENT_45	[p4l1674t1135r2140b1235],
43	only	RB	O	only	advmod	45	SENT_45	[p4l12t1263r194b1363],
44	a	DT	O	a	det	45	SENT_45	[p4l213t1289r258b1341],
45	minority	NN	O	minority	nsubj	48	SENT_45	[p4l280t1263r644b1363],
46	of	IN	O	of	_	0	SENT_45	[p4l664t1262r764b1341],
47	patients	NNS	O	patient	prep_of	45	SENT_45	[p4l768t1263r1101b1363],
48	had	VBD	O	have	ccomp	10	SENT_45	[p4l1127t1262r1282b1341],
49	a	DT	O	a	det	50	SENT_45	[p4l1305t1289r1350b1341],
50	response	NN	O	response	dobj	48	SENT_45	[p4l1372t1288r1773b1363],
51	.	.	O	.	_	0	SENT_45	[p4l1372t1288r1773b1363],

1	Furthermore	RB	O	furthermore	advmod	4	SENT_46	[p4l1801t1263r2145b1342, p4l11t1416r255b1486],
2	,	,	O	,	_	0	SENT_46	[p4l1801t1263r2145b1342, p4l11t1416r255b1486],
3	there	EX	O	there	expl	4	SENT_46	[p4l291t1391r504b1469],
4	was	VBD	O	be	_	0	SENT_46	[p4l530t1417r692b1470],
5	no	DT	O	no	det	6	SENT_46	[p4l723t1416r829b1469],
6	correlation	NN	O	correlation	nsubj	4	SENT_46	[p4l861t1391r1324b1469],
7	between	IN	O	between	_	0	SENT_46	[p4l1354t1391r1706b1470],
8	the	DT	O	the	det	9	SENT_46	[p4l1736t1391r1865b1469],
9	intensity	NN	O	intensity	prep_between	6	SENT_46	[p4l1895t1391r2145b1469, p4l13t1520r155b1620],
10	of	IN	O	of	_	0	SENT_46	[p4l175t1519r276b1598],
11	immunohistochemical	JJ	O	immunohistochemical	amod	12	SENT_46	[p4l280t1519r1239b1599],
12	staining	NN	O	staining	prep_of	9	SENT_46	[p4l1263t1520r1607b1620],
13	of	IN	O	of	_	0	SENT_46	[p4l1629t1519r1729b1598],
14	the	DT	O	the	det	15	SENT_46	[p4l1735t1520r1864b1598],
15	tumor	NN	O	tumor	prep_of	12	SENT_46	[p4l1888t1536r2150b1599],
16	for	IN	O	for	_	0	SENT_46	[p4l11t1647r133b1726],
17	EGFRand	NN	O	egfrand	prep_for	15	SENT_46	[p4l148t1648r569b1731],
18	the	DT	O	the	det	19	SENT_46	[p4l589t1648r716b1726],
19	presence	NN	O	presence	dep	17	SENT_46	[p4l736t1673r1103b1748],
20	or	CC	O	or	_	0	SENT_46	[p4l1124t1673r1212b1726],
21	absence	NN	O	absence	prep_for	15	SENT_46	[p4l1229t1648r1559b1726],
22	of	IN	O	of	_	0	SENT_46	[p4l1580t1647r1680b1726],
23	a	DT	O	a	det	24	SENT_46	[p4l1681t1674r1726b1726],
24	response	NN	O	response	prep_of	21	SENT_46	[p4l1745t1673r2141b1748],
25	.	.	O	.	_	0	SENT_46	[p4l1745t1673r2141b1748],

1	This	DT	O	this	det	2	SENT_47	[p4l8t1775r194b1854],
2	situation	NN	O	situation	nsubj	4	SENT_47	[p4l225t1776r596b1855],
3	has	VBZ	O	have	aux	4	SENT_47	[p4l623t1776r765b1854],
4	left	VBN	O	leave	_	0	SENT_47	[p4l794t1775r934b1854],
5	oncologists	NNS	O	oncologist	dobj	4	SENT_47	[p4l957t1775r1445b1876],
6	with	IN	O	with	_	0	SENT_47	[p4l1471t1775r1661b1855],
7	the	DT	O	the	det	8	SENT_47	[p4l1689t1776r1819b1854],
8	conundrum	NN	O	conundrum	prep_with	4	SENT_47	[p4l1847t1801r2145b1855, p4l12t1903r242b1983],
9	of	IN	O	of	_	0	SENT_47	[p4l274t1903r374b1982],
10	when	WRB	O	when	advmod	12	SENT_47	[p4l382t1904r617b1983],
11	to	TO	O	to	aux	12	SENT_47	[p4l648t1920r727b1982],
12	offer	VB	O	offer	prepc_of	8	SENT_47	[p4l759t1903r962b1982],
13	an	DT	O	a	dobj	12	SENT_47	[p4l989t1929r1091b1982],
14	approved	VBN	O	approve	partmod	13	SENT_47	[p4l1123t1904r1547b2004],
15	,	,	O	,	_	0	SENT_47	[p4l1123t1904r1547b2004],
16	highly	RB	O	highly	advmod	17	SENT_47	[p4l1585t1903r1859b2004],
17	publicized	VBN	O	publicize	dep	14	SENT_47	[p4l1886t1904r2144b2004, p4l12t2032r259b2127],
18	,	,	O	,	_	0	SENT_47	[p4l1886t1904r2144b2004, p4l12t2032r259b2127],
19	expensive	JJ	O	expensive	amod	13	SENT_47	[p4l293t2032r735b2132],
20	,	,	O	,	_	0	SENT_47	[p4l293t2032r735b2132],
21	and	CC	O	and	_	0	SENT_47	[p4l768t2032r927b2110],
22	somewhat	RB	O	somewhat	advmod	23	SENT_47	[p4l956t2032r1402b2111],
23	toxic	JJ	O	toxic	amod	13	SENT_47	[p4l1423t2032r1625b2110],
24	therapy	NN	O	therapy	dep	19	SENT_47	[p4l1651t2032r1969b2132],
25	and	CC	O	and	_	0	SENT_47	[p4l1990t2032r2147b2110],
26	when	WRB	O	when	advmod	28	SENT_47	[p4l7t2160r242b2239],
27	to	TO	O	to	aux	28	SENT_47	[p4l273t2176r352b2238],
28	select	VB	O	select	conj_and	12	SENT_47	[p4l385t2160r624b2238],
29	another	DT	O	another	det	30	SENT_47	[p4l650t2160r981b2238],
30	option	NN	O	option	dobj	28	SENT_47	[p4l1009t2160r1310b2260],
31	.	.	O	.	_	0	SENT_47	[p4l1009t2160r1310b2260],

1	The	DT	O	the	det	2	SENT_48	[p4l1343t2160r1505b2238],
2	work	NN	O	work	nsubj	17	SENT_48	[p4l1532t2160r1755b2239],
3	of	IN	O	of	_	0	SENT_48	[p4l1782t2159r1882b2238],
4	Lynch	NNP	PERSON	Lynch	prep_of	2	SENT_48	[p4l1893t2160r2147b2260],
5	et	FW	O	et	nn	6	SENT_48	[p4l12t2305r89b2367],
6	al.	FW	O	al.	dep	4	SENT_48	[p4l114t2288r238b2384],
7	,	,	O	,	_	0	SENT_48	[p4l114t2288r238b2384],
8	reported	VBN	O	report	partmod	4	SENT_48	[p4l275t2289r636b2389],
9	in	IN	O	in	_	0	SENT_48	[p4l667t2289r748b2366],
10	this	DT	O	this	det	11	SENT_48	[p4l780t2289r933b2367],
11	issue	NN	O	issue	prep_in	8	SENT_48	[p4l965t2289r1178b2368],
12	of	IN	O	of	_	0	SENT_48	[p4l1210t2288r1311b2367],
13	the	DT	O	the	det	16	SENT_48	[p4l1324t2284r1816b2389],
14	]	NN	O	]	nn	16	SENT_48	[p4l1324t2284r1816b2389],
15	oumal	NN	O	oumal	nn	16	SENT_48	[p4l1324t2284r1816b2389],
16	,9	NN	O	,9	prep_of	11	SENT_48	[p4l1324t2284r1816b2389],
17	has	VBZ	O	have	_	0	SENT_48	[p4l1847t2289r1987b2367],
18	the	DT	O	the	det	19	SENT_48	[p4l2018t2289r2147b2367],
19	potential	JJ	O	potential	dobj	17	SENT_48	[p4l10t2417r381b2517],
20	to	TO	O	to	aux	21	SENT_48	[p4l401t2433r479b2495],
21	lift	VB	O	lift	dep	19	SENT_48	[p4l500t2416r619b2495],
22	this	DT	O	this	det	23	SENT_48	[p4l635t2416r785b2495],
23	burden	NN	O	burden	dobj	21	SENT_48	[p4l809t2417r1107b2496],
24	from	IN	O	from	_	0	SENT_48	[p4l1127t2416r1332b2495],
25	patients	NNS	O	patient	prep_from	21	SENT_48	[p4l1352t2417r1687b2517],
26	and	CC	O	and	_	0	SENT_48	[p4l1710t2416r1867b2495],
27	physicians	NNS	O	physician	prep_from	21	SENT_48	[p4l1887t2417r2145b2517, p4l12t2545r252b2623],
28	.	.	O	.	_	0	SENT_48	[p4l1887t2417r2145b2517, p4l12t2545r252b2623],

1	This	DT	O	this	det	2	SENT_49	[p4l283t2544r469b2623],
2	report	NN	O	report	nsubj	4	SENT_49	[p4l498t2561r763b2645],
3	also	RB	O	also	advmod	4	SENT_49	[p4l785t2545r953b2623],
4	provides	VBZ	O	provide	_	0	SENT_49	[p4l982t2545r1341b2645],
5	an	DT	O	a	det	6	SENT_49	[p4l1371t2570r1471b2623],
6	explanation	NN	O	explanation	dobj	4	SENT_49	[p4l1501t2545r1998b2645],
7	for	IN	O	for	_	0	SENT_49	[p4l2026t2544r2149b2623],
8	the	DT	O	the	det	10	SENT_49	[p4l12t2673r141b2751],
9	observed	VBN	O	observe	amod	10	SENT_49	[p4l169t2673r546b2752],
10	lack	NN	O	lack	prep_for	6	SENT_49	[p4l571t2673r746b2752],
11	of	IN	O	of	_	0	SENT_49	[p4l769t2672r870b2751],
12	a	DT	O	a	det	16	SENT_49	[p4l878t2699r923b2751],
13	dose	NN	O	dose	nn	16	SENT_49	[p4l948t2672r1581b2773],
14	—	NN	O	—	nn	16	SENT_49	[p4l948t2672r1581b2773],
15	response	NN	O	response	nn	16	SENT_49	[p4l948t2672r1581b2773],
16	relation	NN	O	relation	prep_of	10	SENT_49	[p4l1608t2673r1934b2751],
17	with	IN	O	with	_	0	SENT_49	[p4l1956t2673r2147b2752],
18	geﬁtinib	NN	O	geﬁtinib	prep_with	16	SENT_49	[p4l11t2800r392b2901],
19	.	.	O	.	_	0	SENT_49	[p4l11t2800r392b2901],

1	More	RBR	O	more	advmod	2	SENT_50	[p4l424t2808r648b2879],
2	globally	RB	O	globally	advmod	5	SENT_50	[p4l677t2800r1027b2901],
3	,	,	O	,	_	0	SENT_50	[p4l677t2800r1027b2901],
4	it	PRP	O	it	nsubj	5	SENT_50	[p4l1061t2801r1121b2879],
5	illustrates	VBZ	O	illustrate	_	0	SENT_50	[p4l1144t2800r1558b2880],
6	how	WRB	O	how	advmod	16	SENT_50	[p4l1589t2801r1774b2880],
7	targeted	VBN	O	target	csubjpass	16	SENT_50	[p4l1799t2800r2147b2901],
8	therapy	NN	O	therapy	dobj	7	SENT_50	[p4l12t2929r326b3029],
9	of	IN	O	of	_	0	SENT_50	[p4l344t2928r444b3007],
10	a	DT	O	a	det	13	SENT_50	[p4l445t2955r490b3007],
11	common	JJ	O	common	amod	13	SENT_50	[p4l511t2954r889b3007],
12	solid	JJ	O	solid	amod	13	SENT_50	[p4l911t2928r1112b3007],
13	tumor	NN	O	tumor	prep_of	8	SENT_50	[p4l1133t2945r1393b3008],
14	can	MD	O	can	aux	16	SENT_50	[p4l1413t2954r1555b3007],
15	be	VB	O	be	auxpass	16	SENT_50	[p4l1577t2929r1672b3007],
16	optimized	VBN	O	optimize	ccomp	5	SENT_50	[p4l1695t2928r2141b3029],
17	.	.	O	.	_	0	SENT_50	[p4l1695t2928r2141b3029],

1	Lynch	NNP	PERSON	Lynch	_	0	SENT_51	[p4l139t3057r393b3157],
2	et	FW	O	et	nn	3	SENT_51	[p4l435t3073r512b3135],
3	al.	FW	O	al.	dep	1	SENT_51	[p4l547t3056r641b3135],
4	hypothesized	VBN	O	hypothesize	partmod	1	SENT_51	[p4l688t3056r1252b3157],
5	that	IN	O	that	complm	13	SENT_51	[p4l1293t3057r1461b3135],
6	a	DT	O	a	det	8	SENT_51	[p4l1497t3083r1541b3135],
7	gain	NN	O	gain	nn	8	SENT_51	[p4l1580t3056r2145b3157],
8	—	NN	O	—	nsubj	13	SENT_51	[p4l1580t3056r2145b3157],
9	of	IN	O	of	_	0	SENT_51	[p4l1580t3056r2145b3157],
10	—	CD	NUMBER	—	num	11	SENT_51	[p4l1580t3056r2145b3157],
11	func	NN	O	func	prep_of	8	SENT_51	[p4l1580t3056r2145b3157],
12	—	NN	O	—	nn	13	SENT_51	[p4l1580t3056r2145b3157],
13	tion	NN	O	tion	ccomp	4	SENT_51	[p4l12t3185r178b3263],
14	somatic	JJ	O	somatic	amod	15	SENT_51	[p4l207t3185r539b3263],
15	mutation	NN	O	mutation	dobj	13	SENT_51	[p4l565t3185r956b3264],
16	of	IN	O	of	_	0	SENT_51	[p4l984t3184r1085b3263],
17	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_51	[p4l1091t3191r1305b3264],
18	accounts	NNS	O	account	prep_of	15	SENT_51	[p4l1324t3201r1698b3264],
19	for	IN	O	for	_	0	SENT_51	[p4l1728t3184r1851b3263],
20	the	DT	O	the	det	21	SENT_51	[p4l1875t3185r2005b3263],
21	response	NN	O	response	prep_for	13	SENT_51	[p4l2032t3211r2144b3263, p4l13t3338r308b3413],

1	of	IN	O	of	_	0	SENT_52	[p4l339t3312r440b3391],
2	some	DT	O	some	det	3	SENT_52	[p4l453t3338r679b3391],
3	patients	NNS	O	patient	prep_of	4	SENT_52	[p4l707t3313r1043b3413],
4	with	IN	O	with	_	0	SENT_52	[p4l1071t3313r1261b3392],
5	non	JJ	O	non	amod	8	SENT_52	[p4l1292t3312r1926b3391],
6	—	JJ	O	—	amod	8	SENT_52	[p4l1292t3312r1926b3391],
7	small	JJ	O	small	amod	8	SENT_52	[p4l1292t3312r1926b3391],
8	—	NN	O	—	pobj	4	SENT_52	[p4l1292t3312r1926b3391],
9	cell	NN	O	cell	nn	11	SENT_52	[p4l1292t3312r1926b3391],
10	lung	NN	O	lung	nn	11	SENT_52	[p4l1955t3313r2150b3413],
11	cancer	NN	O	cancer	dep	4	SENT_52	[p4l12t3466r289b3519],
12	to	TO	O	to	_	0	SENT_52	[p4l319t3457r399b3519],
13	geﬁtinib	NN	O	geﬁtinib	prep_to	11	SENT_52	[p4l433t3440r815b3541],
14	.	.	O	.	_	0	SENT_52	[p4l433t3440r815b3541],

1	To	TO	O	to	aux	2	SENT_53	[p4l851t3446r956b3519],
2	explore	VB	O	explore	purpcl	8	SENT_53	[p4l992t3440r1302b3541],
3	this	DT	O	this	det	4	SENT_53	[p4l1337t3440r1490b3519],
4	possibility	NN	O	possibility	dobj	2	SENT_53	[p4l1524t3441r1977b3541],
5	,	,	O	,	_	0	SENT_53	[p4l1524t3441r1977b3541],
6	the	DT	O	the	det	7	SENT_53	[p4l2017t3441r2146b3519],
7	authors	NNS	O	author	nsubj	8	SENT_53	[p4l11t3568r329b3648],
8	sequenced	VBN	O	sequence	_	0	SENT_53	[p4l355t3568r796b3669],
9	the	DT	O	the	det	12	SENT_53	[p4l819t3569r948b3647],
10	entire	JJ	O	entire	amod	12	SENT_53	[p4l972t3569r1210b3647],
11	coding	NN	O	coding	nn	12	SENT_53	[p4l1234t3569r1524b3669],
12	region	NN	O	region	dobj	8	SENT_53	[p4l1544t3569r1815b3669],
13	of	IN	O	of	_	0	SENT_53	[p4l1839t3568r1939b3647],
14	EGFR	NN	ORGANIZATION	egfr	prep_of	12	SENT_53	[p4l1941t3575r2153b3648],
15	in	IN	O	in	_	0	SENT_53	[p4l11t3697r91b3774],
16	tumors	NNS	O	tumor	prep_in	14	SENT_53	[p4l114t3713r414b3776],
17	from	IN	O	from	_	0	SENT_53	[p4l438t3696r645b3775],
18	patients	NNS	O	patient	prep_from	8	SENT_53	[p4l665t3697r998b3797],
19	with	IN	O	with	_	0	SENT_53	[p4l1017t3697r1205b3776],
20	a	DT	O	a	det	21	SENT_53	[p4l1227t3723r1271b3775],
21	response	NN	O	response	prep_with	18	SENT_53	[p4l1292t3722r1669b3797],
22	to	TO	O	to	_	0	SENT_53	[p4l1692t3713r1771b3775],
23	geﬁtinib	NN	O	geﬁtinib	prep_to	8	SENT_53	[p4l1794t3696r2145b3797],
24	and	CC	O	and	_	0	SENT_53	[p5l11t20r167b99],
25	in	IN	O	in	conj_and	8	SENT_53	[p5l190t21r272b98],
26	tumors	NNS	O	tumor	pobj	25	SENT_53	[p5l296t37r598b100],
27	from	IN	O	from	_	0	SENT_53	[p5l624t20r833b99],
28	those	DT	O	those	prep_from	25	SENT_53	[p5l857t20r1085b99],
29	without	IN	O	without	_	0	SENT_53	[p5l1105t20r1441b100],
30	a	DT	O	a	det	31	SENT_53	[p5l1459t47r1504b99],
31	response	NN	O	response	prep_without	25	SENT_53	[p5l1526t46r1922b121],
32	.	.	O	.	_	0	SENT_53	[p5l1526t46r1922b121],

1	They	PRP	O	they	nsubj	3	SENT_54	[p5l1946t21r2152b121],
2	also	RB	O	also	advmod	3	SENT_54	[p5l11t148r180b227],
3	studied	VBD	O	study	_	0	SENT_54	[p5l221t148r536b228],
4	tumors	NNS	O	tumor	dobj	3	SENT_54	[p5l575t165r883b228],
5	from	IN	O	from	_	0	SENT_54	[p5l924t148r1135b227],
6	25	CD	NUMBER	25	num	7	SENT_54	[p5l1173t154r1273b227],
7	patients	NNS	O	patient	prep_from	3	SENT_54	[p5l1313t149r1657b249],
8	with	IN	O	with	_	0	SENT_54	[p5l1693t149r1886b228],
9	nonsmall	JJ	O	nonsmall	amod	13	SENT_54	[p5l1924t174r2148b227, p5l13t276r433b355],
10	—	NN	O	—	nn	13	SENT_54	[p5l1924t174r2148b227, p5l13t276r433b355],
11	cell	NN	O	cell	nn	13	SENT_54	[p5l1924t174r2148b227, p5l13t276r433b355],
12	lung	NN	O	lung	nn	13	SENT_54	[p5l453t276r645b377],
13	cancer	NN	O	cancer	prep_with	3	SENT_54	[p5l664t302r937b355],
14	Who	WP	O	who	nsubj	17	SENT_54	[p5l951t277r1133b356],
15	had	VBD	O	have	aux	17	SENT_54	[p5l1156t277r1310b355],
16	never	RB	O	never	neg	17	SENT_54	[p5l1331t302r1557b356],
17	received	VBN	O	receive	rcmod	13	SENT_54	[p5l1576t276r1925b356],
18	geﬁtinib	NN	O	geﬁtinib	dobj	17	SENT_54	[p5l1949t276r2144b377, p5l12t404r229b500],
19	,	,	O	,	_	0	SENT_54	[p5l1949t276r2144b377, p5l12t404r229b500],
20	95	CD	NUMBER	95	num	22	SENT_54	[p5l267t410r364b483],
21	extrapulmonary	JJ	O	extrapulmonary	amod	22	SENT_54	[p5l400t405r1069b505],
22	cancers	NNS	O	cancer	dobj	17	SENT_54	[p5l1096t430r1433b500],
23	,	,	O	,	_	0	SENT_54	[p5l1096t430r1433b500],
24	and	CC	O	and	_	0	SENT_54	[p5l1469t405r1625b483],
25	108	CD	NUMBER	108	num	28	SENT_54	[p5l1659t410r1808b483],
26	cancerderived	JJ	O	cancerderived	amod	28	SENT_54	[p5l1842t430r2145b483, p5l12t532r328b612],
27	cell	NN	O	cell	nn	28	SENT_54	[p5l378t533r525b611],
28	lines	NNS	O	line	conj_and	18	SENT_54	[p5l572t533r803b611],
29	.	.	O	.	_	0	SENT_54	[p5l572t533r803b611],

1	Among	IN	O	among	_	0	SENT_55	[p5l854t540r1182b633],
2	nine	CD	NUMBER	nine	num	3	SENT_55	[p5l1227t533r1417b611],
3	patients	NNS	O	patient	prep_among	11	SENT_55	[p5l1464t533r1812b633],
4	with	IN	O	with	_	0	SENT_55	[p5l1858t533r2053b612],
5	a	DT	O	a	det	6	SENT_55	[p5l2102t559r2147b611],
6	response	NN	O	response	prep_with	3	SENT_55	[p5l11t686r399b761],
7	to	TO	O	to	_	0	SENT_55	[p5l427t677r508b739],
8	geﬁtinib	NN	O	geﬁtinib	prep_to	6	SENT_55	[p5l537t660r929b761],
9	,	,	O	,	_	0	SENT_55	[p5l537t660r929b761],
10	eight	CD	NUMBER	eight	nsubj	11	SENT_55	[p5l963t660r1185b761],
11	had	VBD	O	have	_	0	SENT_55	[p5l1208t660r1366b739],
12	tumor	NN	O	tumor	nn	13	SENT_55	[p5l1393t677r1662b740],
13	specimens	NNS	O	specimen	dobj	11	SENT_55	[p5l1689t661r2144b761],
14	with	IN	O	with	_	0	SENT_55	[p5l7t789r201b868],
15	heterozygous	JJ	O	heterozygous	amod	16	SENT_55	[p5l231t789r813b889],
16	mutations	NNS	O	mutation	prep_with	13	SENT_55	[p5l846t789r1291b868],
17	Within	IN	O	within	_	0	SENT_55	[p5l1320t789r1604b868],
18	the	DT	O	the	det	21	SENT_55	[p5l1636t789r1768b867],
19	tyrosine	NN	O	tyrosine	nn	21	SENT_55	[p5l1800t789r2145b889],
20	kinase	NN	O	kinase	nn	21	SENT_55	[p5l11t916r288b996],
21	domain	NN	O	domain	prep_within	11	SENT_55	[p5l331t916r662b995],
22	of	IN	O	of	_	0	SENT_55	[p5l705t916r807b995],
23	EGFR	NN	ORGANIZATION	egfr	prep_of	21	SENT_55	[p5l829t922r1107b1012],
24	,	,	O	,	_	0	SENT_55	[p5l829t922r1107b1012],
25	the	DT	O	the	det	26	SENT_55	[p5l1155t917r1287b995],
26	target	NN	O	target	appos	23	SENT_55	[p5l1329t933r1585b1017],
27	of	IN	O	of	_	0	SENT_55	[p5l1624t916r1725b995],
28	geﬁtinib	NN	O	geﬁtinib	prep_of	26	SENT_55	[p5l1748t916r2140b1017],
29	.	.	O	.	_	0	SENT_55	[p5l1748t916r2140b1017],

1	These	DT	O	these	det	2	SENT_56	[p5l8t1044r260b1123],
2	mutations	NNS	O	mutation	nsubj	4	SENT_56	[p5l294t1045r722b1124],
3	probably	RB	O	probably	advmod	4	SENT_56	[p5l755t1045r1127b1145],
4	stabilize	VBP	O	stabilize	_	0	SENT_56	[p5l1157t1044r1502b1123],
5	the	DT	O	the	det	6	SENT_56	[p5l1535t1044r1663b1123],
6	interaction	NN	O	interaction	dobj	4	SENT_56	[p5l1695t1045r2147b1123],
7	between	IN	O	between	_	0	SENT_56	[p5l12t1173r361b1252],
8	the	DT	O	the	det	9	SENT_56	[p5l391t1173r521b1251],
9	drug	NN	O	drug	prep_between	6	SENT_56	[p5l553t1173r753b1273],
10	and	CC	O	and	_	0	SENT_56	[p5l780t1172r937b1251],
11	the	DT	O	the	det	12	SENT_56	[p5l968t1173r1098b1251],
12	kinase	NN	O	kinase	prep_between	6	SENT_56	[p5l1129t1172r1424b1268],
13	,	,	O	,	_	0	SENT_56	[p5l1129t1172r1424b1268],
14	thereby	RB	O	thereby	advmod	4	SENT_56	[p5l1462t1173r1778b1273],
15	enhanc	JJ	O	enhanc	amod	16	SENT_56	[p5l1805t1173r2145b1251],
16	—	NN	O	—	nsubj	17	SENT_56	[p5l1805t1173r2145b1251],
17	ing	VBG	O	ing	dep	4	SENT_56	[p5l11t1301r150b1401],
18	the	DT	O	the	det	20	SENT_56	[p5l169t1301r298b1379],
19	inhibitory	JJ	O	inhibitory	amod	20	SENT_56	[p5l319t1300r741b1401],
20	effect	NN	O	effect	dobj	17	SENT_56	[p5l759t1300r994b1379],
21	of	IN	O	of	_	0	SENT_56	[p5l1011t1300r1112b1379],
22	geﬁtinib	NN	O	geﬁtinib	prep_of	20	SENT_56	[p5l1114t1300r1496b1401],
23	.	.	O	.	_	0	SENT_56	[p5l1114t1300r1496b1401],

1	By	IN	O	by	_	0	SENT_57	[p5l1522t1307r1627b1401],
2	contrast	NN	O	contrast	agent	8	SENT_57	[p5l1645t1317r2012b1396],
3	,	,	O	,	_	0	SENT_57	[p5l1645t1317r2012b1396],
4	no	DT	O	no	det	6	SENT_57	[p5l2039t1326r2145b1379],
5	such	JJ	O	such	amod	6	SENT_57	[p5l13t1429r208b1508],
6	mutations	NNS	O	mutation	nsubjpass	8	SENT_57	[p5l234t1429r666b1508],
7	were	VBD	O	be	auxpass	8	SENT_57	[p5l689t1455r892b1508],
8	identiﬁed	VBN	O	identiﬁed	_	0	SENT_57	[p5l917t1428r1323b1507],
9	in	IN	O	in	_	0	SENT_57	[p5l1348t1429r1429b1506],
10	the	DT	O	the	det	12	SENT_57	[p5l1455t1428r1585b1507],
11	tumor	NN	O	tumor	nn	12	SENT_57	[p5l1611t1445r1875b1508],
12	specimens	NNS	O	specimen	prep_in	8	SENT_57	[p5l1899t1429r2145b1529, p5l11t1582r242b1635],
13	from	IN	O	from	_	0	SENT_57	[p5l270t1556r482b1635],
14	seven	CD	NUMBER	seven	num	15	SENT_57	[p5l509t1582r744b1636],
15	patients	NNS	O	patient	prep_from	12	SENT_57	[p5l768t1557r1112b1657],
16	with	IN	O	with	_	0	SENT_57	[p5l1136t1556r1329b1636],
17	no	DT	O	no	det	18	SENT_57	[p5l1355t1582r1462b1635],
18	response	NN	O	response	prep_with	15	SENT_57	[p5l1490t1582r1878b1657],
19	to	TO	O	to	_	0	SENT_57	[p5l1905t1573r1986b1635],
20	geﬁtinib	NN	O	geﬁtinib	prep_to	8	SENT_57	[p5l2013t1583r2144b1657, p5l11t1684r293b1780],
21	,	,	O	,	_	0	SENT_57	[p5l2013t1583r2144b1657, p5l11t1684r293b1780],
22	23	CD	NUMBER	23	appos	20	SENT_57	[p5l323t1690r421b1763],
23	of	IN	O	of	_	0	SENT_57	[p5l450t1684r551b1763],
24	25	CD	NUMBER	25	num	27	SENT_57	[p5l557t1690r655b1763],
25	primary	JJ	O	primary	amod	27	SENT_57	[p5l681t1685r1020b1785],
26	lung	NN	O	lung	nn	27	SENT_57	[p5l1039t1685r1234b1785],
27	cancers	NNS	O	cancer	prep_of	22	SENT_57	[p5l1255t1710r1571b1763],
28	that	WDT	O	that	nsubjpass	31	SENT_57	[p5l1598t1685r1765b1763],
29	were	VBD	O	be	auxpass	31	SENT_57	[p5l1780t1711r1982b1764],
30	not	RB	O	not	neg	31	SENT_57	[p5l2008t1701r2152b1763],
31	treated	VBN	O	treat	rcmod	27	SENT_57	[p5l12t1813r298b1891],
32	with	IN	O	with	_	0	SENT_57	[p5l314t1813r501b1892],
33	geﬁtinib	NN	O	geﬁtinib	prep_with	31	SENT_57	[p5l522t1812r896b1913],
34	,	,	O	,	_	0	SENT_57	[p5l522t1812r896b1913],
35	the	DT	O	the	det	42	SENT_57	[p5l923t1812r1051b1891],
36	95	CD	NUMBER	95	num	42	SENT_57	[p5l1073t1818r1169b1891],
37	non	JJ	O	non	amod	42	SENT_57	[p5l1193t1813r1912b1913],
38	—	NN	O	—	nn	42	SENT_57	[p5l1193t1813r1912b1913],
39	lung	NN	O	lung	nn	42	SENT_57	[p5l1193t1813r1912b1913],
40	—	NN	O	—	nn	42	SENT_57	[p5l1193t1813r1912b1913],
41	cancer	NN	O	cancer	nn	42	SENT_57	[p5l1193t1813r1912b1913],
42	specimens	NNS	O	specimen	prep_with	31	SENT_57	[p5l1931t1839r2146b1913, p5l11t1941r293b2036],
43	,	,	O	,	_	0	SENT_57	[p5l1931t1839r2146b1913, p5l11t1941r293b2036],
44	or	CC	O	or	_	0	SENT_57	[p5l324t1966r414b2019],
45	the	DT	O	the	det	47	SENT_57	[p5l436t1941r566b2019],
46	108	CD	NUMBER	108	num	47	SENT_57	[p5l595t1946r745b2019],
47	cancer	NN	O	cancer	prep_with	31	SENT_57	[p5l772t1941r1393b2020],
48	—	CD	NUMBER	—	dep	22	SENT_57	[p5l772t1941r1393b2020],
49	deriVed	VBN	O	derive	partmod	48	SENT_57	[p5l772t1941r1393b2020],
50	cell	NN	O	cell	nn	51	SENT_57	[p5l1419t1941r1561b2019],
51	lines	NNS	O	line	dobj	49	SENT_57	[p5l1584t1941r1808b2019],
52	.	.	O	.	_	0	SENT_57	[p5l1584t1941r1808b2019],

1	The	DT	O	the	det	3	SENT_58	[p5l138t2069r300b2148],
2	nine	CD	NUMBER	nine	num	3	SENT_58	[p5l343t2070r526b2148],
3	patients	NNS	O	patient	nsubj	9	SENT_58	[p5l567t2070r898b2170],
4	with	IN	O	with	_	0	SENT_58	[p5l938t2070r1126b2149],
5	a	DT	O	a	det	6	SENT_58	[p5l1169t2096r1213b2148],
6	response	NN	O	response	prep_with	3	SENT_58	[p5l1254t2095r1629b2170],
7	to	TO	O	to	_	0	SENT_58	[p5l1673t2086r1752b2148],
8	geﬁtinib	NN	O	geﬁtinib	prep_to	6	SENT_58	[p5l1796t2069r2146b2170],
9	had	VBD	O	have	_	0	SENT_58	[p5l11t2198r165b2276],
10	either	CC	O	either	preconj	11	SENT_58	[p5l191t2198r431b2276],
11	adenocarcinoma	NN	O	adenocarcinoma	dobj	9	SENT_58	[p5l453t2198r1151b2276],
12	or	CC	O	or	_	0	SENT_58	[p5l1176t2223r1264b2276],
13	bronchoalveolar	JJ	O	bronchoalveolar	amod	14	SENT_58	[p5l1287t2197r1968b2277],
14	carcinoma	NN	O	carcinoma	dobj	9	SENT_58	[p5l1991t2224r2145b2276, p5l12t2326r348b2404],
15	.	.	O	.	_	0	SENT_58	[p5l1991t2224r2145b2276, p5l12t2326r348b2404],

1	None	NN	O	none	nsubj	4	SENT_59	[p5l386t2333r618b2405],
2	Were	VBD	O	be	cop	4	SENT_59	[p5l648t2352r851b2405],
3	current	JJ	DATE	current	amod	4	SENT_59	[p5l886t2342r1196b2405],
4	smokers	NNS	O	smoker	_	0	SENT_59	[p5l1227t2326r1612b2421],
5	,	,	O	,	_	0	SENT_59	[p5l1227t2326r1612b2421],
6	and	CC	O	and	_	0	SENT_59	[p5l1651t2326r1808b2404],
7	six	CD	NUMBER	six	nsubj	10	SENT_59	[p5l1843t2326r1959b2404],
8	had	VBD	O	have	aux	10	SENT_59	[p5l1991t2326r2147b2404],
9	never	RB	O	never	neg	10	SENT_59	[p5l11t2480r240b2534],
10	smoked	VBN	O	smoke	conj_and	4	SENT_59	[p5l260t2454r619b2550],
11	;	:	O	;	_	0	SENT_59	[p5l260t2454r619b2550],
12	six	CD	NUMBER	six	nsubj	17	SENT_59	[p5l646t2455r762b2533],
13	of	IN	O	of	_	0	SENT_59	[p5l781t2454r881b2533],
14	the	DT	O	the	det	15	SENT_59	[p5l885t2455r1014b2533],
15	nine	CD	NUMBER	nine	prep_of	12	SENT_59	[p5l1035t2455r1220b2533],
16	were	VBD	O	be	cop	17	SENT_59	[p5l1237t2481r1440b2534],
17	Women	NNS	O	woman	parataxis	4	SENT_59	[p5l1456t2480r1799b2534],
18	.	.	O	.	_	0	SENT_59	[p5l1456t2480r1799b2534],

1	The	DT	O	the	det	2	SENT_60	[p5l1822t2455r1985b2533],
2	duration	NN	O	duration	nsubj	6	SENT_60	[p5l2007t2455r2145b2534, p5l11t2584r263b2662],
3	of	IN	O	of	_	0	SENT_60	[p5l295t2583r395b2662],
4	the	DT	O	the	det	5	SENT_60	[p5l408t2584r538b2662],
5	response	NN	O	response	prep_of	2	SENT_60	[p5l568t2609r950b2684],
6	ranged	VBD	O	range	_	0	SENT_60	[p5l981t2583r1274b2684],
7	from	IN	O	from	_	0	SENT_60	[p5l1305t2583r1513b2662],
8	more	JJR	DURATION	more	mwe	9	SENT_60	[p5l1543t2609r1764b2662],
9	than	IN	DURATION	than	quantmod	10	SENT_60	[p5l1796t2583r1985b2662],
10	4.3	CD	DURATION	4.3	num	11	SENT_60	[p5l2014t2589r2143b2662],
11	months	NNS	NUMBER	month	prep_from	6	SENT_60	[p5l11t2712r337b2790],
12	to	TO	O	to	_	0	SENT_60	[p5l365t2728r444b2790],
13	more	JJR	DURATION	more	mwe	14	SENT_60	[p5l471t2737r692b2790],
14	than	IN	DURATION	than	quantmod	15	SENT_60	[p5l719t2712r907b2790],
15	33.5	CD	DURATION	33.5	num	16	SENT_60	[p5l934t2717r1113b2790],
16	months	NNS	NUMBER	month	prep_to	6	SENT_60	[p5l1143t2712r1494b2807],
17	,	,	O	,	_	0	SENT_60	[p5l1143t2712r1494b2807],
18	with	IN	O	with	_	0	SENT_60	[p5l1521t2712r1711b2791],
19	ﬁve	NN	O	ﬁve	nsubj	24	SENT_60	[p5l1737t2711r1882b2791],
20	of	IN	O	of	_	0	SENT_60	[p5l1908t2711r2009b2790],
21	the	DT	O	the	det	22	SENT_60	[p5l2017t2712r2146b2790],
22	patients	NNS	O	patient	prep_of	19	SENT_60	[p5l10t2841r346b2941],
23	still	RB	O	still	advmod	24	SENT_60	[p5l387t2840r540b2919],
24	having	VBG	O	have	prepc_with	6	SENT_60	[p5l576t2841r863b2941],
25	a	DT	O	a	det	26	SENT_60	[p5l895t2867r940b2919],
26	response	NN	O	response	dobj	24	SENT_60	[p5l975t2866r1356b2941],
27	at	IN	O	at	_	0	SENT_60	[p5l1393t2857r1472b2919],
28	the	DT	O	the	det	29	SENT_60	[p5l1504t2840r1634b2919],
29	time	NN	O	time	prep_at	24	SENT_60	[p5l1672t2841r1859b2919],
30	of	IN	O	of	_	0	SENT_60	[p5l1897t2840r1998b2919],
31	the	DT	O	the	det	33	SENT_60	[p5l2017t2841r2146b2919],
32	last	JJ	O	last	amod	33	SENT_60	[p5l11t2969r162b3047],
33	folloW	NN	O	follow	prep_of	29	SENT_60	[p5l201t2968r613b3069],
34	—	CD	NUMBER	—	num	33	SENT_60	[p5l201t2968r613b3069],
35	up	RP	O	up	prep	33	SENT_60	[p5l201t2968r613b3069],
36	visit	NN	O	visit	dep	35	SENT_60	[p5l655t2969r852b3048],
37	.	.	O	.	_	0	SENT_60	[p5l655t2969r852b3048],

1	Among	IN	O	among	_	0	SENT_61	[p5l898t2976r1220b3069],
2	the	DT	O	the	det	4	SENT_61	[p5l1261t2969r1391b3047],
3	25	CD	NUMBER	25	num	4	SENT_61	[p5l1435t2974r1534b3047],
4	patients	NNS	O	patient	prep_among	29	SENT_61	[p5l1580t2969r1917b3069],
5	with	IN	O	with	_	0	SENT_61	[p5l1959t2969r2149b3048],
6	non	JJ	O	non	amod	12	SENT_61	[p5l11t3097r647b3175],
7	—	JJ	O	—	amod	12	SENT_61	[p5l11t3097r647b3175],
8	small	JJ	O	small	amod	12	SENT_61	[p5l11t3097r647b3175],
9	—	NN	O	—	nn	12	SENT_61	[p5l11t3097r647b3175],
10	cell	NN	O	cell	nn	12	SENT_61	[p5l11t3097r647b3175],
11	lung	NN	O	lung	nn	12	SENT_61	[p5l691t3096r886b3197],
12	cancer	NN	O	cancer	prep_with	4	SENT_61	[p5l929t3122r1206b3175],
13	who	WP	O	who	nsubjpass	17	SENT_61	[p5l1244t3097r1428b3176],
14	had	VBD	O	have	aux	17	SENT_61	[p5l1475t3097r1631b3175],
15	never	RB	O	never	neg	17	SENT_61	[p5l1676t3122r1905b3176],
16	been	VBN	O	be	auxpass	17	SENT_61	[p5l1949t3097r2149b3175],
17	treated	VBN	O	treat	rcmod	4	SENT_61	[p5l12t3224r302b3303],
18	with	IN	O	with	_	0	SENT_61	[p5l322t3225r512b3304],
19	geﬁtinib	NN	O	geﬁtinib	prep_with	17	SENT_61	[p5l537t3224r919b3325],
20	,	,	O	,	_	0	SENT_61	[p5l537t3224r919b3325],
21	tumor	NN	O	tumor	nn	22	SENT_61	[p5l949t3241r1213b3304],
22	specimens	NNS	O	specimen	nsubj	29	SENT_61	[p5l1236t3225r1683b3325],
23	from	IN	O	from	_	0	SENT_61	[p5l1710t3224r1918b3303],
24	2	CD	NUMBER	2	num	25	SENT_61	[p5l1943t3230r1990b3302],
25	patients	NNS	O	patient	prep_from	22	SENT_61	[p5l2014t3251r2148b3325, p5l12t3353r242b3431],
26	with	IN	O	with	_	0	SENT_61	[p5l266t3352r456b3432],
27	bronchoalveolar	JJ	O	bronchoalveolar	amod	28	SENT_61	[p5l483t3352r1177b3432],
28	carcinoma	NN	O	carcinoma	prep_with	25	SENT_61	[p5l1200t3353r1648b3431],
29	had	VBD	O	have	_	0	SENT_61	[p5l1672t3352r1828b3431],
30	similar	JJ	O	similar	amod	31	SENT_61	[p5l1855t3352r2152b3431],
31	mutations	NNS	O	mutation	dobj	29	SENT_61	[p5l11t3481r445b3560],
32	in	IN	O	in	_	0	SENT_61	[p5l471t3481r553b3558],
33	the	DT	O	the	det	36	SENT_61	[p5l578t3481r708b3559],
34	tyrosine	NN	O	tyrosine	nn	36	SENT_61	[p5l734t3481r1072b3581],
35	kinase	NN	O	kinase	nn	36	SENT_61	[p5l1096t3481r1369b3560],
36	domain	NN	O	domain	prep_in	31	SENT_61	[p5l1395t3481r1721b3559],
37	of	IN	O	of	_	0	SENT_61	[p5l1747t3480r1848b3559],
38	EGFR	NN	ORGANIZATION	egfr	prep_of	36	SENT_61	[p5l1853t3486r2126b3564],
39	.	.	O	.	_	0	SENT_61	[p5l1853t3486r2126b3564],

1	The	DT	O	the	det	2	SENT_62	[p5l138t3608r301b3687],
2	finding	NN	O	finding	nsubj	6	SENT_62	[p5l348t3608r668b3709],
3	of	IN	O	of	_	0	SENT_62	[p5l713t3608r815b3687],
4	heterozygous	JJ	O	heterozygous	amod	5	SENT_62	[p5l843t3609r1421b3709],
5	mutations	NNS	O	mutation	prep_of	2	SENT_62	[p5l1470t3609r1913b3688],
6	suggested	VBD	O	suggest	_	0	SENT_62	[p5l1963t3635r2147b3709, p6l11t20r290b121],

1	that	IN	O	that	dep	4	SENT_63	[p6l318t21r490b99],
2	the	DT	O	the	det	3	SENT_63	[p6l513t20r643b99],
3	mutation	NN	O	mutation	nsubj	4	SENT_63	[p6l670t21r1061b100],
4	caused	VBD	O	cause	_	0	SENT_63	[p6l1088t21r1377b100],
5	a	DT	O	a	det	6	SENT_63	[p6l1402t47r1447b99],
6	gain	NN	O	gain	dobj	4	SENT_63	[p6l1471t21r1654b121],
7	of	IN	O	of	_	0	SENT_63	[p6l1682t20r1782b99],
8	function	NN	O	function	prep_of	6	SENT_63	[p6l1790t20r2149b100],
9	of	IN	O	of	_	0	SENT_63	[p6l12t148r113b227],
10	EGFR	NN	ORGANIZATION	egfr	prep_of	8	SENT_63	[p6l120t154r398b232],
11	.	.	O	.	_	0	SENT_63	[p6l120t154r398b232],

1	Indeed	RB	O	indeed	advmod	13	SENT_64	[p6l428t148r750b244],
2	,	,	O	,	_	0	SENT_64	[p6l428t148r750b244],
3	in	IN	O	in	_	0	SENT_64	[p6l781t149r864b226],
4	transient	JJ	O	transient	amod	6	SENT_64	[p6l891t149r1281b227],
5	transfection	NN	O	transfection	nn	6	SENT_64	[p6l1302t148r1823b227],
6	experiments	NNS	O	experiment	prep_in	13	SENT_64	[p6l1851t149r2147b249, p6l11t293r302b372],
7	,	,	O	,	_	0	SENT_64	[p6l1851t149r2147b249, p6l11t293r302b372],
8	exposure	NN	O	exposure	nsubj	13	SENT_64	[p6l343t302r725b377],
9	to	TO	O	to	_	0	SENT_64	[p6l760t293r839b355],
10	epidermal	JJ	O	epidermal	amod	12	SENT_64	[p6l875t276r1303b377],
11	growth	NN	O	growth	nn	12	SENT_64	[p6l1336t277r1642b377],
12	factor	NN	O	factor	prep_to	8	SENT_64	[p6l1675t276r1923b355],
13	doubled	VBD	O	double	_	0	SENT_64	[p6l1954t276r2148b356, p6l12t405r192b483],
14	or	CC	O	or	_	0	SENT_64	[p6l218t430r308b483],
15	tripled	VBD	O	triple	conj_or	13	SENT_64	[p6l331t404r610b505],
16	the	DT	O	the	det	17	SENT_64	[p6l636t405r765b483],
17	activation	NN	O	activation	dobj	15	SENT_64	[p6l791t405r1201b484],
18	of	IN	O	of	_	0	SENT_64	[p6l1228t404r1329b483],
19	the	DT	O	the	det	21	SENT_64	[p6l1337t405r1466b483],
20	mutant	JJ	O	mutant	amod	21	SENT_64	[p6l1493t421r1807b484],
21	EGFRS	NN	O	egfr	prep_of	17	SENT_64	[p6l1826t410r2144b500],
22	,	,	O	,	_	0	SENT_64	[p6l1826t410r2144b500],
23	as	IN	O	as	conj_or	13	SENT_64	[p6l11t559r94b611],
24	compared	VBN	O	compare	pcomp	23	SENT_64	[p6l138t533r557b633],
25	with	IN	O	with	pcomp	24	SENT_64	[p6l592t533r780b612],
26	the	DT	O	the	det	30	SENT_64	[p6l821t533r948b611],
27	wild	JJ	O	wild	amod	30	SENT_64	[p6l985t532r1374b633],
28	—	NN	O	—	nn	30	SENT_64	[p6l985t532r1374b633],
29	type	NN	O	type	nn	30	SENT_64	[p6l985t532r1374b633],
30	receptor	NN	O	receptor	pobj	25	SENT_64	[p6l1414t549r1777b633],
31	,	,	O	,	_	0	SENT_64	[p6l1414t549r1777b633],
32	and	CC	O	and	_	0	SENT_64	[p6l1822t532r1977b611],
33	the	DT	O	the	det	35	SENT_64	[p6l2018t533r2148b611],
34	mutant	JJ	O	mutant	amod	35	SENT_64	[p6l11t677r330b740],
35	receptors	NNS	O	receptor	nsubj	39	SENT_64	[p6l350t677r750b761],
36	were	VBD	O	be	cop	39	SENT_64	[p6l772t687r978b740],
37	also	RB	O	also	advmod	39	SENT_64	[p6l1001t660r1173b739],
38	more	RBR	O	more	advmod	39	SENT_64	[p6l1198t686r1422b739],
39	sensitive	JJ	O	sensitive	conj_and	13	SENT_64	[p6l1448t661r1818b740],
40	to	TO	O	to	_	0	SENT_64	[p6l1843t677r1923b739],
41	inhibition	NN	O	inhibition	prep_to	39	SENT_64	[p6l1948t660r2149b738, p6l12t789r257b867],
42	by	IN	O	by	_	0	SENT_64	[p6l286t788r383b889],
43	geﬁtinib	NN	O	geﬁtinib	prep_by	39	SENT_64	[p6l407t788r779b889],
44	.	.	O	.	_	0	SENT_64	[p6l407t788r779b889],

1	In	FW	O	in	nn	2	SENT_65	[p6l813t796r899b866],
2	vitro	FW	O	vitro	nsubj	21	SENT_65	[p6l923t789r1136b884],
3	,	,	O	,	_	0	SENT_65	[p6l923t789r1136b884],
4	the	DT	O	the	det	6	SENT_65	[p6l1171t788r1299b867],
5	geﬁtinib	NN	O	geﬁtinib	nn	6	SENT_65	[p6l1327t788r1676b889],
6	concentrations	NNS	O	concentration	appos	2	SENT_65	[p6l1707t805r2149b867, p6l12t917r216b995],
7	needed	VBN	O	need	partmod	6	SENT_65	[p6l240t916r538b995],
8	for	IN	O	for	_	0	SENT_65	[p6l560t916r682b995],
9	50	CD	PERCENT	50	num	11	SENT_65	[p6l702t922r799b995],
10	percent	NN	PERCENT	percent	nn	11	SENT_65	[p6l821t933r1138b1017],
11	inhibition	NN	O	inhibition	prep_for	7	SENT_65	[p6l1153t916r1569b995],
12	and	CC	O	and	_	0	SENT_65	[p6l1589t916r1744b995],
13	complete	JJ	O	complete	amod	14	SENT_65	[p6l1766t917r2149b1017],
14	abrogation	NN	O	abrogation	conj_and	11	SENT_65	[p6l11t1045r475b1145],
15	of	IN	O	of	_	0	SENT_65	[p6l517t1044r618b1123],
16	phosphorylation	NN	O	phosphorylation	prep_of	14	SENT_65	[p6l639t1044r1346b1145],
17	of	IN	O	of	_	0	SENT_65	[p6l1388t1044r1489b1123],
18	the	DT	O	the	det	20	SENT_65	[p6l1512t1045r1642b1123],
19	mutant	JJ	O	mutant	amod	20	SENT_65	[p6l1683t1061r1997b1124],
20	receptors	NNS	O	receptor	prep_of	16	SENT_65	[p6l2033t1071r2147b1123, p6l12t1189r316b1273],
21	correlated	VBD	O	correlate	_	0	SENT_65	[p6l346t1173r762b1251],
22	favorably	RB	O	favorably	advmod	21	SENT_65	[p6l788t1172r1170b1273],
23	with	IN	O	with	_	0	SENT_65	[p6l1188t1172r1376b1252],
24	mean	JJ	O	mean	amod	27	SENT_65	[p6l1401t1198r1634b1251],
25	steady	JJ	O	steady	amod	27	SENT_65	[p6l1661t1172r2149b1273],
26	—	NN	O	—	nn	27	SENT_65	[p6l1661t1172r2149b1273],
27	state	NN	O	state	prep_with	21	SENT_65	[p6l1661t1172r2149b1273],
28	and	CC	O	and	_	0	SENT_65	[p6l11t1300r168b1379],
29	trough	NN	O	trough	nn	30	SENT_65	[p6l207t1301r498b1401],
30	concentrations	NNS	O	concentration	prep_with	21	SENT_65	[p6l538t1301r1184b1379],
31	achieved	VBN	O	achieve	partmod	27	SENT_65	[p6l1225t1300r1598b1380],
32	with	IN	O	with	_	0	SENT_65	[p6l1632t1301r1826b1380],
33	a	DT	O	a	det	35	SENT_65	[p6l1865t1327r1909b1379],
34	daily	JJ	SET	daily	amod	35	SENT_65	[p6l1948t1301r2152b1401],
35	dose	NN	O	dose	prep_with	31	SENT_65	[p6l12t1428r210b1507],
36	of	IN	O	of	_	0	SENT_65	[p6l238t1428r341b1507],
37	250	CD	NUMBER	250	num	38	SENT_65	[p6l348t1434r505b1507],
38	mg	NN	O	mg	prep_of	35	SENT_65	[p6l534t1455r676b1529],
39	of	IN	O	of	_	0	SENT_65	[p6l700t1428r802b1507],
40	geﬁtinib	NN	O	geﬁtinib	prep_of	38	SENT_65	[p6l810t1428r1203b1529],
41	.	.	O	.	_	0	SENT_65	[p6l810t1428r1203b1529],

1	Is	VBZ	O	be	cop	3	SENT_66	[p6l139t1564r211b1635],
2	this	DT	O	this	nsubj	3	SENT_66	[p6l239t1557r393b1635],
3	pattern	NN	O	pattern	_	0	SENT_66	[p6l420t1573r725b1657],
4	of	IN	O	of	_	0	SENT_66	[p6l752t1556r852b1635],
5	somatic	JJ	O	somatic	amod	6	SENT_66	[p6l862t1557r1194b1635],
6	mutations	NNS	O	mutation	prep_of	3	SENT_66	[p6l1219t1557r1653b1636],
7	speciﬁc	VBP	O	speciﬁc	rcmod	6	SENT_66	[p6l1683t1556r2003b1657],
8	for	IN	O	for	_	0	SENT_66	[p6l2028t1556r2152b1635],
9	adenocarcinomas	NNS	O	adenocarcinoma	prep_for	7	SENT_66	[p6l11t1685r750b1763],
10	of	IN	O	of	_	0	SENT_66	[p6l780t1684r881b1763],
11	the	DT	O	the	det	12	SENT_66	[p6l890t1685r1017b1763],
12	lung	NN	O	lung	prep_of	9	SENT_66	[p6l1044t1684r1256b1785],
13	,	,	O	,	_	0	SENT_66	[p6l1044t1684r1256b1785],
14	and	CC	O	and	_	0	SENT_66	[p6l1288t1684r1443b1763],
15	bronchoalveolar	JJ	O	bronchoalveolar	amod	16	SENT_66	[p6l1471t1685r2153b1764],
16	cancer	NN	O	cancer	prep_for	7	SENT_66	[p6l12t1838r286b1892],
17	in	IN	O	in	_	0	SENT_66	[p6l311t1814r393b1891],
18	particular	JJ	O	particular	prep_in	16	SENT_66	[p6l421t1811r869b1914],
19	?	.	O	?	_	0	SENT_66	[p6l421t1811r869b1914],

1	Why	WRB	O	why	advmod	4	SENT_67	[p6l895t1813r1095b1914],
2	does	VBZ	O	do	aux	4	SENT_67	[p6l1119t1813r1312b1892],
3	it	PRP	O	it	nsubj	4	SENT_67	[p6l1343t1814r1403b1892],
4	occur	VB	O	occur	_	0	SENT_67	[p6l1427t1838r1663b1893],
5	most	RBS	O	most	advmod	6	SENT_67	[p6l1688t1829r1906b1892],
6	often	RB	O	often	advmod	4	SENT_67	[p6l1931t1812r2149b1892],
7	among	IN	O	among	_	0	SENT_67	[p6l11t1967r312b2042],
8	patients	NNS	O	patient	prep_among	4	SENT_67	[p6l343t1942r679b2042],
9	who	WP	O	who	nsubj	12	SENT_67	[p6l712t1942r897b2021],
10	have	VBP	O	have	aux	12	SENT_67	[p6l934t1942r1122b2021],
11	never	RB	O	never	neg	12	SENT_67	[p6l1158t1967r1387b2021],
12	smoked	VBN	O	smoke	rcmod	8	SENT_67	[p6l1421t1941r1757b2021],
13	or	CC	O	or	_	0	SENT_67	[p6l1792t1967r1883b2020],
14	those	DT	O	those	prep_among	4	SENT_67	[p6l1916t1942r2147b2020],
15	who	WP	O	who	nsubj	18	SENT_67	[p6l7t2070r192b2150],
16	have	VBP	O	have	aux	18	SENT_67	[p6l239t2070r432b2150],
17	not	RB	O	not	neg	18	SENT_67	[p6l478t2086r625b2149],
18	smoked	VBN	O	smoke	rcmod	14	SENT_67	[p6l668t2070r1009b2150],
19	for	IN	O	for	_	0	SENT_67	[p6l1055t2069r1181b2149],
20	many	JJ	O	many	amod	21	SENT_67	[p6l1224t2096r1463b2171],
21	years	NNS	DURATION	year	prep_for	18	SENT_67	[p6l1500t2068r1762b2171],
22	?	.	O	?	_	0	SENT_67	[p6l1500t2068r1762b2171],

1	Will	MD	O	will	aux	2	SENT_68	[p6l1805t2070r1987b2149],
2	responses	NNS	O	response	ccomp	15	SENT_68	[p6l2032t2096r2147b2149, p6l13t2224r357b2299],
3	to	TO	O	to	_	0	SENT_68	[p6l386t2215r467b2277],
4	erlotinib	NN	O	erlotinib	prep_to	2	SENT_68	[p6l496t2199r891b2294],
5	,	,	O	,	_	0	SENT_68	[p6l496t2199r891b2294],
6	another	DT	O	another	det	11	SENT_68	[p6l923t2199r1261b2277],
7	oral	JJ	O	oral	amod	11	SENT_68	[p6l1286t2198r1452b2277],
8	small	JJ	O	small	amod	11	SENT_68	[p6l1479t2198r2148b2278],
9	—	NN	O	—	nn	11	SENT_68	[p6l1479t2198r2148b2278],
10	molecule	NN	O	molecule	nn	11	SENT_68	[p6l1479t2198r2148b2278],
11	inhibitor	NN	O	inhibitor	nsubj	15	SENT_68	[p6l11t2326r389b2405],
12	of	IN	O	of	_	0	SENT_68	[p6l414t2326r515b2405],
13	EGFR	NN	ORGANIZATION	egfr	prep_of	11	SENT_68	[p6l522t2332r796b2422],
14	,	,	O	,	_	0	SENT_68	[p6l522t2332r796b2422],
15	correlate	VBP	O	correlate	_	0	SENT_68	[p6l830t2326r1199b2405],
16	with	IN	O	with	_	0	SENT_68	[p6l1222t2327r1412b2406],
17	the	DT	O	the	det	19	SENT_68	[p6l1440t2327r1570b2405],
18	same	JJ	O	same	amod	19	SENT_68	[p6l1600t2353r1818b2405],
19	pattern	NN	O	pattern	prep_with	15	SENT_68	[p6l1844t2343r2149b2427],
20	of	IN	O	of	_	0	SENT_68	[p6l12t2454r113b2534],
21	somatic	JJ	O	somatic	amod	22	SENT_68	[p6l132t2456r469b2534],
22	mutations	NNS	O	mutation	prep_of	19	SENT_68	[p6l507t2452r990b2535],
23	?	.	O	?	_	0	SENT_68	[p6l507t2452r990b2535],

1	Is	VBZ	O	be	cop	4	SENT_69	[p6l1027t2462r1100b2534],
2	this	DT	O	this	det	3	SENT_69	[p6l1141t2455r1298b2534],
3	pattern	NN	O	pattern	nsubj	4	SENT_69	[p6l1337t2471r1648b2556],
4	relevant	JJ	O	relevant	_	0	SENT_69	[p6l1687t2455r2032b2535],
5	to	TO	O	to	_	0	SENT_69	[p6l2066t2471r2147b2534],
6	the	DT	O	the	det	7	SENT_69	[p6l12t2584r142b2663],
7	effects	NNS	O	effect	prep_to	4	SENT_69	[p6l170t2583r442b2663],
8	of	IN	O	of	_	0	SENT_69	[p6l472t2583r573b2663],
9	anti	JJ	O	anti	prep_of	7	SENT_69	[p6l581t2585r1040b2668],
10	.	.	O	.	_	0	SENT_69	[p6l581t2585r1040b2668],

1	—	NN	O	—	_	0	SENT_70	[p6l581t2585r1040b2668],
2	.	.	O	.	_	0	SENT_70	[p6l581t2585r1040b2668],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_71	[p6l581t2585r1040b2668],
2	antibodies	NNS	O	antibody	_	0	SENT_71	[p6l1056t2582r1539b2663],
3	?	.	O	?	_	0	SENT_71	[p6l1056t2582r1539b2663],

1	How	WRB	O	how	advmod	2	SENT_72	[p6l1566t2591r1773b2664],
2	do	VBP	O	do	_	0	SENT_72	[p6l1796t2584r1900b2663],
3	these	DT	O	these	det	5	SENT_72	[p6l1929t2584r2149b2663],
4	new	JJ	O	new	amod	5	SENT_72	[p6l11t2738r187b2792],
5	data	NNS	O	datum	dobj	2	SENT_72	[p6l208t2712r386b2791],
6	ﬁt	NN	O	ﬁt	dep	2	SENT_72	[p6l409t2712r501b2791],
7	with	IN	O	with	_	0	SENT_72	[p6l516t2713r704b2792],
8	the	DT	O	the	prep_with	2	SENT_72	[p6l729t2713r858b2791],
9	ﬁnding	VBG	O	ﬁnding	amod	8	SENT_72	[p6l883t2712r1193b2813],
10	that	IN	O	that	complm	26	SENT_72	[p6l1214t2712r1381b2791],
11	more	JJR	O	more	mwe	12	SENT_72	[p6l1400t2738r1619b2791],
12	than	IN	O	than	quantmod	13	SENT_72	[p6l1644t2713r1831b2791],
13	30	CD	PERCENT	30	num	14	SENT_72	[p6l1857t2718r1956b2791],
14	percent	NN	PERCENT	percent	nsubj	26	SENT_72	[p6l1980t2739r2148b2813, p6l12t2857r190b2919],
15	of	IN	O	of	_	0	SENT_72	[p6l209t2840r311b2919],
16	patients	NNS	O	patient	prep_of	14	SENT_72	[p6l317t2841r661b2941],
17	who	WP	O	who	nsubj	18	SENT_72	[p6l685t2841r872b2920],
18	received	VBD	O	receive	rcmod	16	SENT_72	[p6l899t2840r1250b2920],
19	geﬁtinib	NN	O	geﬁtinib	dobj	18	SENT_72	[p6l1275t2840r1641b2941],
20	in	IN	O	in	_	0	SENT_72	[p6l1667t2841r1751b2918],
21	the	DT	O	the	det	23	SENT_72	[p6l1776t2841r1909b2919],
22	large	JJ	O	large	amod	23	SENT_72	[p6l1934t2841r2148b2941],
23	phase	NN	O	phase	prep_in	18	SENT_72	[p6l10t2969r262b3070],
24	2	CD	NUMBER	2	num	25	SENT_72	[p6l297t2975r345b3047],
25	trials	NNS	O	trial	dep	23	SENT_72	[p6l381t2969r594b3048],
26	had	VBD	O	have	dep	8	SENT_72	[p6l631t2969r790b3048],
27	stable	JJ	O	stable	amod	28	SENT_72	[p6l826t2969r1079b3048],
28	disease	NN	O	disease	dobj	26	SENT_72	[p6l1115t2967r1459b3048],
29	?	.	O	?	_	0	SENT_72	[p6l1115t2967r1459b3048],

1	Did	VBD	O	do	aux	5	SENT_73	[p6l1491t2969r1644b3048],
2	those	DT	O	those	det	3	SENT_73	[p6l1676t2969r1905b3048],
3	trials	NNS	O	trial	nsubj	5	SENT_73	[p6l1938t2969r2147b3048],
4	really	RB	O	really	advmod	5	SENT_73	[p6l11t3098r238b3198],
5	show	VBP	O	show	_	0	SENT_73	[p6l259t3098r484b3177],
6	an	DT	O	a	det	7	SENT_73	[p6l503t3123r603b3176],
7	effect	NN	O	effect	dobj	5	SENT_73	[p6l627t3097r859b3176],
8	of	IN	O	of	_	0	SENT_73	[p6l878t3097r978b3176],
9	geﬁtinib	NN	O	geﬁtinib	prep_of	7	SENT_73	[p6l983t3097r1360b3198],
10	,	,	O	,	_	0	SENT_73	[p6l983t3097r1360b3198],
11	or	CC	O	or	_	0	SENT_73	[p6l1389t3123r1478b3176],
12	were	VBD	O	be	conj_or	5	SENT_73	[p6l1493t3124r1695b3177],
13	we	PRP	O	we	nsubj	12	SENT_73	[p6l1714t3124r1832b3177],
14	overin	VBP	O	overin	rcmod	13	SENT_73	[p6l1857t3098r2148b3177],
15	—	JJ	O	—	amod	18	SENT_73	[p6l1857t3098r2148b3177],
16	terpreting	NN	O	terpreting	nn	18	SENT_73	[p6l12t3227r429b3327],
17	noncomparative	JJ	O	noncomparative	amod	18	SENT_73	[p6l448t3227r1128b3327],
18	phase	NN	O	phase	dobj	14	SENT_73	[p6l1150t3226r1394b3327],
19	2	CD	NUMBER	2	num	20	SENT_73	[p6l1417t3232r1465b3304],
20	data	NNS	O	datum	dep	18	SENT_73	[p6l1489t3224r1703b3305],
21	?	.	O	?	_	0	SENT_73	[p6l1489t3224r1703b3305],

1	These	DT	O	these	nsubj	6	SENT_74	[p6l1723t3226r1972b3305],
2	and	CC	O	and	_	0	SENT_74	[p6l1995t3226r2150b3305],
3	many	JJ	O	many	amod	5	SENT_74	[p6l11t3380r246b3455],
4	other	JJ	O	other	amod	5	SENT_74	[p6l268t3354r493b3433],
5	questions	NNS	O	question	nsubj	6	SENT_74	[p6l516t3355r925b3455],
6	remain	VBP	O	remain	_	0	SENT_74	[p6l952t3355r1252b3433],
7	to	TO	O	to	aux	9	SENT_74	[p6l1278t3371r1357b3433],
8	be	VB	O	be	auxpass	9	SENT_74	[p6l1384t3355r1480b3433],
9	investigated	VBN	O	investigate	xcomp	6	SENT_74	[p6l1505t3355r2038b3455],
10	.	.	O	.	_	0	SENT_74	[p6l1505t3355r2038b3455],

1	Does	VBZ	O	do	csubj	23	SENT_75	[p6l139t3489r354b3561],
2	the	DT	O	the	dobj	1	SENT_75	[p6l381t3482r512b3561],
3	ﬁnding	VBG	O	ﬁnding	amod	2	SENT_75	[p6l538t3482r858b3583],
4	that	IN	O	that	complm	15	SENT_75	[p6l879t3483r1051b3561],
5	one	CD	NUMBER	one	num	6	SENT_75	[p6l1070t3508r1226b3561],
6	patient	NN	O	patient	nsubj	15	SENT_75	[p6l1249t3483r1556b3583],
7	who	WP	O	who	nsubj	8	SENT_75	[p6l1570t3483r1757b3562],
8	had	VBD	O	have	rcmod	6	SENT_75	[p6l1783t3483r1941b3561],
9	a	DT	O	a	det	10	SENT_75	[p6l1965t3509r2009b3561],
10	response	NN	O	response	dobj	8	SENT_75	[p6l2032t3509r2147b3561, p6l13t3636r314b3711],
11	to	TO	O	to	_	0	SENT_75	[p6l356t3627r437b3689],
12	geﬁtinib	NN	O	geﬁtinib	prep_to	10	SENT_75	[p6l479t3610r846b3711],
13	did	VBD	O	do	aux	15	SENT_75	[p6l889t3611r1025b3689],
14	not	RB	O	not	neg	15	SENT_75	[p6l1066t3627r1213b3689],
15	have	VB	O	have	dep	2	SENT_75	[p6l1249t3611r1442b3690],
16	a	DT	O	a	det	17	SENT_75	[p6l1483t3637r1527b3689],
17	tumor	NN	O	tumor	dobj	15	SENT_75	[p6l1567t3627r1836b3690],
18	with	IN	O	with	_	0	SENT_75	[p6l1870t3611r2064b3690],
19	a	DT	O	a	det	20	SENT_75	[p6l2105t3637r2149b3689],
20	mutation	NN	O	mutation	prep_with	17	SENT_75	[p7l11t21r403b100],
21	in	IN	O	in	_	0	SENT_75	[p7l425t21r507b98],
22	EGFR	NN	ORGANIZATION	egfr	prep_in	20	SENT_75	[p7l527t27r741b100],
23	signify	VBP	O	signify	_	0	SENT_75	[p7l759t20r1046b121],
24	that	IN	O	that	complm	36	SENT_75	[p7l1064t21r1232b99],
25	other	JJ	O	other	amod	27	SENT_75	[p7l1250t20r1476b99],
26	facilitating	VBG	O	facilitate	amod	27	SENT_75	[p7l1495t20r1957b121],
27	mutations	NNS	O	mutation	nsubj	36	SENT_75	[p7l1976t47r2148b100, p7l12t149r303b227],
28	in	IN	O	in	_	0	SENT_75	[p7l340t149r423b226],
29	non	JJ	O	non	amod	35	SENT_75	[p7l457t148r1107b227],
30	—	JJ	O	—	amod	35	SENT_75	[p7l457t148r1107b227],
31	small	JJ	O	small	amod	35	SENT_75	[p7l457t148r1107b227],
32	—	NN	O	—	nn	35	SENT_75	[p7l457t148r1107b227],
33	cell	NN	O	cell	nn	35	SENT_75	[p7l457t148r1107b227],
34	lung	NN	O	lung	nn	35	SENT_75	[p7l1140t149r1339b249],
35	cancer	NN	O	cancer	prep_in	27	SENT_75	[p7l1371t174r1653b227],
36	have	VBP	O	have	ccomp	23	SENT_75	[p7l1685t149r1878b228],
37	yet	RB	O	yet	advmod	36	SENT_75	[p7l1909t165r2036b249],
38	to	TO	O	to	aux	40	SENT_75	[p7l2066t165r2147b227],
39	be	VB	O	be	auxpass	40	SENT_75	[p7l12t277r109b356],
40	identified	VBN	O	identify	xcomp	36	SENT_75	[p7l146t275r602b356],
41	?	.	O	?	_	0	SENT_75	[p7l146t275r602b356],

1	Does	VBZ	O	do	csubj	4	SENT_76	[p7l638t284r853b356],
2	this	DT	O	this	nsubj	3	SENT_76	[p7l893t277r1050b356],
3	ﬁnding	JJ	O	ﬁnding	xcomp	1	SENT_76	[p7l1089t276r1409b378],
4	suggest	VBP	O	suggest	_	0	SENT_76	[p7l1445t293r1779b378],
5	that	IN	O	that	complm	9	SENT_76	[p7l1813t277r1983b356],
6	the	DT	O	the	det	7	SENT_76	[p7l2016t277r2148b356],
7	mutation	NN	O	mutation	nsubj	9	SENT_76	[p7l11t406r411b485],
8	is	VBZ	O	be	cop	9	SENT_76	[p7l442t406r508b484],
9	unstable	JJ	O	unstable	ccomp	4	SENT_76	[p7l543t406r914b485],
10	and	CC	O	and	_	0	SENT_76	[p7l946t406r1105b484],
11	heterogeneous	JJ	O	heterogeneous	conj_and	9	SENT_76	[p7l1137t405r1776b506],
12	with	IN	O	with	_	0	SENT_76	[p7l1806t406r2000b485],
13	respect	NN	O	respect	prep_with	9	SENT_76	[p7l2032t432r2147b484, p7l13t550r238b635],
14	to	TO	O	to	_	0	SENT_76	[p7l259t550r340b613],
15	the	DT	O	the	det	17	SENT_76	[p7l366t534r498b613],
16	tumor	NN	O	tumor	nn	17	SENT_76	[p7l524t550r793b614],
17	burden	NN	O	burden	prep_to	9	SENT_76	[p7l816t534r1124b614],
18	as	IN	O	as	_	0	SENT_76	[p7l1148t560r1234b613],
19	a	DT	O	a	det	20	SENT_76	[p7l1260t560r1304b613],
20	whole	NN	O	whole	prep_as	9	SENT_76	[p7l1322t532r1622b614],
21	?	.	O	?	_	0	SENT_76	[p7l1322t532r1622b614],

1	Or	CC	O	or	cc	14	SENT_77	[p7l1648t540r1776b630],
2	,	,	O	,	_	0	SENT_77	[p7l1648t540r1776b630],
3	because	IN	O	because	mark	9	SENT_77	[p7l1807t534r2148b614],
4	multifocal	JJ	O	multifocal	amod	6	SENT_77	[p7l11t662r438b742],
5	bronchoalveolar	JJ	O	bronchoalveolar	amod	6	SENT_77	[p7l464t662r1146b742],
6	carcinoma	NN	O	carcinoma	nsubj	9	SENT_77	[p7l1169t663r1609b741],
7	may	MD	O	may	aux	9	SENT_77	[p7l1633t689r1809b763],
8	be	VB	O	be	cop	9	SENT_77	[p7l1831t663r1926b741],
9	multiclonal	JJ	O	multiclonal	dep	14	SENT_77	[p7l1952t663r2148b742, p7l12t785r436b886],
10	,1	NN	O	,1	nn	11	SENT_77	[p7l1952t663r2148b742, p7l12t785r436b886],
11	°	NN	O	°	nsubj	14	SENT_77	[p7l1952t663r2148b742, p7l12t785r436b886],
12	is	VBZ	O	be	cop	14	SENT_77	[p7l461t792r527b869],
13	it	PRP	O	it	npadvmod	14	SENT_77	[p7l555t792r616b869],
14	possible	JJ	O	possible	_	0	SENT_77	[p7l635t791r990b891],
15	that	IN	O	that	complm	21	SENT_77	[p7l1014t791r1182b869],
16	this	DT	O	this	det	18	SENT_77	[p7l1201t791r1355b869],
17	one	CD	NUMBER	one	num	18	SENT_77	[p7l1382t816r1535b869],
18	specimen	NN	O	specimen	nsubj	21	SENT_77	[p7l1561t792r1965b891],
19	was	VBD	O	be	cop	21	SENT_77	[p7l1985t817r2147b870],
20	truly	RB	O	truly	advmod	21	SENT_77	[p7l12t919r206b1019],
21	negative	JJ	O	negative	ccomp	14	SENT_77	[p7l229t919r583b1019],
22	for	IN	O	for	_	0	SENT_77	[p7l613t918r739b997],
23	mutations	NNS	O	mutation	prep_for	21	SENT_77	[p7l766t919r1208b998],
24	and	CC	O	and	_	0	SENT_77	[p7l1240t919r1399b997],
25	that	IN	O	that	complm	41	SENT_77	[p7l1429t919r1600b997],
26	other	JJ	O	other	amod	28	SENT_77	[p7l1626t919r1855b997],
27	tumor	NN	O	tumor	nn	28	SENT_77	[p7l1883t935r2151b998],
28	cells	NNS	O	cell	nsubj	41	SENT_77	[p7l12t1046r227b1142],
29	,	,	O	,	_	0	SENT_77	[p7l12t1046r227b1142],
30	which	WDT	O	which	nsubj	31	SENT_77	[p7l251t1046r517b1126],
31	were	VBD	O	be	rcmod	28	SENT_77	[p7l535t1073r742b1126],
32	not	RB	O	not	neg	31	SENT_77	[p7l765t1063r911b1125],
33	in	IN	O	in	_	0	SENT_77	[p7l928t1047r1011b1124],
34	the	DT	O	the	det	36	SENT_77	[p7l1034t1047r1166b1125],
35	tested	VBN	O	test	amod	36	SENT_77	[p7l1190t1047r1445b1125],
36	specimen	NN	O	specimen	prep_in	31	SENT_77	[p7l1469t1047r1906b1147],
37	,	,	O	,	_	0	SENT_77	[p7l1469t1047r1906b1147],
38	actu	NN	O	actu	nn	40	SENT_77	[p7l1934t1063r2147b1126],
39	—	CD	NUMBER	—	num	40	SENT_77	[p7l1934t1063r2147b1126],
40	ally	NN	O	ally	appos	36	SENT_77	[p7l11t1174r160b1275],
41	carried	VBD	O	carry	conj_and	21	SENT_77	[p7l194t1175r488b1253],
42	the	DT	O	the	det	43	SENT_77	[p7l521t1175r650b1253],
43	mutation	NN	O	mutation	dobj	41	SENT_77	[p7l684t1175r1074b1254],
44	that	WDT	O	that	nsubj	46	SENT_77	[p7l1109t1175r1277b1253],
45	was	VBD	O	be	cop	46	SENT_77	[p7l1302t1201r1464b1254],
46	responsible	JJ	O	responsible	rcmod	43	SENT_77	[p7l1500t1174r1994b1275],
47	for	IN	O	for	_	0	SENT_77	[p7l2028t1174r2152b1253],
48	the	DT	O	the	det	49	SENT_77	[p7l12t1303r142b1382],
49	response	NN	O	response	prep_for	46	SENT_77	[p7l167t1329r549b1404],
50	to	TO	O	to	_	0	SENT_77	[p7l574t1319r654b1382],
51	geﬁtinib	NN	O	geﬁtinib	prep_to	46	SENT_77	[p7l680t1300r1077b1404],
52	?	.	O	?	_	0	SENT_77	[p7l680t1300r1077b1404],

1	Can	MD	O	can	_	0	SENT_78	[p7l141t1437r308b1510],
2	a	DT	O	a	det	3	SENT_78	[p7l343t1458r388b1510],
3	therapy	NN	O	therapy	nsubj	1	SENT_78	[p7l422t1432r747b1532],
4	that	WDT	O	that	nsubj	5	SENT_78	[p7l779t1432r950b1510],
5	causes	VBZ	O	cause	dep	1	SENT_78	[p7l981t1458r1260b1511],
6	tumor	NN	O	tumor	nn	7	SENT_78	[p7l1299t1448r1567b1511],
7	shrinkage	NN	O	shrinkage	nsubjpass	19	SENT_78	[p7l1601t1431r2030b1532],
8	in	IN	O	in	_	0	SENT_78	[p7l2066t1432r2148b1509],
9	only	RB	O	only	advmod	12	SENT_78	[p7l12t1559r198b1660],
10	a	DT	O	a	det	12	SENT_78	[p7l219t1586r264b1638],
11	small	JJ	O	small	amod	12	SENT_78	[p7l290t1560r523b1638],
12	subgroup	NN	O	subgroup	prep_in	7	SENT_78	[p7l548t1559r953b1660],
13	of	IN	O	of	_	0	SENT_78	[p7l980t1559r1081b1638],
14	patients	NNS	O	patient	prep_of	12	SENT_78	[p7l1086t1560r1422b1660],
15	with	IN	O	with	_	0	SENT_78	[p7l1444t1560r1635b1639],
16	lung	NN	O	lung	nn	17	SENT_78	[p7l1658t1559r1853b1660],
17	cancer	NN	O	cancer	prep_with	14	SENT_78	[p7l1875t1585r2152b1638],
18	be	VB	O	be	auxpass	19	SENT_78	[p7l12t1688r108b1767],
19	considered	VBN	O	consider	ccomp	5	SENT_78	[p7l131t1688r596b1767],
20	meaningful	JJ	O	meaningful	acomp	19	SENT_78	[p7l617t1686r1148b1789],
21	?	.	O	?	_	0	SENT_78	[p7l617t1686r1148b1789],

1	The	DT	O	the	det	2	SENT_79	[p7l1166t1688r1329b1767],
2	answer	NN	O	answer	nsubj	3	SENT_79	[p7l1350t1714r1656b1768],
3	is	VBZ	O	be	_	0	SENT_79	[p7l1674t1689r1739b1767],
4	in	IN	O	in	_	0	SENT_79	[p7l1762t1689r1844b1766],
5	the	DT	O	the	det	6	SENT_79	[p7l1866t1688r1996b1767],
6	denominator	NN	O	denominator	prep_in	3	SENT_79	[p7l2018t1688r2148b1767, p7l11t1817r489b1895],
7	:	:	O	:	_	0	SENT_79	[p7l2018t1688r2148b1767, p7l11t1817r489b1895],
8	each	DT	SET	each	det	9	SENT_79	[p7l523t1817r715b1895],
9	year	NN	SET	year	tmod	24	SENT_79	[p7l739t1843r933b1917],
10	,	,	O	,	_	0	SENT_79	[p7l739t1843r933b1917],
11	more	JJR	O	more	mwe	12	SENT_79	[p7l968t1842r1189b1895],
12	than	IN	O	than	quantmod	13	SENT_79	[p7l1219t1816r1408b1895],
13	140,000	CD	NUMBER	140,000	num	14	SENT_79	[p7l1441t1822r1781b1912],
14	patients	NNS	O	patient	nsubjpass	24	SENT_79	[p7l1810t1817r2147b1917],
15	with	IN	O	with	_	0	SENT_79	[p7l7t1944r197b2024],
16	non	JJ	O	non	amod	22	SENT_79	[p7l237t1944r873b2023],
17	—	JJ	O	—	amod	22	SENT_79	[p7l237t1944r873b2023],
18	small	JJ	O	small	amod	22	SENT_79	[p7l237t1944r873b2023],
19	—	NN	O	—	nn	22	SENT_79	[p7l237t1944r873b2023],
20	cell	NN	O	cell	nn	22	SENT_79	[p7l237t1944r873b2023],
21	lung	NN	O	lung	nn	22	SENT_79	[p7l911t1945r1106b2045],
22	cancer	NN	O	cancer	prep_with	14	SENT_79	[p7l1143t1970r1420b2023],
23	are	VBP	O	be	auxpass	24	SENT_79	[p7l1456t1971r1583b2023],
24	identified	VBN	O	identify	parataxis	3	SENT_79	[p7l1622t1944r2029b2023],
25	in	IN	O	in	_	0	SENT_79	[p7l2067t1945r2149b2022],
26	the	DT	O	the	det	28	SENT_79	[p7l12t2072r141b2151],
27	United	NNP	LOCATION	United	nn	28	SENT_79	[p7l178t2073r465b2152],
28	States	NNPS	LOCATION	States	prep_in	24	SENT_79	[p7l504t2078r750b2152],
29	alone	RB	O	alone	amod	28	SENT_79	[p7l788t2072r1042b2167],
30	,	,	O	,	_	0	SENT_79	[p7l788t2072r1042b2167],
31	and	CC	O	and	_	0	SENT_79	[p7l1084t2072r1241b2152],
32	more	JJR	O	more	mwe	33	SENT_79	[p7l1278t2098r1499b2152],
33	than	IN	O	than	quantmod	35	SENT_79	[p7l1536t2073r1725b2151],
34	a	DT	O	a	quantmod	35	SENT_79	[p7l1762t2099r1806b2151],
35	million	CD	NUMBER	million	conj_and	28	SENT_79	[p7l1841t2072r2149b2152],

1	2192	CD	DATE	2192	num	3	SENT_80	[p7l149t2242r226b2264],
2	N	NN	O	n	nn	3	SENT_80	[p7l908t2244r922b2259],
3	ENGLJ	NN	O	englj	_	0	SENT_80	[p7l937t2243r1021b2265],
4	MED	VBD	O	med	partmod	3	SENT_80	[p7l1036t2244r1089b2259],
5	35o	CD	NUMBER	35o	dobj	4	SENT_80	[p7l1101t2243r1180b2265],
6	;	:	O	;	_	0	SENT_80	[p7l1101t2243r1180b2265],
7	21	CD	NUMBER	21	dep	3	SENT_80	[p7l1101t2243r1180b2265],
8	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	9	SENT_80	[p7l1217t2243r1429b2265],
9	MAY	NNP	DATE	MAY	dep	7	SENT_80	[p7l1468t2243r1519b2259],
10	20	CD	DATE	20	num	9	SENT_80	[p7l1531t2243r1570b2263],
11	,	,	DATE	,	_	0	SENT_80	[p7l1531t2243r1570b2263],
12	2004	CD	DATE	2004	num	9	SENT_80	[p7l1583t2243r1651b2265],

1	The	DT	O	the	det	4	SENT_81	[p7l936t2276r987b2300],
2	New	NNP	O	New	nn	4	SENT_81	[p7l996t2277r1058b2300],
3	England	NNP	O	England	nn	4	SENT_81	[p7l1067t2276r1178b2307],
4	Journal	NNP	O	Journal	_	0	SENT_81	[p7l1187t2276r1284b2300],
5	of	IN	O	of	_	0	SENT_81	[p7l1294t2276r1323b2300],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_81	[p7l1330t2276r1455b2300],

1	Downloaded	VBN	O	download	_	0	SENT_82	[p7l378t2317r548b2340],
2	from	IN	O	from	_	0	SENT_82	[p7l557t2317r621b2340],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_82	[p7l630t2317r748b2347],
4	at	IN	O	at	_	0	SENT_82	[p7l759t2321r782b2340],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_82	[p7l790t2317r973b2340],
6	on	IN	O	on	_	0	SENT_82	[p7l982t2324r1015b2340],
7	January	NNP	DATE	January	prep_on	1	SENT_82	[p7l1023t2317r1126b2347],
8	5	CD	DATE	5	num	7	SENT_82	[p7l1136t2317r1159b2344],
9	,	,	DATE	,	_	0	SENT_82	[p7l1136t2317r1159b2344],
10	2014	CD	DATE	2014	num	7	SENT_82	[p7l1170t2317r1242b2340],
11	.	.	O	.	_	0	SENT_82	[p7l1170t2317r1242b2340],

1	For	IN	O	for	_	0	SENT_83	[p7l1252t2317r1299b2340],
2	personal	JJ	O	personal	amod	3	SENT_83	[p7l1307t2317r1419b2347],
3	use	NN	O	use	pobj	1	SENT_83	[p7l1428t2324r1472b2340],
4	only	RB	O	only	advmod	3	SENT_83	[p7l1482t2317r1546b2347],
5	.	.	O	.	_	0	SENT_83	[p7l1482t2317r1546b2347],

1	No	DT	O	no	det	3	SENT_84	[p7l1557t2317r1597b2340],
2	other	JJ	O	other	amod	3	SENT_84	[p7l1607t2317r1675b2340],
3	uses	NNS	O	use	_	0	SENT_84	[p7l1683t2324r1739b2340],
4	without	IN	O	without	_	0	SENT_84	[p7l1749t2317r1850b2340],
5	permission	NN	O	permission	prep_without	3	SENT_84	[p7l1859t2317r2011b2347],
6	.	.	O	.	_	0	SENT_84	[p7l1859t2317r2011b2347],

1	Copyright	NN	O	copyright	_	0	SENT_85	[p7l728t2358r863b2389],
2	©	CD	NUMBER	©	num	6	SENT_85	[p7l872t2358r896b2382],
3	2004	CD	DATE	2004	num	6	SENT_85	[p7l906t2358r971b2382],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_85	[p7l980t2358r1171b2382],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_85	[p7l1181t2358r1289b2382],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_85	[p7l1300t2358r1405b2389],
7	.	.	O	.	_	0	SENT_85	[p7l1300t2358r1405b2389],

1	All	DT	O	all	det	2	SENT_86	[p7l1416t2358r1457b2382],
2	rights	NNS	O	rights	nsubj	3	SENT_86	[p7l1466t2358r1541b2389],
3	reserved	VBN	O	reserve	_	0	SENT_86	[p7l1551t2358r1670b2382],
4	.	.	O	.	_	0	SENT_86	[p7l1551t2358r1670b2382],

1	EDITORIALS	NNS	O	editorial	_	0	SENT_87	[p7l979t2464r1181b2483],

1	are	VBP	O	be	auxpass	2	SENT_88	[p7l11t2705r139b2757],
2	identiﬁed	VBN	O	identiﬁed	_	0	SENT_88	[p7l178t2678r594b2757],
3	worldwide	RB	O	worldwide	advmod	2	SENT_88	[p7l629t2678r1115b2758],
4	.	.	O	.	_	0	SENT_88	[p7l629t2678r1115b2758],

1	Most	JJS	O	most	nsubj	7	SENT_89	[p7l1157t2686r1381b2757],
2	of	IN	O	of	_	0	SENT_89	[p7l1416t2678r1518b2757],
3	these	DT	O	these	det	4	SENT_89	[p7l1539t2679r1764b2757],
4	patients	NNS	O	patient	prep_of	1	SENT_89	[p7l1802t2679r2146b2779],
5	will	MD	O	will	aux	7	SENT_89	[p7l7t2807r165b2886],
6	eventually	RB	O	eventually	advmod	7	SENT_89	[p7l186t2807r612b2907],
7	require	VB	O	require	_	0	SENT_89	[p7l629t2807r930b2907],
8	systemic	JJ	O	systemic	amod	9	SENT_89	[p7l952t2807r1316b2907],
9	therapy	NN	O	therapy	dobj	7	SENT_89	[p7l1337t2807r1667b2907],
10	.	.	O	.	_	0	SENT_89	[p7l1337t2807r1667b2907],

1	Even	RB	O	even	advmod	9	SENT_90	[p7l1692t2814r1894b2886],
2	if	IN	O	if	dep	9	SENT_90	[p7l1914t2806r1990b2884],
3	less	JJR	O	less	mwe	4	SENT_90	[p7l1992t2807r2148b2885],
4	than	IN	O	than	quantmod	5	SENT_90	[p7l12t2934r199b3013],
5	10	CD	PERCENT	10	num	6	SENT_90	[p7l224t2940r320b3013],
6	percent	NN	PERCENT	percent	nsubj	9	SENT_90	[p7l340t2951r659b3035],
7	of	IN	O	of	_	0	SENT_90	[p7l675t2934r776b3013],
8	them	PRP	O	they	prep_of	6	SENT_90	[p7l778t2935r994b3013],
9	have	VBP	O	have	advcl	22	SENT_90	[p7l1014t2935r1203b3014],
10	tumors	NNS	O	tumor	dobj	9	SENT_90	[p7l1223t2951r1524b3014],
11	with	IN	O	with	_	0	SENT_90	[p7l1541t2935r1730b3014],
12	a	DT	O	a	det	14	SENT_90	[p7l1750t2961r1795b3013],
13	gain	NN	O	gain	nn	14	SENT_90	[p7l1813t2934r2148b3035],
14	—	NN	O	—	prep_with	9	SENT_90	[p7l1813t2934r2148b3035],
15	of	IN	O	of	_	0	SENT_90	[p7l1813t2934r2148b3035],
16	—	CD	NUMBER	—	num	18	SENT_90	[p7l1813t2934r2148b3035],
17	function	NN	O	function	nn	18	SENT_90	[p7l12t3062r363b3142],
18	mutation	NN	O	mutation	prep_of	14	SENT_90	[p7l386t3063r792b3158],
19	,	,	O	,	_	0	SENT_90	[p7l386t3063r792b3158],
20	we	PRP	O	we	nsubjpass	22	SENT_90	[p7l817t3089r934b3142],
21	are	VBP	O	be	auxpass	22	SENT_90	[p7l958t3089r1082b3141],
22	left	VBN	O	leave	_	0	SENT_90	[p7l1105t3062r1242b3141],
23	with	IN	O	with	_	0	SENT_90	[p7l1256t3062r1443b3142],
24	many	JJ	O	many	amod	25	SENT_90	[p7l1466t3088r1699b3163],
25	thousands	NNS	O	thousand	prep_with	22	SENT_90	[p7l1718t3062r2148b3142],
26	in	IN	O	in	_	0	SENT_90	[p7l11t3191r91b3268],
27	whom	WP	O	whom	rel	31	SENT_90	[p7l112t3191r386b3270],
28	geﬁtinib	NN	O	geﬁtinib	nsubjpass	31	SENT_90	[p7l413t3190r770b3291],
29	would	MD	O	would	aux	31	SENT_90	[p7l795t3191r1062b3270],
30	be	VB	O	be	auxpass	31	SENT_90	[p7l1091t3191r1186b3269],
31	indicated	VBN	O	indicate	rcmod	25	SENT_90	[p7l1214t3190r1629b3286],
32	,	,	O	,	_	0	SENT_90	[p7l1214t3190r1629b3286],
33	probably	RB	O	probably	advmod	22	SENT_90	[p7l1661t3190r2040b3291],
34	as	IN	O	as	_	0	SENT_90	[p7l2063t3217r2147b3269],
35	ﬁrst	NN	O	ﬁrst	nn	38	SENT_90	[p7l12t3318r365b3397],
36	—	CD	NUMBER	—	num	38	SENT_90	[p7l12t3318r365b3397],
37	line	NN	O	line	nn	38	SENT_90	[p7l12t3318r365b3397],
38	therapy	NN	O	therapy	prep_as	22	SENT_90	[p7l387t3319r699b3419],
39	for	IN	O	for	_	0	SENT_90	[p7l716t3318r837b3397],
40	advanced	JJ	O	advanced	amod	41	SENT_90	[p7l855t3319r1240b3398],
41	disease	NN	O	disease	prep_for	38	SENT_90	[p7l1262t3318r1582b3397],
42	.	.	O	.	_	0	SENT_90	[p7l1262t3318r1582b3397],

1	Phase	NN	O	phase	amod	3	SENT_91	[p7l1608t3319r1848b3397],
2	3	CD	NUMBER	3	number	1	SENT_91	[p7l1871t3324r1916b3397],
3	studies	NNS	O	study	nsubj	7	SENT_91	[p7l1941t3318r2149b3398, p7l11t3447r120b3525],
4	of	IN	O	of	_	0	SENT_91	[p7l160t3446r260b3525],
5	adjuvant	JJ	O	adjuvant	amod	6	SENT_91	[p7l281t3446r644b3547],
6	geﬁtinib	NN	O	geﬁtinib	prep_of	3	SENT_91	[p7l678t3446r1035b3547],
7	are	VBP	O	be	_	0	SENT_91	[p7l1076t3473r1203b3525],
8	already	RB	O	already	advmod	7	SENT_91	[p7l1242t3446r1547b3547],
9	under	IN	O	under	_	0	SENT_91	[p7l1583t3447r1833b3526],
10	way	NN	O	way	prep_under	7	SENT_91	[p7l1865t3473r2033b3547],
11	in	IN	O	in	_	0	SENT_91	[p7l2067t3447r2149b3524],
12	patients	NNS	O	patient	prep_in	10	SENT_91	[p7l10t3575r347b3675],
13	with	IN	O	with	_	0	SENT_91	[p7l385t3574r575b3654],
14	completely	RB	O	completely	advmod	15	SENT_91	[p7l616t3575r1082b3675],
15	resected	JJ	O	resected	amod	17	SENT_91	[p7l1117t3574r1465b3653],
16	non	JJ	O	non	amod	17	SENT_91	[p7l1504t3574r2149b3653],
17	—	NN	O	—	prep_with	12	SENT_91	[p7l1504t3574r2149b3653],
18	small	JJ	O	small	amod	22	SENT_91	[p7l1504t3574r2149b3653],
19	—	NN	O	—	nn	22	SENT_91	[p7l1504t3574r2149b3653],
20	cell	NN	O	cell	nn	22	SENT_91	[p7l1504t3574r2149b3653],
21	lung	NN	O	lung	nn	22	SENT_91	[p7l11t3703r207b3803],
22	cancer	NN	O	cancer	dep	17	SENT_91	[p7l226t3728r520b3781],
23	.	.	O	.	_	0	SENT_91	[p7l226t3728r520b3781],

1	Studies	NNS	O	study	_	0	SENT_92	[p7l550t3702r854b3782],
2	integrating	VBG	O	integrate	partmod	1	SENT_92	[p7l877t3703r1351b3803],
3	geﬁtinib	NN	O	geﬁtinib	dobj	2	SENT_92	[p7l1369t3702r1726b3803],
4	in	IN	O	in	_	0	SENT_92	[p7l1749t3703r1831b3780],
5	the	DT	O	the	det	6	SENT_92	[p7l1853t3703r1983b3781],
6	initial	JJ	O	initial	prep_in	3	SENT_92	[p7l2005t3703r2148b3780, p8l12t21r143b99],

1	treatment	NN	O	treatment	nsubj	20	SENT_93	[p8l178t37r603b99],
2	of	IN	O	of	_	0	SENT_93	[p8l634t20r737b99],
3	locally	RB	O	locally	advmod	4	SENT_93	[p8l751t20r1033b121],
4	advanced	JJ	O	advanced	amod	6	SENT_93	[p8l1062t20r1464b100],
5	non	JJ	O	non	amod	6	SENT_93	[p8l1499t20r2149b99],
6	—	NN	O	—	prep_of	1	SENT_93	[p8l1499t20r2149b99],
7	small	JJ	O	small	amod	11	SENT_93	[p8l1499t20r2149b99],
8	—	NN	O	—	nn	11	SENT_93	[p8l1499t20r2149b99],
9	cell	NN	O	cell	nn	11	SENT_93	[p8l1499t20r2149b99],
10	lung	NN	O	lung	nn	11	SENT_93	[p8l11t149r209b249],
11	cancer	NN	O	cancer	dep	6	SENT_93	[p8l258t174r536b227],
12	as	IN	O	as	_	0	SENT_93	[p8l577t175r659b227],
13	either	CC	O	either	preconj	14	SENT_93	[p8l707t149r946b227],
14	concurrent	JJ	O	concurrent	prep_as	11	SENT_93	[p8l987t165r1444b228],
15	or	CC	O	or	_	0	SENT_93	[p8l1485t174r1573b227],
16	maintenance	NN	O	maintenance	nn	17	SENT_93	[p8l1614t149r2151b227],
17	therapy	NN	O	therapy	conj_or	14	SENT_93	[p8l12t277r324b377],
18	are	VBP	O	be	cop	20	SENT_93	[p8l339t303r464b355],
19	also	RB	O	also	advmod	20	SENT_93	[p8l485t276r649b355],
20	ongoing	JJ	O	ongoing	_	0	SENT_93	[p8l673t277r1044b377],
21	.	.	O	.	_	0	SENT_93	[p8l673t277r1044b377],

1	Whether	IN	O	whether	complm	5	SENT_94	[p8l1067t276r1434b355],
2	these	DT	O	these	det	3	SENT_94	[p8l1453t277r1668b355],
3	studies	NNS	O	study	nsubj	5	SENT_94	[p8l1691t277r1978b356],
4	will	MD	O	will	aux	5	SENT_94	[p8l1997t276r2152b356],
5	need	VB	O	need	csubjpass	21	SENT_94	[p8l12t405r210b483],
6	to	TO	O	to	aux	8	SENT_94	[p8l234t421r313b483],
7	be	VB	O	be	aux	8	SENT_94	[p8l340t405r436b483],
8	redone	NN	O	redone	xcomp	5	SENT_94	[p8l461t405r755b483],
9	with	IN	O	with	_	0	SENT_94	[p8l775t405r965b484],
10	patients	NNS	O	patient	prep_with	8	SENT_94	[p8l989t405r1326b505],
11	selected	VBN	O	select	partmod	10	SENT_94	[p8l1354t404r1691b483],
12	on	IN	O	on	_	0	SENT_94	[p8l1718t430r1826b483],
13	the	DT	O	the	det	14	SENT_94	[p8l1854t404r1986b483],
14	basis	NN	O	basis	prep_on	11	SENT_94	[p8l2014t404r2147b483, p8l13t533r122b611],
15	of	IN	O	of	_	0	SENT_94	[p8l152t532r255b611],
16	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_94	[p8l261t539r478b612],
17	mutation	NN	O	mutation	nn	18	SENT_94	[p8l499t533r899b612],
18	status	NN	O	status	prep_of	14	SENT_94	[p8l927t549r1179b612],
19	must	MD	O	must	aux	21	SENT_94	[p8l1209t549r1430b612],
20	be	VB	O	be	auxpass	21	SENT_94	[p8l1453t533r1551b611],
21	considered	VBN	O	consider	_	0	SENT_94	[p8l1579t532r2075b611],
22	.	.	O	.	_	0	SENT_94	[p8l1579t532r2075b611],

1	The	DT	O	the	det	2	SENT_95	[p8l138t661r302b739],
2	work	NN	O	work	nsubj	17	SENT_95	[p8l331t661r558b740],
3	of	IN	O	of	_	0	SENT_95	[p8l587t660r689b739],
4	Lynch	NNP	PERSON	Lynch	prep_of	2	SENT_95	[p8l702t661r956b761],
5	et	FW	O	et	nn	6	SENT_95	[p8l987t677r1064b739],
6	al.	FW	O	al.	dep	4	SENT_95	[p8l1089t661r1214b756],
7	,	,	O	,	_	0	SENT_95	[p8l1089t661r1214b756],
8	if	IN	O	if	mark	9	SENT_95	[p8l1252t660r1329b738],
9	borne	VBN	O	bear	dep	2	SENT_95	[p8l1344t661r1595b739],
10	out	RP	O	out	prt	9	SENT_95	[p8l1629t677r1772b740],
11	by	IN	O	by	_	0	SENT_95	[p8l1801t661r1899b761],
12	additional	JJ	O	additional	amod	13	SENT_95	[p8l1927t660r2147b739, p8l12t788r260b867],
13	studies	NNS	O	study	prep_by	9	SENT_95	[p8l290t789r615b884],
14	,	,	O	,	_	0	SENT_95	[p8l290t789r615b884],
15	will	MD	O	will	aux	17	SENT_95	[p8l643t788r800b868],
16	fundamentally	RB	O	fundamentally	advmod	17	SENT_95	[p8l826t788r1448b889],
17	change	VB	O	change	_	0	SENT_95	[p8l1471t789r1774b889],
18	targeted	VBN	O	target	dep	17	SENT_95	[p8l1802t788r2149b889],
19	therapy	NN	O	therapy	dobj	18	SENT_95	[p8l12t917r331b1017],
20	for	IN	O	for	_	0	SENT_95	[p8l370t916r494b995],
21	solid	JJ	O	solid	amod	22	SENT_95	[p8l537t916r741b995],
22	tumors	NNS	O	tumor	prep_for	19	SENT_95	[p8l785t933r1113b996],
23	.	.	O	.	_	0	SENT_95	[p8l785t933r1113b996],

1	For	IN	O	for	_	0	SENT_96	[p8l1161t924r1307b995],
2	patients	NNS	O	patient	prep_for	15	SENT_96	[p8l1346t917r1683b1017],
3	with	IN	O	with	_	0	SENT_96	[p8l1724t917r1915b996],
4	lung	NN	O	lung	nn	5	SENT_96	[p8l1958t917r2153b1017],
5	cancer	NN	O	cancer	prep_with	2	SENT_96	[p8l12t1070r306b1140],
6	,	,	O	,	_	0	SENT_96	[p8l12t1070r306b1140],
7	mutational	JJ	O	mutational	amod	8	SENT_96	[p8l335t1045r803b1124],
8	analysis	NN	O	analysis	nsubj	15	SENT_96	[p8l826t1045r1159b1145],
9	of	IN	O	of	_	0	SENT_96	[p8l1186t1044r1287b1123],
10	EGFR	NN	ORGANIZATION	egfr	prep_of	8	SENT_96	[p8l1291t1051r1505b1124],
11	by	IN	O	by	_	0	SENT_96	[p8l1523t1045r1621b1145],
12	experienced	JJ	O	experienced	amod	13	SENT_96	[p8l1641t1045r2149b1145],
13	laboratories	NNS	O	laboratory	prep_by	10	SENT_96	[p8l11t1173r517b1251],
14	should	MD	O	should	aux	15	SENT_96	[p8l556t1172r845b1252],
15	provide	VB	O	provide	_	0	SENT_96	[p8l878t1172r1196b1273],
16	guidance	NN	O	guidance	dobj	15	SENT_96	[p8l1231t1172r1616b1273],
17	about	IN	O	about	_	0	SENT_96	[p8l1651t1173r1896b1252],
18	treatment	NN	O	treatment	prep_about	15	SENT_96	[p8l1926t1189r2148b1251, p8l12t1317r254b1379],
19	.	.	O	.	_	0	SENT_96	[p8l1926t1189r2148b1251, p8l12t1317r254b1379],

1	More	RBR	O	more	advmod	2	SENT_97	[p8l286t1308r510b1379],
2	generally	RB	O	generally	ccomp	6	SENT_97	[p8l539t1301r939b1401],
3	,	,	O	,	_	0	SENT_97	[p8l539t1301r939b1401],
4	this	DT	O	this	det	5	SENT_97	[p8l975t1300r1129b1379],
5	Work	NN	O	work	nsubj	6	SENT_97	[p8l1156t1301r1379b1380],
6	suggests	VBZ	O	suggest	_	0	SENT_97	[p8l1406t1317r1770b1401],
7	the	DT	O	the	det	8	SENT_97	[p8l1802t1300r1932b1379],
8	relevance	NN	O	relevance	dobj	6	SENT_97	[p8l1962t1301r2148b1379, p8l7t1454r246b1508],
9	of	IN	O	of	_	0	SENT_97	[p8l277t1428r378b1507],
10	a	DT	O	a	det	14	SENT_97	[p8l389t1455r433b1507],
11	tWo	NN	NUMBER	two	nn	14	SENT_97	[p8l461t1445r827b1529],
12	—	CD	NUMBER	—	num	14	SENT_97	[p8l461t1445r827b1529],
13	step	NN	O	step	nn	14	SENT_97	[p8l461t1445r827b1529],
14	evaluation	NN	O	evaluation	prep_of	8	SENT_97	[p8l859t1429r1292b1508],
15	of	IN	O	of	_	0	SENT_97	[p8l1323t1428r1424b1507],
16	targeted	VBN	O	target	amod	17	SENT_97	[p8l1435t1428r1783b1529],
17	therapy	NN	O	therapy	prep_of	14	SENT_97	[p8l1814t1429r2144b1529],
18	.	.	O	.	_	0	SENT_97	[p8l1814t1429r2144b1529],

1	Identiﬁcation	NN	O	identiﬁcation	nsubj	17	SENT_98	[p8l10t1556r585b1635],
2	of	IN	O	of	_	0	SENT_98	[p8l609t1556r710b1635],
3	the	DT	O	the	det	4	SENT_98	[p8l715t1557r845b1635],
4	target	NN	O	target	prep_of	1	SENT_98	[p8l869t1573r1120b1657],
5	and	CC	O	and	_	0	SENT_98	[p8l1137t1557r1294b1635],
6	a	DT	O	a	det	8	SENT_98	[p8l1316t1583r1360b1635],
7	therapeutic	JJ	O	therapeutic	amod	8	SENT_98	[p8l1382t1557r1861b1657],
8	ligand	NN	O	ligand	conj_and	4	SENT_98	[p8l1882t1556r2150b1657],
9	Will	MD	O	will	aux	17	SENT_98	[p8l7t1685r162b1764],
10	remain	VB	O	remain	cop	17	SENT_98	[p8l187t1685r482b1763],
11	a	DT	O	a	det	17	SENT_98	[p8l507t1711r551b1763],
12	critical	JJ	O	critical	amod	17	SENT_98	[p8l576t1685r855b1763],
13	but	CC	O	but	_	0	SENT_98	[p8l881t1684r1021b1764],
14	relatively	RB	O	relatively	advmod	15	SENT_98	[p8l1040t1685r1411b1785],
15	crude	JJ	O	crude	conj_but	12	SENT_98	[p8l1432t1685r1663b1764],
16	initial	JJ	O	initial	amod	17	SENT_98	[p8l1688t1685r1927b1763],
17	step	NN	O	step	_	0	SENT_98	[p8l1953t1701r2145b1785],
18	.	.	O	.	_	0	SENT_98	[p8l1953t1701r2145b1785],

1	Subsequent	JJ	O	subsequent	amod	2	SENT_99	[p8l14t1813r511b1913],
2	Work	NN	O	work	nsubj	5	SENT_99	[p8l534t1813r758b1892],
3	must	MD	O	must	aux	5	SENT_99	[p8l786t1829r1004b1892],
4	then	RB	O	then	advmod	5	SENT_99	[p8l1031t1813r1220b1891],
5	facilitate	VB	O	facilitate	_	0	SENT_99	[p8l1252t1812r1616b1891],
6	the	DT	O	the	det	7	SENT_99	[p8l1649t1812r1778b1891],
7	identiﬁcation	NN	O	identiﬁcation	dobj	5	SENT_99	[p8l1810t1812r2148b1891, p8l12t1941r272b2019],
8	of	IN	O	of	_	0	SENT_99	[p8l309t1940r411b2019],
9	the	DT	O	the	det	11	SENT_99	[p8l429t1941r559b2019],
10	responsive	JJ	O	responsive	amod	11	SENT_99	[p8l596t1941r1048b2041],
11	subgroup	NN	O	subgroup	prep_of	7	SENT_99	[p8l1087t1940r1518b2041],
12	.	.	O	.	_	0	SENT_99	[p8l1087t1940r1518b2041],

1	Seeking	VBG	O	seek	dep	32	SENT_100	[p8l1562t1941r1899b2041],
2	gainof	JJ	O	gainof	amod	5	SENT_100	[p8l1932t1941r2148b2041, p8l12t2068r494b2148],
3	—	NN	O	—	nn	5	SENT_100	[p8l1932t1941r2148b2041, p8l12t2068r494b2148],
4	function	NN	O	function	nn	5	SENT_100	[p8l1932t1941r2148b2041, p8l12t2068r494b2148],
5	mutations	NNS	O	mutation	dobj	1	SENT_100	[p8l517t2069r950b2148],
6	clustered	VBN	O	cluster	partmod	5	SENT_100	[p8l976t2069r1360b2148],
7	around	IN	O	around	_	0	SENT_100	[p8l1382t2068r1687b2148],
8	the	DT	O	the	det	11	SENT_100	[p8l1710t2069r1840b2147],
9	critical	JJ	O	critical	amod	11	SENT_100	[p8l1865t2069r2150b2147],
10	binding	NN	O	binding	nn	11	SENT_100	[p8l12t2196r343b2297],
11	pocket	NN	O	pocket	prep_around	6	SENT_100	[p8l362t2197r647b2297],
12	of	IN	O	of	_	0	SENT_100	[p8l666t2196r767b2275],
13	the	DT	O	the	det	16	SENT_100	[p8l772t2197r899b2275],
14	tyrosine	NN	O	tyrosine	nn	16	SENT_100	[p8l923t2197r1255b2297],
15	kinase	NN	O	kinase	nn	16	SENT_100	[p8l1278t2197r1546b2276],
16	domain	NN	O	domain	prep_of	11	SENT_100	[p8l1570t2197r1914b2292],
17	,	,	O	,	_	0	SENT_100	[p8l1570t2197r1914b2292],
18	analogous	JJ	O	analogous	ccomp	32	SENT_100	[p8l1943t2197r2149b2275, p8l12t2350r270b2425],
19	to	TO	O	to	_	0	SENT_100	[p8l299t2341r379b2403],
20	what	WP	O	what	nsubjpass	23	SENT_100	[p8l402t2325r620b2404],
21	has	VBZ	O	have	aux	23	SENT_100	[p8l640t2325r785b2403],
22	been	VBN	O	be	auxpass	23	SENT_100	[p8l813t2325r1017b2403],
23	demonstrated	VBN	O	demonstrate	prepc_to	18	SENT_100	[p8l1044t2324r1646b2403],
24	by	IN	O	by	_	0	SENT_100	[p8l1672t2325r1770b2425],
25	Lynch	NNP	PERSON	Lynch	agent	23	SENT_100	[p8l1791t2325r2048b2425],
26	et	FW	O	et	nn	27	SENT_100	[p8l2075t2341r2153b2403],
27	al.	FW	O	al.	dobj	23	SENT_100	[p8l11t2453r137b2548],
28	,	,	O	,	_	0	SENT_100	[p8l11t2453r137b2548],
29	seems	VBZ	O	seem	cop	32	SENT_100	[p8l171t2479r433b2531],
30	a	DT	O	a	det	32	SENT_100	[p8l460t2479r505b2531],
31	reasonable	JJ	O	reasonable	amod	32	SENT_100	[p8l530t2453r990b2531],
32	Way	NN	O	way	_	0	SENT_100	[p8l1010t2479r1178b2553],
33	to	TO	O	to	aux	34	SENT_100	[p8l1200t2469r1279b2531],
34	begin	VB	O	begin	infmod	32	SENT_100	[p8l1307t2453r1567b2553],
35	.	.	O	.	_	0	SENT_100	[p8l1307t2453r1567b2553],

1	From	IN	O	from	dep	13	SENT_101	[p8l16t2752r175b2808],
2	the	DT	O	the	det	5	SENT_101	[p8l210t2747r311b2808],
3	Hollings	NNP	ORGANIZATION	Hollings	nn	5	SENT_101	[p8l351t2747r617b2827],
4	Cancer	NNP	ORGANIZATION	Cancer	nn	5	SENT_101	[p8l653t2752r874b2808],
5	Center	NNP	ORGANIZATION	Center	pobj	1	SENT_101	[p8l906t2752r1117b2808],
6	and	CC	O	and	_	0	SENT_101	[p8l1149t2747r1263b2808],
7	the	DT	O	the	det	8	SENT_101	[p8l1299t2747r1400b2808],
8	Department	NNP	ORGANIZATION	Department	conj_and	5	SENT_101	[p8l1439t2752r1826b2826],
9	of	IN	ORGANIZATION	of	_	0	SENT_101	[p8l1859t2746r1930b2808],
10	Medicine	NNP	ORGANIZATION	Medicine	prep_of	8	SENT_101	[p8l1958t2747r2138b2808, p8l11t2850r156b2915],
11	,	,	O	,	_	0	SENT_101	[p8l1958t2747r2138b2808, p8l11t2850r156b2915],
12	Medical	NNP	ORGANIZATION	Medical	nn	13	SENT_101	[p8l188t2844r434b2905],
13	University	NNP	ORGANIZATION	University	_	0	SENT_101	[p8l465t2850r785b2924],
14	ofSouth	NNP	ORGANIZATION	ofSouth	nn	15	SENT_101	[p8l807t2844r1074b2905],
15	Carolina	NNP	ORGANIZATION	Carolina	dep	13	SENT_101	[p8l1101t2844r1382b2915],
16	,	,	O	,	_	0	SENT_101	[p8l1101t2844r1382b2915],
17	Charleston	NNP	LOCATION	Charleston	dep	13	SENT_101	[p8l1409t2844r1775b2905],
18	.	.	O	.	_	0	SENT_101	[p8l1409t2844r1775b2905],

1	This	DT	O	this	det	2	SENT_102	[p8l7t3037r142b3098],
2	editorial	NN	O	editorial	nsubjpass	4	SENT_102	[p8l166t3037r421b3098],
3	was	VBD	O	be	auxpass	4	SENT_102	[p8l445t3059r566b3098],
4	published	VBN	O	publish	_	0	SENT_102	[p8l593t3037r901b3116],
5	at	IN	O	at	_	0	SENT_102	[p8l927t3049r984b3098],
6	www.nejm.org	NN	O	www.nejm.org	prep_at	4	SENT_102	[p8l1003t3043r1464b3117],
7	on	IN	O	on	_	0	SENT_102	[p8l1486t3059r1564b3098],
8	April	NNP	DATE	April	prep_on	6	SENT_102	[p8l1589t3037r1741b3116],
9	29	CD	DATE	29	num	8	SENT_102	[p8l1769t3042r1861b3108],
10	,	,	DATE	,	_	0	SENT_102	[p8l1769t3042r1861b3108],
11	2004	CD	DATE	2004	num	8	SENT_102	[p8l1889t3041r2062b3098],
12	.	.	O	.	_	0	SENT_102	[p8l1889t3041r2062b3098],

1	1	LS	NUMBER	1	_	0	SENT_103	[p9l12t51r61b103],
2	.	.	O	.	_	0	SENT_103	[p9l12t51r61b103],

1	Vogel	NNP	ORGANIZATION	Vogel	nn	2	SENT_104	[p9l136t43r314b120],
2	CL	NN	ORGANIZATION	cl	_	0	SENT_104	[p9l335t48r438b115],
3	,	,	O	,	_	0	SENT_104	[p9l335t48r438b115],
4	Cobleigh	NNP	ORGANIZATION	Cobleigh	nn	5	SENT_104	[p9l463t43r751b120],
5	MA	NNP	ORGANIZATION	MA	appos	2	SENT_104	[p9l770t48r900b116],
6	,	,	O	,	_	0	SENT_104	[p9l770t48r900b116],
7	Tripathy	NNP	PERSON	Tripathy	nn	8	SENT_104	[p9l922t43r1192b119],
8	D	NNP	O	D	appos	2	SENT_104	[p9l1208t48r1275b115],
9	,	,	O	,	_	0	SENT_104	[p9l1208t48r1275b115],
10	et	FW	O	et	nn	11	SENT_104	[p9l1301t56r1359b102],
11	al.	FW	O	al.	appos	2	SENT_104	[p9l1375t43r1446b103],
12	.	.	O	.	_	0	SENT_104	[p9l1375t43r1446b103],

1	Efficacy	NN	O	efficacy	_	0	SENT_105	[p9l1471t43r1720b119],
2	and	CC	O	and	_	0	SENT_105	[p9l1737t43r1855b103],
3	safety	NN	O	safety	conj_and	1	SENT_105	[p9l1877t43r2059b119],
4	of	IN	O	of	_	0	SENT_105	[p9l2077t43r2152b103],
5	trastuzumab	NN	O	trastuzumab	prep_of	1	SENT_105	[p9l10t140r409b200],
6	as	IN	O	as	_	0	SENT_105	[p9l431t160r494b199],
7	a	DT	O	a	det	9	SENT_105	[p9l517t160r550b199],
8	single	JJ	O	single	amod	9	SENT_105	[p9l572t140r760b217],
9	agent	NN	O	agent	prep_as	1	SENT_105	[p9l781t153r959b217],
10	in	IN	O	in	_	0	SENT_105	[p9l976t141r1037b199],
11	ﬁrst-line	JJ	O	ﬁrst-line	amod	12	SENT_105	[p9l1059t140r1330b199],
12	treatment	NN	O	treatment	prep_in	1	SENT_105	[p9l1352t153r1664b199],
13	of	IN	O	of	_	0	SENT_105	[p9l1682t140r1758b200],
14	HER2overexpressing	VBG	O	her2overexpress	prepc_of	1	SENT_105	[p9l1764t145r2139b203, p9l10t238r354b313],
15	metastatic	JJ	O	metastatic	amod	17	SENT_105	[p9l370t238r699b295],
16	breast	NN	O	breast	nn	17	SENT_105	[p9l718t237r913b296],
17	cancer	NN	O	cancer	dobj	14	SENT_105	[p9l928t256r1147b296],
18	.	.	O	.	_	0	SENT_105	[p9l928t256r1147b296],

1	J	NNP	O	J	nn	3	SENT_106	[p9l1162t242r1190b305],
2	Clin	NNP	O	Clin	nn	3	SENT_106	[p9l1207t237r1338b296],
3	Oncol	NNP	O	Oncol	_	0	SENT_106	[p9l1356t237r1547b296],
4	2002	CD	DATE	2002	num	3	SENT_106	[p9l1566t241r2087b308],
5	;	:	O	;	_	0	SENT_106	[p9l1566t241r2087b308],
6	20:719	CD	NUMBER	20:719	number	7	SENT_106	[p9l1566t241r2087b308],
7	-26	CD	NUMBER	-26	dep	3	SENT_106	[p9l1566t241r2087b308],
8	.	.	O	.	_	0	SENT_106	[p9l1566t241r2087b308],

1	2	LS	NUMBER	2	_	0	SENT_107	[p9l9t341r61b392],
2	.	.	O	.	_	0	SENT_107	[p9l9t341r61b392],

1	Slamon	NNP	PERSON	Slamon	nn	2	SENT_108	[p9l140t333r381b392],
2	DJ	NNP	O	DJ	_	0	SENT_108	[p9l398t338r490b405],
3	,	,	O	,	_	0	SENT_108	[p9l398t338r490b405],
4	Leyland-Jones	NNP	PERSON	Leyland-Jones	nn	5	SENT_108	[p9l511t333r954b408],
5	B	NNP	PERSON	B	appos	2	SENT_108	[p9l973t338r1034b405],
6	,	,	O	,	_	0	SENT_108	[p9l973t338r1034b405],
7	Shak	NNP	PERSON	Shak	nn	8	SENT_108	[p9l1059t333r1214b393],
8	S	NNP	O	S	appos	2	SENT_108	[p9l1231t337r1282b405],
9	,	,	O	,	_	0	SENT_108	[p9l1231t337r1282b405],
10	et	FW	O	et	nn	11	SENT_108	[p9l1305t346r1364b392],
11	al.	FW	O	al.	appos	2	SENT_108	[p9l1377t333r1448b392],
12	.	.	O	.	_	0	SENT_108	[p9l1377t333r1448b392],

1	Use	NN	O	use	_	0	SENT_109	[p9l1469t338r1587b392],
2	of	IN	O	of	_	0	SENT_109	[p9l1606t333r1682b392],
3	chemotherapy	NN	O	chemotherapy	prep_of	1	SENT_109	[p9l1687t333r2143b408],
4	plus	CC	O	plus	prep	1	SENT_109	[p9l9t429r142b505],
5	a	DT	O	a	det	7	SENT_109	[p9l159t449r192b488],
6	monoclonal	JJ	O	monoclonal	amod	7	SENT_109	[p9l207t429r590b489],
7	antibody	NN	O	antibody	dep	4	SENT_109	[p9l605t429r885b505],
8	against	IN	O	against	_	0	SENT_109	[p9l897t430r1130b506],
9	HER2	NN	O	her2	prep_against	1	SENT_109	[p9l1141t433r1328b492],
10	for	IN	O	for	_	0	SENT_109	[p9l1345t428r1438b489],
11	metastatic	JJ	O	metastatic	amod	13	SENT_109	[p9l1451t430r1780b488],
12	breast	NN	O	breast	nn	13	SENT_109	[p9l1796t429r1992b489],
13	cancer	NN	O	cancer	prep_for	1	SENT_109	[p9l2004t449r2137b488, p9l10t545r105b584],
14	that	WDT	O	that	nsubj	15	SENT_109	[p9l122t526r247b584],
15	overexpresses	VBZ	O	overexpress	rcmod	13	SENT_109	[p9l263t545r700b601],
16	HER2	NN	O	her2	dobj	15	SENT_109	[p9l719t530r925b588],
17	.	.	O	.	_	0	SENT_109	[p9l719t530r925b588],

1	N	NN	O	n	nn	2	SENT_110	[p9l946t531r1002b585],
2	EnglJ	NN	O	englj	nsubj	3	SENT_110	[p9l1019t526r1204b602],
3	Med	VBD	O	med	_	0	SENT_110	[p9l1219t526r1359b585],
4	2001	CD	DATE	2001	dobj	3	SENT_110	[p9l1377t530r1939b597],
5	;	:	O	;	_	0	SENT_110	[p9l1377t530r1939b597],
6	344:783	CD	NUMBER	344:783	num	7	SENT_110	[p9l1377t530r1939b597],
7	-92	CD	NUMBER	-92	dep	4	SENT_110	[p9l1377t530r1939b597],
8	.	.	O	.	_	0	SENT_110	[p9l1377t530r1939b597],

1	3	LS	NUMBER	3	_	0	SENT_111	[p9l10t630r61b682],
2	.	.	O	.	_	0	SENT_111	[p9l10t630r61b682],

1	Baselga	NNP	PERSON	Baselga	nn	2	SENT_112	[p9l138t622r382b699],
2	J	NNP	PERSON	J	_	0	SENT_112	[p9l392t628r436b695],
3	,	,	O	,	_	0	SENT_112	[p9l392t628r436b695],
4	Rischin	NNP	PERSON	Rischin	nn	5	SENT_112	[p9l458t622r700b685],
5	D	NNP	O	D	appos	2	SENT_112	[p9l718t627r784b695],
6	,	,	O	,	_	0	SENT_112	[p9l718t627r784b695],
7	Ranson	NNP	PERSON	Ranson	nn	8	SENT_112	[p9l807t627r1049b685],
8	M	NNP	O	M	appos	2	SENT_112	[p9l1065t627r1147b695],
9	,	,	O	,	_	0	SENT_112	[p9l1065t627r1147b695],
10	et	FW	O	et	nn	11	SENT_112	[p9l1170t635r1228b681],
11	al.	FW	O	al.	appos	2	SENT_112	[p9l1242t622r1313b682],
12	.	.	O	.	_	0	SENT_112	[p9l1242t622r1313b682],

1	Phase	NN	O	phase	_	0	SENT_113	[p9l1335t622r1519b681],
2	I	CD	NUMBER	i	num	3	SENT_113	[p9l1537t628r1560b681],
3	safety	NN	O	safety	dep	1	SENT_113	[p9l1579t621r1768b698],
4	,	,	O	,	_	0	SENT_113	[p9l1579t621r1768b698],
5	pharmacokinetic	JJ	O	pharmacokinetic	amod	3	SENT_113	[p9l1790t622r2137b698, p9l10t719r241b790],
6	,	,	O	,	_	0	SENT_113	[p9l1790t622r2137b698, p9l10t719r241b790],
7	and	CC	O	and	_	0	SENT_113	[p9l265t719r382b778],
8	pharmacodynamic	JJ	O	pharmacodynamic	amod	9	SENT_113	[p9l401t719r997b794],
9	trial	NN	O	trial	conj_and	3	SENT_113	[p9l1017t719r1142b778],
10	of	IN	O	of	_	0	SENT_113	[p9l1163t719r1239b778],
11	ZD1839	NN	O	zd1839	prep_of	1	SENT_113	[p9l1243t723r1515b791],
12	,	,	O	,	_	0	SENT_113	[p9l1243t723r1515b791],
13	a	DT	O	a	det	22	SENT_113	[p9l1540t739r1573b778],
14	selective	JJ	O	selective	amod	22	SENT_113	[p9l1594t719r1856b779],
15	oral	JJ	O	oral	amod	22	SENT_113	[p9l1878t719r1999b778],
16	epidermal	JJ	O	epidermal	amod	22	SENT_113	[p9l2020t720r2139b794, p9l10t815r232b875],
17	growth	NN	O	growth	nn	22	SENT_113	[p9l253t815r481b892],
18	factor	NN	O	factor	nn	22	SENT_113	[p9l502t815r687b875],
19	receptor	NN	O	receptor	nn	22	SENT_113	[p9l706t828r970b891],
20	tyrosine	NN	O	tyrosine	nn	22	SENT_113	[p9l989t816r1241b891],
21	kinase	NN	O	kinase	nn	22	SENT_113	[p9l1262t815r1466b875],
22	inhibitor	NN	O	inhibitor	appos	11	SENT_113	[p9l1486t815r1779b887],
23	,	,	O	,	_	0	SENT_113	[p9l1486t815r1779b887],
24	in	IN	O	in	_	0	SENT_113	[p9l1804t816r1865b874],
25	patients	NNS	O	patient	prep_in	1	SENT_113	[p9l1885t816r2136b891],
26	with	IN	O	with	_	0	SENT_113	[p9l6t912r149b972],
27	ﬁve	NN	O	ﬁve	prep_with	25	SENT_113	[p9l165t912r275b972],
28	selected	VBN	O	select	partmod	27	SENT_113	[p9l293t912r544b971],
29	solid	JJ	O	solid	amod	31	SENT_113	[p9l561t912r714b971],
30	tumor	NN	O	tumor	nn	31	SENT_113	[p9l731t925r929b972],
31	types	NNS	O	type	dobj	28	SENT_113	[p9l944t925r1122b987],
32	.	.	O	.	_	0	SENT_113	[p9l944t925r1122b987],

1	J	NNP	O	J	nn	3	SENT_114	[p9l1136t917r1164b981],
2	Clin	NNP	O	Clin	nn	3	SENT_114	[p9l1179t912r1310b971],
3	Oncol	NNP	O	Oncol	_	0	SENT_114	[p9l1326t912r1518b971],
4	2002	CD	DATE	2002	num	3	SENT_114	[p9l1534t916r2135b983],
5	;	:	O	;	_	0	SENT_114	[p9l1534t916r2135b983],
6	20:4292	CD	NUMBER	20:4292	num	7	SENT_114	[p9l1534t916r2135b983],
7	—	NN	O	—	dep	3	SENT_114	[p9l1534t916r2135b983],
8	302	CD	NUMBER	302	dep	7	SENT_114	[p9l1534t916r2135b983],
9	.	.	O	.	_	0	SENT_114	[p9l1534t916r2135b983],

1	4	LS	NUMBER	4	_	0	SENT_115	[p9l8t1015r61b1066],
2	.	.	O	.	_	0	SENT_115	[p9l8t1015r61b1066],

1	Fukuoka	NNP	LOCATION	Fukuoka	nn	2	SENT_116	[p9l138t1007r416b1066],
2	M	NNP	O	M	_	0	SENT_116	[p9l436t1012r518b1079],
3	,	,	O	,	_	0	SENT_116	[p9l436t1012r518b1079],
4	Yano	NNP	PERSON	Yano	nn	5	SENT_116	[p9l543t1012r698b1066],
5	S	NNP	O	S	appos	2	SENT_116	[p9l725t1011r776b1079],
6	,	,	O	,	_	0	SENT_116	[p9l725t1011r776b1079],
7	Giaccone	NNP	PERSON	Giaccone	nn	8	SENT_116	[p9l804t1008r1100b1066],
8	G	NNP	O	G	appos	2	SENT_116	[p9l1125t1011r1196b1079],
9	,	,	O	,	_	0	SENT_116	[p9l1125t1011r1196b1079],
10	et	FW	O	et	nn	11	SENT_116	[p9l1225t1020r1283b1065],
11	al.	FW	O	al.	appos	2	SENT_116	[p9l1302t1007r1373b1066],
12	.	.	O	.	_	0	SENT_116	[p9l1302t1007r1373b1066],

1	Multi-institutional	JJ	O	multi-institutional	nsubj	10	SENT_117	[p9l1399t1007r1987b1066],
2	randomized	VBN	O	randomize	partmod	1	SENT_117	[p9l2010t1026r2138b1065, p9l10t1103r285b1163],
3	phase	NN	O	phase	nn	5	SENT_117	[p9l300t1103r484b1179],
4	II	CD	NUMBER	ii	num	5	SENT_117	[p9l500t1108r547b1162],
5	trial	NN	O	trial	dobj	2	SENT_117	[p9l564t1103r687b1162],
6	of	IN	O	of	_	0	SENT_117	[p9l704t1103r780b1163],
7	gefitinib	NN	O	gefitinib	prep_of	5	SENT_117	[p9l782t1103r1046b1180],
8	for	IN	O	for	prep	2	SENT_117	[p9l1064t1103r1155b1163],
9	previously	RB	DATE	previously	advmod	10	SENT_117	[p9l1168t1103r1492b1179],
10	treated	VBN	O	treat	_	0	SENT_117	[p9l1505t1103r1719b1163],
11	patients	NNS	O	patient	dobj	10	SENT_117	[p9l1736t1104r1984b1179],
12	with	IN	O	with	_	0	SENT_117	[p9l1999t1103r2140b1163],
13	advanced	JJ	O	advanced	amod	16	SENT_117	[p9l9t1200r301b1259],
14	non-small-cell	JJ	O	non-small-cell	amod	16	SENT_117	[p9l318t1200r775b1259],
15	lung	NN	O	lung	nn	16	SENT_117	[p9l791t1200r936b1276],
16	cancer	NN	O	cancer	prep_with	10	SENT_117	[p9l951t1219r1167b1259],
17	.	.	O	.	_	0	SENT_117	[p9l951t1219r1167b1259],

1	J	NNP	O	J	nn	3	SENT_118	[p9l1181t1205r1210b1268],
2	Clin	NNP	O	Clin	nn	3	SENT_118	[p9l1226t1200r1355b1259],
3	Oncol	NNP	O	Oncol	_	0	SENT_118	[p9l1373t1200r1562b1259],
4	2003	CD	DATE	2003	num	3	SENT_118	[p9l1579t1204r2135b1271],
5	;	:	O	;	_	0	SENT_118	[p9l1579t1204r2135b1271],
6	21:2237	CD	NUMBER	21:2237	number	7	SENT_118	[p9l1579t1204r2135b1271],
7	-46	CD	NUMBER	-46	dep	3	SENT_118	[p9l1579t1204r2135b1271],
8	.	.	O	.	_	0	SENT_118	[p9l1579t1204r2135b1271],

1	5	CD	NUMBER	5	_	0	SENT_119	[p9l11t1304r61b1356],
2	.	.	O	.	_	0	SENT_119	[p9l11t1304r61b1356],

1	Kris	NNP	PERSON	Kris	nn	2	SENT_120	[p9l139t1297r266b1357],
2	MG	NN	PERSON	mg	_	0	SENT_120	[p9l292t1300r431b1368],
3	,	,	O	,	_	0	SENT_120	[p9l292t1300r431b1368],
4	Natale	NNP	PERSON	Natale	nn	5	SENT_120	[p9l460t1296r666b1356],
5	RB	NN	O	rb	appos	2	SENT_120	[p9l692t1301r802b1369],
6	,	,	O	,	_	0	SENT_120	[p9l692t1301r802b1369],
7	Herbst	NNP	ORGANIZATION	Herbst	nn	8	SENT_120	[p9l832t1296r1051b1356],
8	RS	NN	ORGANIZATION	r	appos	2	SENT_120	[p9l1073t1301r1176b1368],
9	,	,	O	,	_	0	SENT_120	[p9l1073t1301r1176b1368],
10	et	FW	O	et	nn	11	SENT_120	[p9l1207t1309r1265b1355],
11	al.	FW	O	al.	appos	2	SENT_120	[p9l1287t1296r1357b1356],
12	.	.	O	.	_	0	SENT_120	[p9l1287t1296r1357b1356],

1	Efficacy	NN	O	efficacy	_	0	SENT_121	[p9l1387t1295r1637b1372],
2	of	IN	O	of	_	0	SENT_121	[p9l1661t1296r1736b1356],
3	gefitinib	NN	O	gefitinib	prep_of	1	SENT_121	[p9l1748t1296r2033b1373],
4	,	,	O	,	_	0	SENT_121	[p9l1748t1296r2033b1373],
5	an	DT	O	a	det	6	SENT_121	[p9l2064t1316r2139b1355],
6	inhibitor	NN	O	inhibitor	appos	3	SENT_121	[p9l9t1393r292b1453],
7	of	IN	O	of	_	0	SENT_121	[p9l308t1393r383b1453],
8	the	DT	O	the	det	14	SENT_121	[p9l387t1393r484b1452],
9	epidermal	JJ	O	epidermal	amod	14	SENT_121	[p9l503t1393r823b1469],
10	growth	NN	O	growth	nn	14	SENT_121	[p9l840t1393r1068b1470],
11	factor	NN	O	factor	nn	14	SENT_121	[p9l1086t1393r1271b1453],
12	receptor	NN	O	receptor	nn	14	SENT_121	[p9l1286t1406r1550b1469],
13	tyrosine	NN	O	tyrosine	nn	14	SENT_121	[p9l1566t1394r1818b1469],
14	kinase	NN	O	kinase	prep_of	6	SENT_121	[p9l1836t1393r2057b1465],
15	,	,	O	,	_	0	SENT_121	[p9l1836t1393r2057b1465],
16	in	IN	O	in	_	0	SENT_121	[p9l2078t1394r2140b1452],
17	symptomatic	JJ	O	symptomatic	amod	18	SENT_121	[p9l11t1491r422b1565],
18	patients	NNS	O	patient	prep_in	3	SENT_121	[p9l448t1491r700b1565],
19	with	IN	O	with	_	0	SENT_121	[p9l725t1490r867b1549],
20	non-small	JJ	O	non-small	amod	23	SENT_121	[p9l894t1490r1219b1549],
21	cell	NN	O	cell	nn	23	SENT_121	[p9l1247t1490r1353b1548],
22	lung	NN	O	lung	nn	23	SENT_121	[p9l1379t1490r1525b1566],
23	cancer	NN	O	cancer	prep_with	18	SENT_121	[p9l1550t1509r1773b1549],
24	:	:	O	:	_	0	SENT_121	[p9l1550t1509r1773b1549],
25	a	DT	O	a	det	27	SENT_121	[p9l1803t1509r1837b1548],
26	randomized	JJ	O	randomized	amod	27	SENT_121	[p9l1862t1490r2139b1549, p9l9t1586r139b1645],
27	trial	NN	O	trial	dep	1	SENT_121	[p9l158t1586r301b1645],
28	.	.	O	.	_	0	SENT_121	[p9l158t1586r301b1645],

1	JAMA	NNP	O	JAMA	_	0	SENT_122	[p9l316t1591r506b1654],
2	2003	CD	DATE	2003	num	1	SENT_122	[p9l523t1590r1125b1657],
3	;	:	O	;	_	0	SENT_122	[p9l523t1590r1125b1657],
4	290:2149	CD	NUMBER	290:2149	number	5	SENT_122	[p9l523t1590r1125b1657],
5	-58	CD	NUMBER	-58	dep	1	SENT_122	[p9l523t1590r1125b1657],
6	.	.	O	.	_	0	SENT_122	[p9l523t1590r1125b1657],

1	6	CD	NUMBER	6	_	0	SENT_123	[p9l10t1689r61b1742],
2	.	.	O	.	_	0	SENT_123	[p9l10t1689r61b1742],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_124	[p9l139t1682r358b1742],
2	RS	NN	ORGANIZATION	r	_	0	SENT_124	[p9l372t1686r476b1754],
3	,	,	O	,	_	0	SENT_124	[p9l372t1686r476b1754],
4	Giaccone	NNP	PERSON	Giaccone	nn	5	SENT_124	[p9l499t1683r795b1742],
5	G	NNP	PERSON	G	appos	2	SENT_124	[p9l815t1687r886b1755],
6	,	,	O	,	_	0	SENT_124	[p9l815t1687r886b1755],
7	Schiller	NNP	PERSON	Schiller	nn	8	SENT_124	[p9l911t1682r1149b1742],
8	JH	NNP	O	JH	appos	2	SENT_124	[p9l1159t1688r1262b1755],
9	,	,	O	,	_	0	SENT_124	[p9l1159t1688r1262b1755],
10	et	FW	O	et	nn	11	SENT_124	[p9l1286t1695r1343b1741],
11	al.	FW	O	al.	appos	2	SENT_124	[p9l1358t1682r1429b1742],
12	.	.	O	.	_	0	SENT_124	[p9l1358t1682r1429b1742],

1	Gefitinib	NNP	O	Gefitinib	_	0	SENT_125	[p9l1453t1682r1736b1742],
2	in	IN	O	in	_	0	SENT_125	[p9l1755t1683r1817b1741],
3	combination	NN	O	combination	prep_in	1	SENT_125	[p9l1836t1682r2139b1742, p9l10t1779r135b1837],
4	with	IN	O	with	_	0	SENT_125	[p9l148t1778r290b1837],
5	paclitaxel	NN	O	paclitaxel	prep_with	3	SENT_125	[p9l304t1778r607b1853],
6	and	CC	O	and	_	0	SENT_125	[p9l622t1778r739b1837],
7	carboplatin	NN	O	carboplatin	conj_and	5	SENT_125	[p9l755t1778r1117b1853],
8	in	IN	O	in	_	0	SENT_125	[p9l1132t1779r1193b1836],
9	advanced	JJ	O	advanced	amod	12	SENT_125	[p9l1209t1778r1503b1837],
10	non-small-cell	JJ	O	non-small-cell	amod	12	SENT_125	[p9l1520t1778r1981b1837],
11	lung	NN	O	lung	nn	12	SENT_125	[p9l1995t1778r2142b1854],
12	cancer	NN	O	cancer	prep_in	1	SENT_125	[p9l10t1893r234b1933],
13	:	:	O	:	_	0	SENT_125	[p9l10t1893r234b1933],
14	a	DT	O	a	det	17	SENT_125	[p9l255t1893r289b1933],
15	phase	NN	O	phase	nn	17	SENT_125	[p9l305t1874r490b1949],
16	III	CD	NUMBER	iii	num	17	SENT_125	[p9l508t1879r580b1932],
17	trial	NN	O	trial	dep	1	SENT_125	[p9l599t1874r724b1933],
18	—	CD	NUMBER	—	num	19	SENT_125	[p9l740t1908r820b1914],
19	INTACT	NN	O	intact	dep	17	SENT_125	[p9l835t1878r1098b1934],
20	2	CD	NUMBER	2	dep	19	SENT_125	[p9l1114t1878r1169b1933],
21	.	.	O	.	_	0	SENT_125	[p9l1114t1878r1169b1933],

1	J	NNP	O	J	nn	3	SENT_126	[p9l1184t1879r1212b1943],
2	Clin	NNP	O	Clin	nn	3	SENT_126	[p9l1229t1874r1360b1933],
3	Oncol	NNP	O	Oncol	_	0	SENT_126	[p9l1378t1874r1569b1933],
4	2004	CD	DATE	2004	num	3	SENT_126	[p9l1587t1878r2109b1945],
5	;	:	O	;	_	0	SENT_126	[p9l1587t1878r2109b1945],
6	22:785	CD	NUMBER	22:785	number	7	SENT_126	[p9l1587t1878r2109b1945],
7	—	CD	NUMBER	—	dep	3	SENT_126	[p9l1587t1878r2109b1945],
8	94	CD	NUMBER	94	dep	7	SENT_126	[p9l1587t1878r2109b1945],
9	.	.	O	.	_	0	SENT_126	[p9l1587t1878r2109b1945],

1	7	CD	NUMBER	7	_	0	SENT_127	[p9l11t1978r61b2030],
2	.	.	O	.	_	0	SENT_127	[p9l11t1978r61b2030],

1	Giaccone	NNP	PERSON	Giaccone	nn	2	SENT_128	[p9l139t1971r432b2030],
2	G	NNP	PERSON	G	_	0	SENT_128	[p9l449t1974r519b2043],
3	,	,	O	,	_	0	SENT_128	[p9l449t1974r519b2043],
4	Herbst	NNP	ORGANIZATION	Herbst	nn	5	SENT_128	[p9l539t1970r756b2030],
5	RS	NN	ORGANIZATION	r	appos	2	SENT_128	[p9l768t1975r870b2043],
6	,	,	O	,	_	0	SENT_128	[p9l768t1975r870b2043],
7	Manegold	NNP	ORGANIZATION	Manegold	nn	8	SENT_128	[p9l888t1970r1207b2047],
8	C	NNP	ORGANIZATION	C	appos	2	SENT_128	[p9l1223t1974r1285b2042],
9	,	,	O	,	_	0	SENT_128	[p9l1223t1974r1285b2042],
10	et	FW	O	et	nn	11	SENT_128	[p9l1307t1983r1364b2029],
11	al.	FW	O	al.	appos	2	SENT_128	[p9l1375t1970r1445b2030],
12	.	.	O	.	_	0	SENT_128	[p9l1375t1970r1445b2030],

1	Geﬁtinib	NNP	O	Geﬁtinib	_	0	SENT_129	[p9l1466t1970r1746b2030],
2	in	IN	O	in	_	0	SENT_129	[p9l1762t1971r1823b2029],
3	combination	NN	O	combination	prep_in	1	SENT_129	[p9l1840t1970r2139b2030, p9l10t2068r134b2126],
4	with	IN	O	with	_	0	SENT_129	[p9l149t2067r290b2126],
5	gemcitabine	NN	O	gemcitabine	prep_with	3	SENT_129	[p9l308t2067r697b2143],
6	and	CC	O	and	_	0	SENT_129	[p9l715t2067r832b2126],
7	cisplatin	NN	O	cisplatin	conj_and	5	SENT_129	[p9l851t2067r1117b2142],
8	in	IN	O	in	_	0	SENT_129	[p9l1135t2068r1196b2125],
9	advanced	JJ	O	advanced	amod	12	SENT_129	[p9l1214t2067r1505b2126],
10	non-small-cell	JJ	O	non-small-cell	amod	12	SENT_129	[p9l1524t2067r1980b2126],
11	lung	NN	O	lung	nn	12	SENT_129	[p9l1998t2067r2142b2143],
12	cancer	NN	O	cancer	prep_in	1	SENT_129	[p9l10t2182r231b2222],
13	:	:	O	:	_	0	SENT_129	[p9l10t2182r231b2222],
14	a	DT	O	a	det	17	SENT_129	[p9l252t2182r285b2222],
15	phase	NN	O	phase	nn	17	SENT_129	[p9l300t2163r484b2238],
16	III	CD	NUMBER	iii	num	17	SENT_129	[p9l502t2168r573b2221],
17	trial	NN	O	trial	dep	1	SENT_129	[p9l591t2163r714b2222],
18	—	CD	NUMBER	—	num	19	SENT_129	[p9l729t2197r810b2203],
19	INTACT	NN	O	intact	dep	17	SENT_129	[p9l824t2167r1085b2223],
20	1	CD	NUMBER	1	dep	19	SENT_129	[p9l1103t2167r1154b2222],
21	.	.	O	.	_	0	SENT_129	[p9l1103t2167r1154b2222],

1	J	NNP	O	J	nn	3	SENT_130	[p9l1169t2168r1197b2232],
2	Clin	NNP	O	Clin	nn	3	SENT_130	[p9l1213t2163r1342b2222],
3	Oncol	NNP	O	Oncol	_	0	SENT_130	[p9l1360t2163r1550b2222],
4	2004	CD	DATE	2004	num	3	SENT_130	[p9l1567t2167r2083b2234],
5	;	:	O	;	_	0	SENT_130	[p9l1567t2167r2083b2234],
6	22:777	CD	NUMBER	22:777	number	7	SENT_130	[p9l1567t2167r2083b2234],
7	-84	CD	NUMBER	-84	dep	3	SENT_130	[p9l1567t2167r2083b2234],
8	.	.	O	.	_	0	SENT_130	[p9l1567t2167r2083b2234],

1	8	CD	NUMBER	8	_	0	SENT_131	[p9l9t2265r61b2318],
2	.	.	O	.	_	0	SENT_131	[p9l9t2265r61b2318],

1	Shah	NNP	O	Shah	nn	2	SENT_132	[p9l140t2259r299b2318],
2	NT	NNP	O	NT	_	0	SENT_132	[p9l320t2264r433b2330],
3	,	,	O	,	_	0	SENT_132	[p9l320t2264r433b2330],
4	Miller	NNP	ORGANIZATION	Miller	nn	5	SENT_132	[p9l457t2259r652b2317],
5	VA	NNP	ORGANIZATION	VA	appos	2	SENT_132	[p9l670t2264r776b2331],
6	,	,	O	,	_	0	SENT_132	[p9l670t2264r776b2331],
7	Kris	NNP	PERSON	Kris	nn	8	SENT_132	[p9l802t2260r930b2320],
8	MG	NN	PERSON	mg	appos	2	SENT_132	[p9l950t2263r1089b2330],
9	,	,	O	,	_	0	SENT_132	[p9l950t2263r1089b2330],
10	et	FW	O	et	nn	11	SENT_132	[p9l1114t2272r1172b2317],
11	al.	FW	O	al.	appos	2	SENT_132	[p9l1188t2259r1259b2318],
12	.	.	O	.	_	0	SENT_132	[p9l1188t2259r1259b2318],

1	Bronchioalveolar	JJ	PERSON	bronchioalveolar	amod	2	SENT_133	[p9l1283t2259r1828b2318],
2	histology	NN	O	histology	nsubj	6	SENT_133	[p9l1847t2259r2143b2335],
3	and	CC	O	and	_	0	SENT_133	[p9l9t2355r126b2415],
4	smoking	NN	O	smoking	nn	5	SENT_133	[p9l146t2355r428b2432],
5	history	NN	O	history	nsubj	6	SENT_133	[p9l444t2355r665b2431],
6	predict	VBP	O	predict	_	0	SENT_133	[p9l679t2355r905b2431],
7	reponse	NN	O	reponse	dobj	6	SENT_133	[p9l919t2375r1172b2431],
8	to	TO	O	to	_	0	SENT_133	[p9l1190t2368r1250b2415],
9	geﬁtinib	NN	O	geﬁtinib	prep_to	6	SENT_133	[p9l1269t2354r1555b2432],
10	.	.	O	.	_	0	SENT_133	[p9l1269t2354r1555b2432],

1	Prog	NN	O	prog	_	0	SENT_134	[p9l1577t2360r1727b2432],
2	Proc	NNP	O	Proc	nn	6	SENT_134	[p9l1741t2360r1883b2415],
3	Am	NNP	O	Am	nn	6	SENT_134	[p9l1898t2361r2011b2414],
4	Soc	NNP	O	Soc	nn	6	SENT_134	[p9l2031t2360r2140b2415],
5	Clin	NNP	O	Clin	nn	6	SENT_134	[p9l10t2452r140b2511],
6	Oncol	NNP	O	Oncol	dep	1	SENT_134	[p9l159t2452r350b2511],
7	2003	CD	DATE	2003	num	9	SENT_134	[p9l369t2456r784b2523],
8	;	:	O	;	_	0	SENT_134	[p9l369t2456r784b2523],
9	22:628	CD	NUMBER	22:628	dep	6	SENT_134	[p9l369t2456r784b2523],
10	.	.	O	.	_	0	SENT_134	[p9l369t2456r784b2523],

1	abstract	JJ	O	abstract	_	0	SENT_135	[p9l807t2452r1075b2511],
2	.	.	O	.	_	0	SENT_135	[p9l807t2452r1075b2511],

1	9	CD	NUMBER	9	_	0	SENT_136	[p9l10t2555r60b2607],
2	.	.	O	.	_	0	SENT_136	[p9l10t2555r60b2607],

1	Lynch	NNP	PERSON	Lynch	nn	3	SENT_137	[p9l138t2548r328b2623],
2	T	NN	O	t	nn	3	SENT_137	[p9l345t2553r429b2619],
3	]	NN	O	]	_	0	SENT_137	[p9l345t2553r429b2619],
4	,	,	O	,	_	0	SENT_137	[p9l345t2553r429b2619],
5	Bell	NNP	ORGANIZATION	Bell	nn	6	SENT_137	[p9l452t2548r572b2606],
6	DW	NNP	ORGANIZATION	DW	appos	3	SENT_137	[p9l590t2553r720b2619],
7	,	,	O	,	_	0	SENT_137	[p9l590t2553r720b2619],
8	Sordella	NNP	PERSON	Sordella	nn	9	SENT_137	[p9l746t2548r1003b2607],
9	R	NNP	PERSON	R	appos	3	SENT_137	[p9l1021t2553r1085b2620],
10	,	,	O	,	_	0	SENT_137	[p9l1021t2553r1085b2620],
11	et	FW	O	et	nn	12	SENT_137	[p9l1110t2561r1168b2606],
12	al.	FW	O	al.	appos	3	SENT_137	[p9l1183t2548r1254b2607],
13	.	.	O	.	_	0	SENT_137	[p9l1183t2548r1254b2607],

1	Activating	VBG	O	activate	amod	2	SENT_138	[p9l1275t2549r1599b2624],
2	mutations	NNS	O	mutation	_	0	SENT_138	[p9l1616t2549r1939b2607],
3	in	IN	O	in	_	0	SENT_138	[p9l1959t2549r2020b2606],
4	the	DT	O	the	det	7	SENT_138	[p9l2041t2548r2138b2606],
5	epidermal	JJ	O	epidermal	amod	7	SENT_138	[p9l10t2644r327b2720],
6	growth	NN	O	growth	nn	7	SENT_138	[p9l342t2644r568b2721],
7	factor	NN	O	factor	prep_in	2	SENT_138	[p9l583t2644r766b2704],
8	receptor	NN	O	receptor	nn	10	SENT_138	[p9l780t2657r1041b2720],
9	underlying	VBG	O	underlie	amod	10	SENT_138	[p9l1055t2644r1396b2721],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_138	[p9l1409t2645r1883b2720],
11	of	IN	O	of	_	0	SENT_138	[p9l1901t2644r1976b2704],
12	nonsmall-cell	JJ	O	nonsmall-cell	amod	14	SENT_138	[p9l1978t2664r2142b2704, p9l11t2741r325b2800],
13	lung	NN	O	lung	nn	14	SENT_138	[p9l349t2741r498b2818],
14	cancer	NN	O	cancer	prep_of	10	SENT_138	[p9l521t2761r732b2800],
15	to	TO	O	to	_	0	SENT_138	[p9l755t2754r816b2801],
16	geﬁtinib	NN	O	geﬁtinib	prep_to	14	SENT_138	[p9l842t2740r1134b2818],
17	.	.	O	.	_	0	SENT_138	[p9l842t2740r1134b2818],

1	N	NN	O	n	nn	2	SENT_139	[p9l1162t2746r1219b2801],
2	EnglJ	NN	O	englj	nsubj	3	SENT_139	[p9l1242t2741r1436b2818],
3	Med	VBD	O	med	_	0	SENT_139	[p9l1458t2741r1599b2801],
4	2004	CD	DATE	2004	dobj	3	SENT_139	[p9l1624t2745r2138b2813, p9l11t2843r105b2899],
5	;	:	O	;	_	0	SENT_139	[p9l1624t2745r2138b2813, p9l11t2843r105b2899],
6	350:212939	CD	NUMBER	350:212939	dep	4	SENT_139	[p9l1624t2745r2138b2813, p9l11t2843r105b2899],
7	.	.	O	.	_	0	SENT_139	[p9l1624t2745r2138b2813, p9l11t2843r105b2899],

1	10	CD	NUMBER	10	_	0	SENT_140	[p9l12t2941r99b2994],
2	.	.	O	.	_	0	SENT_140	[p9l12t2941r99b2994],

1	Barsky	NNP	PERSON	Barsky	nn	2	SENT_141	[p9l138t2935r353b3010],
2	SH	NNP	O	SH	_	0	SENT_141	[p9l374t2939r484b3007],
3	,	,	O	,	_	0	SENT_141	[p9l374t2939r484b3007],
4	Grossman	NNP	PERSON	Grossman	nn	5	SENT_141	[p9l511t2939r843b2994],
5	DA	NNP	PERSON	DA	appos	2	SENT_141	[p9l865t2940r981b3006],
6	,	,	O	,	_	0	SENT_141	[p9l865t2940r981b3006],
7	Ho	NNP	O	Ho	nn	8	SENT_141	[p9l1008t2940r1103b2994],
8	I	NNP	O	I	appos	2	SENT_141	[p9l1119t2940r1164b3007],
9	,	,	O	,	_	0	SENT_141	[p9l1119t2940r1164b3007],
10	Holmes	NNP	ORGANIZATION	Holmes	nn	11	SENT_141	[p9l1190t2935r1439b2994],
11	EC	NNP	ORGANIZATION	EC	appos	2	SENT_141	[p9l1462t2939r1569b2994],
12	.	.	O	.	_	0	SENT_141	[p9l1462t2939r1569b2994],

1	The	DT	O	the	det	2	SENT_142	[p9l1593t2935r1715b2994],
2	multifocality	NN	O	multifocality	_	0	SENT_142	[p9l1738t2935r2143b3010],
3	of	IN	O	of	_	0	SENT_142	[p9l10t3031r86b3091],
4	bronchioloalveolar	JJ	O	bronchioloalveolar	amod	6	SENT_142	[p9l90t3031r691b3091],
5	lung	NN	O	lung	nn	6	SENT_142	[p9l706t3031r851b3108],
6	carcinoma	NN	O	carcinoma	prep_of	2	SENT_142	[p9l867t3032r1219b3091],
7	:	:	O	:	_	0	SENT_142	[p9l867t3032r1219b3091],
8	evidence	NN	O	evidence	dep	2	SENT_142	[p9l1240t3031r1511b3091],
9	and	CC	O	and	_	0	SENT_142	[p9l1528t3031r1645b3091],
10	implications	NNS	O	implication	conj_and	8	SENT_142	[p9l1662t3031r2058b3107],
11	of	IN	O	of	_	0	SENT_142	[p9l2078t3031r2153b3091],
12	a	DT	O	a	det	14	SENT_142	[p9l9t3147r42b3186],
13	multiclonal	JJ	O	multiclonal	amod	14	SENT_142	[p9l60t3128r424b3187],
14	origin	NN	O	origin	prep_of	8	SENT_142	[p9l444t3129r652b3204],
15	.	.	O	.	_	0	SENT_142	[p9l444t3129r652b3204],

1	Mod	NNP	O	Mod	nn	2	SENT_143	[p9l672t3128r819b3187],
2	Pathol	NNP	O	Pathol	_	0	SENT_143	[p9l837t3128r1038b3187],
3	1994	CD	DATE	1994	num	2	SENT_143	[p9l1060t3132r1538b3199],
4	;	:	O	;	_	0	SENT_143	[p9l1060t3132r1538b3199],
5	7:633	CD	NUMBER	7:633	number	6	SENT_143	[p9l1060t3132r1538b3199],
6	-40	CD	NUMBER	-40	dep	2	SENT_143	[p9l1060t3132r1538b3199],
7	.	.	O	.	_	0	SENT_143	[p9l1060t3132r1538b3199],

1	Copyright	NN	O	copyright	_	0	SENT_144	[p9l11t3235r251b3300],
2	©	CD	NUMBER	©	num	6	SENT_144	[p9l272t3240r326b3294],
3	2004	CD	DATE	2004	num	6	SENT_144	[p9l350t3238r476b3284],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_144	[p9l496t3235r859b3283],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_144	[p9l879t3235r1078b3284],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_144	[p9l1095t3237r1279b3299],
7	.	.	O	.	_	0	SENT_144	[p9l1095t3237r1279b3299],

1	Electromechanical	NNP	O	Electromechanical	nn	2	SENT_145	[p9l669t3375r1149b3423],
2	Associations	NNS	O	association	_	0	SENT_145	[p9l1167t3376r1503b3423],
3	Joseph	NNP	PERSON	Joseph	nn	5	SENT_145	[p9l643t3454r762b3494],
4	G.	NNP	PERSON	G.	nn	5	SENT_145	[p9l777t3456r812b3485],
5	Rogers	NNP	PERSON	Rogers	dep	2	SENT_145	[p9l829t3457r951b3495],
6	,	,	O	,	_	0	SENT_145	[p9l829t3457r951b3495],
7	M.D.	NNP	O	M.D.	conj_and	5	SENT_145	[p9l969t3457r1059b3491],
8	,	,	O	,	_	0	SENT_145	[p9l969t3457r1059b3491],
9	and	CC	O	and	_	0	SENT_145	[p9l1074t3454r1133b3485],
10	Michael	NNP	PERSON	Michael	nn	14	SENT_145	[p9l1151t3454r1280b3485],
11	E.	NNP	PERSON	E.	nn	14	SENT_145	[p9l1297t3457r1323b3485],
12	Cain	NNP	PERSON	Cain	nn	14	SENT_145	[p9l1338t3456r1420b3491],
13	,	,	O	,	_	0	SENT_145	[p9l1338t3456r1420b3491],
14	M.D.	NNP	O	M.D.	conj_and	5	SENT_145	[p9l1437t3457r1517b3485],

1	The	DT	O	the	det	3	SENT_146	[p9l7t3650r170b3728],
2	left	JJ	O	left	amod	3	SENT_146	[p9l196t3649r336b3728],
3	ventricle	NN	O	ventricle	nsubj	4	SENT_146	[p9l354t3650r716b3729],
4	strives	VBZ	O	strive	_	0	SENT_146	[p9l745t3650r1010b3729],
5	valiantly	RB	O	valiantly	advmod	4	SENT_146	[p9l1035t3650r1393b3750],
6	with	IN	O	with	_	0	SENT_146	[p9l1410t3650r1601b3729],
7	each	DT	O	each	det	9	SENT_146	[p9l1629t3649r1820b3728],
8	cardiac	JJ	O	cardiac	amod	9	SENT_146	[p9l1848t3649r2149b3728],
9	cycle	NN	O	cycle	prep_with	4	SENT_146	[p10l11t21r213b121],
10	to	TO	O	to	aux	11	SENT_146	[p10l241t37r320b99],
11	maximize	VB	O	maximize	xcomp	4	SENT_146	[p10l348t21r763b99],
12	contractility	NN	O	contractility	dobj	11	SENT_146	[p10l791t21r1299b121],
13	and	CC	O	and	_	0	SENT_146	[p10l1321t20r1477b99],
14	provide	VB	O	provide	xcomp	4	SENT_146	[p10l1502t21r1820b121],
15	protection	NN	O	protection	dobj	14	SENT_146	[p10l1845t37r2147b121, p10l11t149r178b227],
16	against	IN	O	against	_	0	SENT_146	[p10l217t149r528b249],
17	lethal	JJ	O	lethal	amod	19	SENT_146	[p10l561t148r798b227],
18	ventricular	JJ	O	ventricular	amod	19	SENT_146	[p10l833t149r1292b228],
19	arrhythmias	NNS	O	arrhythmia	prep_against	14	SENT_146	[p10l1329t148r1867b249],
20	.	.	O	.	_	0	SENT_146	[p10l1329t148r1867b249],

1	Heart	NNP	O	Heart	nn	2	SENT_147	[p10l1912t156r2153b227],
2	failure	NN	O	failure	nsubj	4	SENT_147	[p10l11t276r281b356],
3	can	MD	O	can	aux	4	SENT_147	[p10l308t302r453b355],
4	make	VB	O	make	_	0	SENT_147	[p10l478t277r708b356],
5	this	DT	O	this	det	7	SENT_147	[p10l734t277r888b355],
6	coordination	NN	O	coordination	nn	7	SENT_147	[p10l917t276r1465b355],
7	difﬁcult	NN	O	difﬁcult	dobj	4	SENT_147	[p10l1491t276r1847b356],
8	.	.	O	.	_	0	SENT_147	[p10l1491t276r1847b356],

1	Heartrhythm	NN	PERSON	heartrhythm	_	0	SENT_148	[p10l1878t284r2147b355, p10l11t404r321b505],

1	and	CC	O	and	dep	2	SENT_149	[p10l342t404r498b483],
2	heart	NN	O	heart	_	0	SENT_149	[p10l520t404r1045b484],
3	—	CD	NUMBER	—	num	2	SENT_149	[p10l520t404r1045b484],
4	failure	NN	O	failure	nn	5	SENT_149	[p10l520t404r1045b484],
5	specialists	NNS	O	specialist	nsubj	8	SENT_149	[p10l1068t405r1501b505],
6	are	VBP	O	be	aux	8	SENT_149	[p10l1524t431r1651b483],
7	increasingly	RB	O	increasingly	advmod	8	SENT_149	[p10l1671t405r2147b505, p10l10t533r80b633],
8	working	VBG	O	work	rcmod	2	SENT_149	[p10l94t533r451b633],
9	together	RB	O	together	advmod	8	SENT_149	[p10l471t532r822b633],
10	to	TO	O	to	aux	11	SENT_149	[p10l842t549r920b611],
11	restore	VB	O	restore	xcomp	8	SENT_149	[p10l944t549r1231b611],
12	nature	NN	O	nature	poss	14	SENT_149	[p10l1253t538r1588b612],
13	’s	POS	O	’s	_	0	SENT_149	[p10l1253t538r1588b612],
14	performance	NN	O	performance	dobj	11	SENT_149	[p10l1611t532r2149b633],
15	and	CC	O	and	_	0	SENT_149	[p10l10t661r167b739],
16	lifesaving	JJ	O	lifesaving	amod	17	SENT_149	[p10l199t660r608b761],
17	features	NNS	O	feature	dobj	11	SENT_149	[p10l638t660r973b740],
18	to	TO	O	to	_	0	SENT_149	[p10l1009t677r1088b739],
19	the	DT	O	the	det	22	SENT_149	[p10l1123t661r1254b739],
20	failing	VBG	O	fail	amod	22	SENT_149	[p10l1287t660r1563b761],
21	left	JJ	O	left	amod	22	SENT_149	[p10l1592t660r1732b739],
22	ventricle	NN	O	ventricle	prep_to	11	SENT_149	[p10l1756t661r2143b740],
23	.	.	O	.	_	0	SENT_149	[p10l1756t661r2143b740],

1	Our	PRP$	O	we	poss	2	SENT_150	[p10l11t794r174b868],
2	jobs	NNS	O	job	nsubj	4	SENT_150	[p10l177t788r359b889],
3	are	VBP	O	be	aux	4	SENT_150	[p10l380t815r505b867],
4	becoming	VBG	O	become	_	0	SENT_150	[p10l525t789r946b889],
5	progressively	RB	O	progressively	advmod	4	SENT_150	[p10l961t789r1512b889],
6	more	RBR	O	more	advmod	7	SENT_150	[p10l1527t814r1744b867],
7	entwined	VBN	O	entwine	dep	10	SENT_150	[p10l1766t789r2149b868],
8	as	IN	O	as	mark	10	SENT_150	[p10l10t943r96b995],
9	we	PRP	O	we	nsubj	10	SENT_150	[p10l134t943r254b996],
10	evaluate	VBP	O	evaluate	dep	4	SENT_150	[p10l297t917r643b996],
11	treatments	NNS	O	treatment	nsubj	19	SENT_150	[p10l685t933r1147b995],
12	involving	VBG	O	involve	_	0	SENT_150	[p10l1190t916r1593b1017],
13	pacemakers	NNS	O	pacemaker	prep_involving	11	SENT_150	[p10l1629t917r2145b1017],
14	and	CC	O	and	_	0	SENT_150	[p10l10t1045r166b1123],
15	implantable	JJ	O	implantable	amod	18	SENT_150	[p10l196t1044r703b1145],
16	cardioverter	NN	O	cardioverter	nn	18	SENT_150	[p10l735t1044r1834b1124],
17	—	NN	O	—	nn	18	SENT_150	[p10l735t1044r1834b1124],
18	deﬁbrillators	NNS	O	deﬁbrillators	conj_and	13	SENT_150	[p10l735t1044r1834b1124],
19	(	VBP	O	(	ccomp	10	SENT_150	[p10l1874t1050r2143b1136],
20	ICDs	NNS	O	icd	dobj	19	SENT_150	[p10l1874t1050r2143b1136],
21	)	CD	NUMBER	)	nsubj	26	SENT_150	[p10l1874t1050r2143b1136],
22	in	IN	O	in	_	0	SENT_150	[p10l10t1173r92b1250],
23	an	DT	O	a	det	24	SENT_150	[p10l114t1198r215b1251],
24	effort	NN	O	effort	prep_in	21	SENT_150	[p10l238t1172r475b1251],
25	to	TO	O	to	aux	26	SENT_150	[p10l493t1189r572b1251],
26	improve	VB	O	improve	ccomp	4	SENT_150	[p10l596t1173r945b1273],
27	the	DT	O	the	det	28	SENT_150	[p10l969t1172r1099b1251],
28	quality	NN	O	quality	dobj	26	SENT_150	[p10l1122t1172r1410b1273],
29	of	IN	O	of	_	0	SENT_150	[p10l1429t1172r1530b1251],
30	life	NN	O	life	prep_of	28	SENT_150	[p10l1534t1172r1665b1251],
31	and	CC	O	and	_	0	SENT_150	[p10l1688t1173r1844b1251],
32	reduce	VB	O	reduce	ccomp	4	SENT_150	[p10l1867t1172r2148b1252],
33	the	DT	O	the	det	34	SENT_150	[p10l11t1300r140b1379],
34	risk	NN	O	risk	dobj	32	SENT_150	[p10l163t1301r324b1380],
35	of	IN	O	of	_	0	SENT_150	[p10l342t1300r443b1379],
36	complications	NNS	O	complication	prep_of	34	SENT_150	[p10l447t1300r1042b1401],
37	and	CC	O	and	_	0	SENT_150	[p10l1065t1300r1221b1379],
38	death	NN	O	death	prep_of	34	SENT_150	[p10l1244t1300r1475b1379],
39	among	IN	O	among	_	0	SENT_150	[p10l1497t1326r1796b1401],
40	patients	NNS	O	patient	prep_among	32	SENT_150	[p10l1814t1301r2147b1401],
41	with	IN	O	with	_	0	SENT_150	[p10l6t1428r200b1508],
42	left	JJ	O	left	amod	45	SENT_150	[p10l226t1428r370b1507],
43	ventricular	JJ	O	ventricular	amod	45	SENT_150	[p10l387t1429r858b1508],
44	systolic	JJ	O	systolic	amod	45	SENT_150	[p10l884t1429r1203b1529],
45	dysfunction	NN	O	dysfunction	prep_with	40	SENT_150	[p10l1231t1428r1758b1529],
46	.	.	O	.	_	0	SENT_150	[p10l1231t1428r1758b1529],

1	Several	JJ	O	several	amod	2	SENT_151	[p10l142t1557r437b1636],
2	factors	NNS	O	factor	nsubj	3	SENT_151	[p10l461t1556r747b1635],
3	contribute	VBP	O	contribute	_	0	SENT_151	[p10l774t1556r1212b1636],
4	to	TO	O	to	_	0	SENT_151	[p10l1237t1573r1316b1635],
5	this	DT	O	this	det	7	SENT_151	[p10l1343t1557r1496b1635],
6	new	JJ	O	new	amod	7	SENT_151	[p10l1522t1582r1699b1636],
7	collaboration	NN	O	collaboration	prep_to	3	SENT_151	[p10l1721t1557r2147b1635, p10l11t1685r206b1763],
8	.	.	O	.	_	0	SENT_151	[p10l1721t1557r2147b1635, p10l11t1685r206b1763],

1	First	RB	ORDINAL	first	advmod	7	SENT_152	[p10l239t1685r459b1780],
2	,	,	O	,	_	0	SENT_152	[p10l239t1685r459b1780],
3	heart	NN	O	heart	nn	6	SENT_152	[p10l494t1685r1072b1785],
4	—	NN	O	—	nn	6	SENT_152	[p10l494t1685r1072b1785],
5	rhythm	NN	O	rhythm	nn	6	SENT_152	[p10l494t1685r1072b1785],
6	specialists	NNS	O	specialist	nsubj	7	SENT_152	[p10l1103t1685r1546b1785],
7	acknowledge	VBP	O	acknowledge	_	0	SENT_152	[p10l1578t1684r2147b1785],
8	the	DT	O	the	det	14	SENT_152	[p10l11t1813r139b1891],
9	dramatic	JJ	O	dramatic	amod	14	SENT_152	[p10l162t1812r531b1891],
10	effect	NN	O	effect	nn	14	SENT_152	[p10l552t1812r784b1891],
11	heart	NN	O	heart	nn	14	SENT_152	[p10l800t1812r1315b1892],
12	—	CD	NUMBER	—	num	14	SENT_152	[p10l800t1812r1315b1892],
13	failure	NN	O	failure	nn	14	SENT_152	[p10l800t1812r1315b1892],
14	specialists	NNS	O	specialist	nsubj	16	SENT_152	[p10l1338t1812r1763b1913],
15	have	VBP	O	have	aux	16	SENT_152	[p10l1787t1813r1973b1892],
16	had	VBN	O	have	ccomp	7	SENT_152	[p10l1995t1813r2149b1891],
17	using	VBG	O	use	xcomp	16	SENT_152	[p10l11t1941r249b2041],
18	contemporary	JJ	O	contemporary	dobj	17	SENT_152	[p10l273t1957r884b2041],
19	,	,	O	,	_	0	SENT_152	[p10l273t1957r884b2041],
20	evidence	NN	O	evidence	nn	21	SENT_152	[p10l917t1940r1564b2020],
21	—	NN	O	—	appos	18	SENT_152	[p10l917t1940r1564b2020],
22	based	VBN	O	base	partmod	21	SENT_152	[p10l917t1940r1564b2020],
23	medical	JJ	O	medical	amod	24	SENT_152	[p10l1591t1941r1925b2019],
24	regimens	NNS	O	regimen	dobj	22	SENT_152	[p10l1952t1941r2147b2041, p10l8t2094r235b2147],
25	to	TO	O	to	aux	26	SENT_152	[p10l276t2085r355b2147],
26	improve	VB	O	improve	xcomp	22	SENT_152	[p10l392t2069r740b2169],
27	left	JJ	O	left	amod	29	SENT_152	[p10l776t2068r916b2147],
28	ventricular	JJ	O	ventricular	amod	29	SENT_152	[p10l944t2069r1401b2148],
29	function	NN	O	function	dobj	26	SENT_152	[p10l1436t2068r1793b2148],
30	and	CC	O	and	_	0	SENT_152	[p10l1830t2069r1985b2147],
31	reduce	VB	O	reduce	xcomp	22	SENT_152	[p10l2022t2095r2134b2147, p10l9t2196r204b2276],
32	the	DT	O	the	det	33	SENT_152	[p10l236t2197r365b2275],
33	risks	NNS	O	risk	dobj	31	SENT_152	[p10l396t2196r595b2276],
34	of	IN	O	of	_	0	SENT_152	[p10l628t2196r729b2275],
35	death	NN	O	death	prep_of	33	SENT_152	[p10l742t2196r974b2275],
36	from	IN	O	from	_	0	SENT_152	[p10l1004t2196r1212b2275],
37	arrhythmia	NN	O	arrhythmium	prep_from	31	SENT_152	[p10l1242t2196r1713b2297],
38	and	CC	O	and	_	0	SENT_152	[p10l1741t2197r1897b2275],
39	from	IN	O	from	_	0	SENT_152	[p10l1928t2196r2135b2275],
40	any	DT	O	any	det	41	SENT_152	[p10l7t2350r155b2425],
41	cause	NN	O	cause	conj_and	37	SENT_152	[p10l178t2351r409b2404],
42	among	IN	O	among	_	0	SENT_152	[p10l436t2350r736b2425],
43	patients	NNS	O	patient	prep_among	41	SENT_152	[p10l758t2325r1093b2425],
44	with	IN	O	with	_	0	SENT_152	[p10l1117t2325r1307b2404],
45	heart	NN	O	heart	nn	46	SENT_152	[p10l1334t2325r1553b2403],
46	failure	NN	O	failure	prep_with	43	SENT_152	[p10l1574t2324r1868b2404],
47	.	.	O	.	_	0	SENT_152	[p10l1574t2324r1868b2404],

1	How	WRB	O	how	advmod	3	SENT_153	[p10l1900t2332r2134b2404],
2	—	RB	O	—	advmod	3	SENT_153	[p10l1900t2332r2134b2404],
3	ever	RB	O	ever	dep	10	SENT_153	[p10l9t2479r195b2548],
4	,	,	O	,	_	0	SENT_153	[p10l9t2479r195b2548],
5	even	RB	O	even	advmod	6	SENT_153	[p10l228t2478r414b2532],
6	heart	NN	O	heart	nsubj	10	SENT_153	[p10l441t2452r964b2532],
7	—	CD	NUMBER	—	num	9	SENT_153	[p10l441t2452r964b2532],
8	failure	NN	O	failure	nn	9	SENT_153	[p10l441t2452r964b2532],
9	specialists	NNS	O	specialist	dep	6	SENT_153	[p10l993t2452r1423b2553],
10	admit	VBP	O	admit	_	0	SENT_153	[p10l1451t2453r1701b2531],
11	that	IN	O	that	complm	24	SENT_153	[p10l1723t2453r1890b2531],
12	a	DT	O	a	det	14	SENT_153	[p10l1911t2479r1955b2531],
13	further	JJ	O	further	amod	14	SENT_153	[p10l1980t2452r2134b2532, p10l8t2581r178b2659],
14	beneﬁt	NN	O	beneﬁt	nsubj	24	SENT_153	[p10l202t2580r499b2659],
15	from	IN	O	from	_	0	SENT_153	[p10l520t2580r728b2659],
16	drugs	NNS	O	drug	prep_from	14	SENT_153	[p10l755t2580r993b2681],
17	that	WDT	O	that	nsubj	18	SENT_153	[p10l1022t2581r1188b2659],
18	antagonize	VBP	O	antagonize	rcmod	16	SENT_153	[p10l1210t2581r1679b2681],
19	neurohor	NN	O	neurohor	nn	22	SENT_153	[p10l1706t2580r2134b2660],
20	—	NN	O	—	nn	22	SENT_153	[p10l1706t2580r2134b2660],
21	monal	JJ	O	monal	amod	22	SENT_153	[p10l8t2709r278b2787],
22	pathways	NNS	O	pathway	dobj	18	SENT_153	[p10l298t2708r691b2809],
23	is	VBZ	O	be	cop	24	SENT_153	[p10l715t2709r780b2787],
24	unlikely	JJ	O	unlikely	ccomp	10	SENT_153	[p10l804t2708r1143b2809],
25	to	TO	O	to	aux	27	SENT_153	[p10l1161t2725r1240b2787],
26	be	VB	O	be	auxpass	27	SENT_153	[p10l1264t2709r1359b2787],
27	achieved	VBN	O	achieve	xcomp	24	SENT_153	[p10l1381t2709r1768b2788],
28	.	.	O	.	_	0	SENT_153	[p10l1381t2709r1768b2788],

1	Trials	NNS	O	trial	nsubj	26	SENT_154	[p10l1792t2708r2028b2787],
2	of	IN	O	of	_	0	SENT_154	[p10l2053t2708r2153b2787],
3	new	JJ	O	new	amod	4	SENT_154	[p10l8t2862r184b2916],
4	agents	NNS	O	agent	prep_of	1	SENT_154	[p10l209t2853r507b2937],
5	,	,	O	,	_	0	SENT_154	[p10l209t2853r507b2937],
6	such	JJ	O	such	_	0	SENT_154	[p10l543t2837r738b2916],
7	as	IN	O	as	_	0	SENT_154	[p10l766t2863r850b2915],
8	endothelin	NN	O	endothelin	nn	9	SENT_154	[p10l882t2837r1338b2915],
9	antagonists	NNS	O	antagonist	prep_such_as	1	SENT_154	[p10l1366t2837r1884b2937],
10	,	,	O	,	_	0	SENT_154	[p10l1366t2837r1884b2937],
11	vaso	FW	O	vaso	nn	13	SENT_154	[p10l1914t2862r2134b2916],
12	—	FW	O	—	nn	13	SENT_154	[p10l1914t2862r2134b2916],
13	peptidase	NN	O	peptidase	conj_and	9	SENT_154	[p10l7t2965r421b3065],
14	inhibitors	NNS	O	inhibitor	dep	13	SENT_154	[p10l453t2964r904b3060],
15	,	,	O	,	_	0	SENT_154	[p10l453t2964r904b3060],
16	and	CC	O	and	_	0	SENT_154	[p10l942t2965r1100b3043],
17	soluble	JJ	O	soluble	amod	20	SENT_154	[p10l1135t2965r1445b3044],
18	tumor	NN	O	tumor	nn	20	SENT_154	[p10l1479t2981r1746b3044],
19	necrosis	NN	O	necrosis	nn	20	SENT_154	[p10l1776t2965r2132b3043],
20	factor	NN	O	factor	prep_such_as	1	SENT_154	[p10l8t3092r254b3171],
21	a	DT	O	a	det	22	SENT_154	[p10l277t3122r335b3170],
22	receptors	NNS	O	receptor	dep	20	SENT_154	[p10l365t3109r781b3193],
23	,	,	O	,	_	0	SENT_154	[p10l365t3109r781b3193],
24	have	VBP	O	have	aux	26	SENT_154	[p10l812t3093r1001b3172],
25	not	RB	O	not	neg	26	SENT_154	[p10l1028t3109r1171b3171],
26	shown	VBN	O	show	_	0	SENT_154	[p10l1194t3093r1474b3172],
27	an	DT	O	a	det	31	SENT_154	[p10l1499t3118r1600b3171],
28	incremental	JJ	O	incremental	amod	31	SENT_154	[p10l1626t3093r2135b3171],
29	survival	NN	O	survival	nn	31	SENT_154	[p10l10t3221r328b3300],
30	beneﬁt	NN	O	beneﬁt	nn	31	SENT_154	[p10l353t3215r780b3299],
31	.1	NN	NUMBER	.1	dobj	26	SENT_154	[p10l353t3215r780b3299],
32	'	''	O	'	_	0	SENT_154	[p10l353t3215r780b3299],
33	3	CD	NUMBER	3	dep	31	SENT_154	[p10l353t3215r780b3299],

1	Second	RB	ORDINAL	second	advmod	7	SENT_155	[p10l139t3348r467b3444],
2	,	,	O	,	_	0	SENT_155	[p10l139t3348r467b3444],
3	heart	NN	O	heart	nn	6	SENT_155	[p10l505t3348r1028b3428],
4	—	NN	O	—	nn	6	SENT_155	[p10l505t3348r1028b3428],
5	failure	NN	O	failure	nn	6	SENT_155	[p10l505t3348r1028b3428],
6	specialists	NNS	O	specialist	nsubj	7	SENT_155	[p10l1063t3348r1494b3449],
7	recognize	VBP	O	recognize	_	0	SENT_155	[p10l1529t3349r1940b3449],
8	that	IN	O	that	_	0	SENT_155	[p10l1973t3348r2140b3427],
9	at	IN	O	at	quantmod	11	SENT_155	[p10l7t3493r86b3555],
10	least	JJS	O	least	quantmod	11	SENT_155	[p10l115t3477r312b3555],
11	half	PDT	O	half	prep_that	7	SENT_155	[p10l342t3476r521b3555],
12	their	PRP$	O	they	poss	13	SENT_155	[p10l538t3477r735b3555],
13	patients	NNS	O	patient	nsubj	14	SENT_155	[p10l766t3477r1100b3577],
14	die	VB	O	die	rcmod	11	SENT_155	[p10l1139t3477r1262b3555],
15	suddenly	RB	O	suddenly	advmod	14	SENT_155	[p10l1298t3476r1691b3577],
16	.	.	O	.	_	0	SENT_155	[p10l1298t3476r1691b3577],

1	They	PRP	O	they	nsubj	3	SENT_156	[p10l1728t3477r1937b3577],
2	also	RB	O	also	advmod	3	SENT_156	[p10l1967t3476r2134b3555],
3	acknowledge	VBP	O	acknowledge	_	0	SENT_156	[p10l7t3605r575b3705],
4	that	IN	O	that	complm	17	SENT_156	[p10l624t3605r794b3683],
5	ICD	NN	O	icd	nn	6	SENT_156	[p10l836t3610r1005b3683],
6	therapy	NN	O	therapy	nsubj	17	SENT_156	[p10l1055t3605r1379b3705],
7	in	IN	O	in	_	0	SENT_156	[p10l1423t3605r1505b3682],
8	patients	NNS	O	patient	prep_in	6	SENT_156	[p10l1552t3605r1895b3705],
9	with	IN	O	with	_	0	SENT_156	[p10l1941t3605r2134b3684],
10	healed	VBN	O	heal	prepc_with	8	SENT_156	[p11l8t20r289b99],
11	myocardial	JJ	O	myocardial	amod	12	SENT_156	[p11l326t20r804b121],
12	infarction	NN	O	infarction	dobj	10	SENT_156	[p11l841t20r1266b99],
13	and	CC	O	and	_	0	SENT_156	[p11l1303t20r1461b99],
14	left	VBD	O	leave	conj_and	10	SENT_156	[p11l1498t20r1640b99],
15	ventricular	JJ	O	ventricular	amod	16	SENT_156	[p11l1669t21r2137b100],
16	dysfunction	NN	O	dysfunction	dobj	14	SENT_156	[p11l9t149r518b250],
17	decreases	VBZ	O	decrease	ccomp	3	SENT_156	[p11l566t149r977b228],
18	overall	JJ	O	overall	amod	31	SENT_156	[p11l1028t150r1313b229],
19	mortality	NN	O	mortality	nn	21	SENT_156	[p11l1361t145r1819b250],
20	.4	CD	NUMBER	.4	num	21	SENT_156	[p11l1361t145r1819b250],
21	Third	NNP	ORDINAL	Third	tmod	18	SENT_156	[p11l1862t150r2128b245],
22	,	,	O	,	_	0	SENT_156	[p11l1862t150r2128b245],
23	both	DT	O	both	det	26	SENT_156	[p11l9t278r205b356],
24	heart	NN	O	heart	nn	26	SENT_156	[p11l259t278r833b378],
25	—	NN	O	—	nn	26	SENT_156	[p11l259t278r833b378],
26	rhythm	NN	O	rhythm	conj_and	21	SENT_156	[p11l259t278r833b378],
27	and	CC	O	and	_	0	SENT_156	[p11l887t278r1045b356],
28	heart	NN	O	heart	tmod	18	SENT_156	[p11l1099t277r1635b357],
29	—	CD	NUMBER	—	num	28	SENT_156	[p11l1099t277r1635b357],
30	failure	NN	O	failure	nn	31	SENT_156	[p11l1099t277r1635b357],
31	specialists	NNS	O	specialist	nsubj	32	SENT_156	[p11l1690t278r2132b378],
32	agree	VBP	O	agree	ccomp	17	SENT_156	[p11l7t432r238b506],
33	that	IN	O	that	_	0	SENT_156	[p11l293t406r463b484],
34	patients	NNS	O	patient	prep_that	32	SENT_156	[p11l511t406r854b506],
35	with	IN	O	with	_	0	SENT_156	[p11l905t405r1098b485],
36	heart	NN	O	heart	nn	37	SENT_156	[p11l1152t406r1376b484],
37	failure	NN	O	failure	prep_with	34	SENT_156	[p11l1425t405r1701b485],
38	with	IN	O	with	_	0	SENT_156	[p11l1751t406r1944b485],
39	left	NN	O	left	prep_with	32	SENT_156	[p11l1997t405r2139b484],

1	N	NN	O	n	nn	2	SENT_157	[p11l516t583r530b598],
2	ENGLJ	NN	O	englj	_	0	SENT_157	[p11l545t582r629b604],
3	MED	VBD	O	med	partmod	2	SENT_157	[p11l644t583r696b598],
4	35o	CD	NUMBER	35o	dobj	3	SENT_157	[p11l709t582r787b604],
5	;	:	O	;	_	0	SENT_157	[p11l709t582r787b604],
6	21	CD	NUMBER	21	num	8	SENT_157	[p11l709t582r787b604],
7	WWW.NEjM.ORG	NNP	O	WWW.NEjM.ORG	nn	8	SENT_157	[p11l825t582r1036b604],
8	MAY	NNP	DATE	MAY	dep	2	SENT_157	[p11l1075t582r1127b598],
9	20	CD	DATE	20	num	8	SENT_157	[p11l1139t582r1178b602],
10	,	,	DATE	,	_	0	SENT_157	[p11l1139t582r1178b602],
11	2004	CD	DATE	2004	num	12	SENT_157	[p11l1191t582r1259b604],
12	2193	CD	DATE	2193	appos	8	SENT_157	[p11l1940t581r2016b603],

1	The	DT	O	the	det	4	SENT_158	[p11l702t615r753b639],
2	New	NNP	O	New	nn	4	SENT_158	[p11l762t616r824b639],
3	England	NNP	O	England	nn	4	SENT_158	[p11l833t615r944b646],
4	Journal	NNP	O	Journal	_	0	SENT_158	[p11l953t615r1050b639],
5	of	IN	O	of	_	0	SENT_158	[p11l1060t615r1089b639],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_158	[p11l1095t615r1221b639],

1	Downloaded	VBN	O	download	_	0	SENT_159	[p11l144t656r314b679],
2	from	IN	O	from	_	0	SENT_159	[p11l323t656r387b679],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_159	[p11l396t656r514b686],
4	at	IN	O	at	_	0	SENT_159	[p11l524t660r548b679],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_159	[p11l556t656r739b679],
6	on	IN	O	on	_	0	SENT_159	[p11l748t663r780b679],
7	January	NNP	DATE	January	prep_on	1	SENT_159	[p11l789t656r892b686],
8	5	CD	DATE	5	num	7	SENT_159	[p11l902t656r925b683],
9	,	,	DATE	,	_	0	SENT_159	[p11l902t656r925b683],
10	2014	CD	DATE	2014	num	7	SENT_159	[p11l935t656r1007b679],
11	.	.	O	.	_	0	SENT_159	[p11l935t656r1007b679],

1	For	IN	O	for	_	0	SENT_160	[p11l1018t656r1064b679],
2	personal	JJ	O	personal	amod	3	SENT_160	[p11l1073t656r1185b686],
3	use	NN	O	use	pobj	1	SENT_160	[p11l1194t663r1238b679],
4	only	RB	O	only	advmod	3	SENT_160	[p11l1247t656r1312b686],
5	.	.	O	.	_	0	SENT_160	[p11l1247t656r1312b686],

1	No	DT	O	no	det	3	SENT_161	[p11l1323t656r1363b679],
2	other	JJ	O	other	amod	3	SENT_161	[p11l1373t656r1441b679],
3	uses	NNS	O	use	_	0	SENT_161	[p11l1449t663r1505b679],
4	without	IN	O	without	_	0	SENT_161	[p11l1515t656r1616b679],
5	permission	NN	O	permission	prep_without	3	SENT_161	[p11l1624t656r1777b686],
6	.	.	O	.	_	0	SENT_161	[p11l1624t656r1777b686],

1	Copyright	NN	O	copyright	_	0	SENT_162	[p11l494t697r629b728],
2	©	CD	NUMBER	©	num	6	SENT_162	[p11l638t697r661b721],
3	2004	CD	DATE	2004	num	6	SENT_162	[p11l672t697r737b721],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_162	[p11l746t697r937b721],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_162	[p11l947t697r1055b721],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_162	[p11l1066t697r1171b728],
7	.	.	O	.	_	0	SENT_162	[p11l1066t697r1171b728],

1	All	DT	O	all	det	2	SENT_163	[p11l1182t697r1223b721],
2	rights	NNS	O	rights	nsubj	3	SENT_163	[p11l1232t697r1307b728],
3	reserved	VBN	O	reserve	_	0	SENT_163	[p11l1317t697r1436b721],
4	.	.	O	.	_	0	SENT_163	[p11l1317t697r1436b721],

